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Abstract
Indoleamine 2,3-dioxygenase-1 (IDO) is an immunosuppressive molecule expressed by
most human tumours. IDO levels correlate with poor prognosis in cancer patients and
IDO

inhibitors

are

under

investigation

to

enhance

endogenous

anticancer

immunosurveillance. Little is known regarding the immune-independent functions of
IDO relevant to cancer therapy. In this thesis I show, for the first time, that IDO mediates
human tumour cell resistance, in a cell-autonomous fashion, to single and combination
treatment with a diverse group of chemotherapy drugs and γ radiation. These drugs
include a PARP inhibitor (olaparib), a DNA cross-linking agent (cisplatin), a folate
antimetabolite (pemetrexed), a nucleoside analogue (gemcitabine), a base excision repair
inhibitor (methoxyamine), an NAD+ inhibitor (FK866) and combined treatments with
olaparib and radiation and methoxyamine and pemetrexed in the absence of immune cells.
Antisense-mediated reduction of IDO, alone and (in a synthetic lethal approach) in
combination with antisense to the DNA repair protein BRCA2 sensitizes human lung
cancer cells to olaparib and cisplatin. Antisense-mediated reduction of IDO (in a
synthetic lethal approach) in combination with antisense to thymidylate synthase
sensitizes human lung cancer cells to pemetrexed and 5FUdR. Antisense reduction of
IDO decreased NAD+ in human tumour cells. NAD+ is essential for PARP activity and
these data suggest that IDO mediates treatment resistance independent of its wellestablished immunomodulatory effects, and at least partially due to a previously
unrecognized role for IDO in DNA repair. Furthermore, increased IDO levels correlated
with the accumulation of tumour cells in G1 and depletion of cells in the G2/M phases of
the cell cycle, suggesting that the effects of IDO on the cell cycle may also modulate
sensitivity to radiation and chemotherapeutic agents. IDO is a potentially valuable
therapeutic target in cancer treatment, independent of immune function and in
combination with other therapies.
Keywords:
Indoleamine 2,3-dioxygenase (IDO), cancer, breast cancer type-2 susceptibility protein
(BRCA2), Thymidylate synthase (TS), DNA repair, chemotherapy, γ radiation, olaparib,
cisplatin, pemetrexed, 5FUdR, gemcitabine, FK866, methoxyamine
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Chapter 1
1.1

Introduction synopsis
In this chapter I briefly describe non-surgical methods common in cancer treatment,

including chemotherapy, radiation, immunotherapy, and combinations utilizing more
than one therapeutic approach. This review illuminates the exploration of cancer-relevant
functions of the immunoregulatory molecule indoleamine 2,3-dioxygenase (IDO), a
cellular enzyme potentially involved in mediating resistance to these treatments and the
subject of this thesis.
In the chemotherapy section, major chemotherapeutic agents used in patient
treatment (and assessed in the context of altered IDO expression in this thesis) are
introduced and their mechanism of action described. Cellular mechanisms mediating
resistance to major treatment methods are then described, followed by a description of
IDO and its known role(s) in immune regulation and cancer.
IDO inhibitors and the effect of IDO inhibition in cancer treatment is then
described as a background to understanding the strategies and experimental consequences
of IDO inhibition in human tumour cell response to chemotherapy and/or radiation.
DNA repair events in tumour cells, including base excision repair (BER) and
homologous recombination repair (HRR) are then reviewed as a background to
understanding IDO functions proposed, in this thesis, to be associated with those repair
events. Poly(adenosine diphosphate-ribose) polymerase (PARP) molecules and their role
in BER and HRR is described as a basis for understanding the hypothesis that PARP
activity is affected by IDO activity. Because PARP activity depends on nicotinamide
adenine dinucleotide (NAD+), and IDO mediates de novo NAD+ synthesis, NAD+ and its
role in DNA repair is described; data presented in this thesis show that IDO
downregulation decreases NAD+ levels in cancer cells, and NAD+ inhibition is proposed
as a strategy to treat cancer. A role for IDO in mediating resistance to such strategies is
described in this thesis.
Thymidylate synthase (TS) is introduced as a background to understanding the role
of IDO downregulation in resistance to three TS-targeting drugs (pemetrexed, 5FUdR,
and gemcitabine), alone or in combination with TS inhibition.
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Finally, and to assist in understanding the technology used in this thesis to
modulate IDO and TS in human tumour cells, antisense-mediated downregulation of
messenger RNA (mRNA) as a technology to reduce specific cellular targets, both as a
discovery tool and as potential therapeutic strategy, is described.
1.2

General Introduction
Malignancy in cancer cells occurs in a stepwise fashion and is enhanced by

genomic instability, which is a major generator of mutations that are the basis of selection
for cells by conditions existing in host organisms (availability of nutrients, growth factors
or lack of them, oxygenation, sensitivity to drug treatments, capacity to evade immune
detection, and others) [1]. Genetic instability in cancer was first hypothesized by Boveri,
based on the consequences of aneuploidy on the growth of sea urchin embryos [2].
Because of genomic instability, individual cancer cells each harbour on the order of
10,000 mutations that distinguish them from a parental stem cell. Clinically detectable
tumours contain 108-109 cells and can have more than 1011 mutations [3]. Because a high
mutation rate and selection pressures driving Darwinian evolution are not mutually
exclusive, genomic instability has the potential to enhance fitness of cells comprising
tumours, such that they are well-adapted to survive and grow in their hosts [3]. However,
it is likely that there is a maximum number of unrepaired DNA damage events and
resulting mutations, DNA duplications, DNA translocations, and chromosomal
abnormalities arising from DNA damage, that tumour cells can tolerate before reaching a
limit that, when exceeded, alters cellular fitness and becomes a detriment to fitness [3].
This has been proposed as a reason, with the exception of P53 [4] and the DNA
polymerase β encoding gene POLB [5], that most genes involved in DNA repair and/or
DNA replication are intact in cancer cells [3]. A high mutation rate and resulting
heterogeneity in tumour cell populations can also be a source of cells with resistance to
chemotherapy, which could impede personalized medicine for cancer treatment [3].
Moreover, the possibility of converting a passenger mutation to a driver because of the
changes in the tumour microenvironment due to selective pressure of internal and/or
external factors, such as the immune system or chemotherapy, can also inhibit the
effectiveness of cancer treatment [6]. This is an important phenomenon that should be
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considered when proposing and testing treatments for cancer, since passenger mutations
normally do not have any functional consequences such as conferring clonal growth
advantage to cancer cells, but driver mutations are often selected for and they could
confer growth or survival advantages to cancer cells [6].
1.3
1.3.1

Major Non-Surgical Methods of Cancer Treatment
Chemotherapy
Modern chemotherapy began in 1942, with the discovery of nitrogen mustard as

an effective cancer treatment [7]. However, early observations of tumours developing
resistance to chemotherapy after application of therapeutic drugs [8, 9] continue to the
present day, and remain a major obstacle in the treatment of cancer patients with
chemotherapy [10]. Traditionally, chemotherapy involves treatment with cytotoxic drugs
that interfere with DNA synthesis and cell proliferation [11]. In the new era of
chemotherapy, drugs also target many of the signaling networks that regulate cell
proliferation and survival in cancer cells -- either targets that are unique to cancer cells
(proteins or peptides not found in non-tumour cells) or that are preferentially expressed or
depended on to mediate malignant characteristics and/or survival – in a strategy termed
“targeted therapy” [7]. These drugs mainly consist of antibodies and small molecule
kinase inhibitors that target specific molecules important to different signaling events,
and that result in decreased cell proliferation and survival [11]. For example,
Trastuzumab, a humanized monoclonal antibody that targets human epidermal growth
factor 2 (HER2), in combination with common chemotherapy agents cisplatin plus
capecitabine or 5-fluorouracil (5FU) is more effective than chemotherapy alone in
increasing the median overall survival of gastric cancer patients [12]. Gefitinib, which is
a small-molecule epidermal growth factor receptor-tyrosine kinase inhibitor, is used to
treat patients with non-small cell lung cancer (NSCLC) [13].
1.3.1.1 Cisplatin
Cisplatin (cis-diammine-dichloro-platinum) is a platinum-based chemotherapy
drug that is commonly used to treat various forms of solid tumours including ovarian,
testicular, and head and neck [14]. Cisplatin primarily targets DNA by forming DNA3

protein and DNA-DNA interstrand and intrastrand crosslinks [15]. However, its cytotoxic
function is mostly attributed to its ability to form interstrand adducts [16]. P53 plays a
major role in cisplatin-induced apoptosis. Cisplatin is known to preferentially activate
ATM- and RAD3-related protein kinase (ATR) that regulates the stability and
transcriptional activity of P53 in cells [17]. Cisplatin-mediated induction and/or
activation of P53 results in transactivation of several genes that are associated with cell
cycle inhibition, DNA repair, and apoptosis including p21Waf1/Clip1, the DNA damageinducible gadd45a gene, and the pro-apoptotic gene bax [18]. The Gadd45a protein
enhances nucleotide excision repair (NER) activity counteracting cisplatin function [19].
However, cisplatin-induced DNA damage can exceed cellular DNA repair capacity and
induce apoptosis in the treated cells [14]. Translocation of the pro-apoptotic bax protein
following cisplatin treatment triggers a cascade of events in the treated cells that finally
results in apoptosis, including release of cytochrome c followed by the activation of
caspase 9-caspase 3 pathway [20, 21].
1.3.1.2 Pemetrexed
Pemetrexed (Alimta) is an antifolate antimetabolite that targets multiple enzymes
involved in both pyrimidine and purine synthesis. Those enzymes include TS,
glycinamide

ribonucleotide

formyltransferase,

dihydrofolate

reductase,

and

aminoimidazole carboxamide ribonucleotide formyltransferase [22]. TS inhibition is the
primary mechanism of action of pemetrexed, which results in decrease of available
thymidine necessary for DNA synthesis [23, 24]. Pemetrexed enters the cells via the
reduced folate carrier, the α-folate receptor, and proton-coupled folate transporter [25].
Inside the cell, pemetrexed has high affinity for folylpolyglutamate synthase that renders
it to a polyglutamated form that is 60-fold more potent in TS inhibition [26]. Glutamation
also increases the retention of pemetrexed inside the cell resulting in both extended
exposure time and increased intracellular levels of it in treated cells [22]. Pemetrexed
induces G1/S cell cycle arrest arising from its antifolate activity and induces P53independent cell death in cancer cells [22]. Combining pemetrexed with other cytotoxic
agents has shown additive or synergistic effects both in vitro and in vivo. For example,
combinations of pemetrexed with each of the platinum agents cisplatin, carboplatin, and
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oxaliplatin results in either additive or greater than additive sensitivity of Calu-6 and
H460 non-small cell lung carcinoma (NSCLC) xenografts to the treatment [27].
Moreover, pretreatment of H460 NSCLC xenografts with pemetrexed before fractionated
radiation therapy delays tumour growth in mice as compared to radiation treatment alone.
Therefore, combining pemetrexed to radiotherapy may increase the effectiveness of the
latter [27].
1.3.1.3 5FUdR
5-Fluoro-2'-deoxyuridine (5FUdR) is a pyrimidine analog that inhibits TS,
resulting in the depletion of intracellular thymidine monophosphate (TMP) [28]. This
drug is approved for the treatment of a wide range of cancers including brain, colorectal,
and liver [29-31]. 5FUdR is the deoxyribonucleoside derivative of 5FU [30]. It inhibits
TS through 5-fluoro-2ʹ′-deoxyuridine-5ʹ′-monophosphate (FdUMP). 5FUdR enters cells
via facilitated nucleoside transport systems [32]. Upon entry, 5FUdR is either
phosphorylated to its active nucleotide FdUMP by thymidine kinase (TK), or cleaved to
5FU by thymidine phosphorylase [30]. In the presence of adequate amounts of TS cosubstrate 5, 10-methylene-tetra hydrofolate (CH2-THF), FdUMP and TS form a stable
ternary complex that strikingly increases the extent and duration of TS inhibition
resulting in enhanced antitumour activity [33].
1.3.1.4 Gemcitabine
Gemcitabine (2ʹ′, 2ʹ′-difluorodeoxycytidine) is a pyrimidine antimetabolite that is
widely used to treat diverse malignancies, including pancreatic cancer, ovarian cancer,
malignant mesothelioma, and NSCLC [34, 35]. Deoxycytidine kinase (dCK)
phosphorylates gemcitabine to its cytotoxic nucleotides, gemcitabine diphosphate
(dFdCDP) and triphosphate (dFdCTP) [36]. These phosphorylated nucleotides are
retained inside cells [37]. Gemcitabine nucleotides inhibit deoxycytidine monophosphate
(dCMP) deaminase and ribonucleotide reductase (RR). dCMP deaminase is responsible
for production of deoxyuridine monophosphate (dUMP) from dCMP and RR is essential
for the de novo synthesis of the deoxyribonucleotides required for DNA replication [35].
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Thus, gemcitabine inhibits cellular DNA synthesis and induces DNA fragmentation and
apoptosis in cells [38].
1.3.2

Radiation
Invention of the linear accelerator in 1960 was a major breakthrough that made

radiotherapy an invaluable treatment modality for local and regional tumours [7]. Today,
radiation is used to treat approximately 50% of all cancer patients. Patient outcome after
radiation varies among different cancers and different stages of the disease. For example,
patients with early stage NSCLC have a much higher survival rate after radiotherapy
compared to patients with late stage NSCLC [39]. Also, and despite all the advances in
radiation techniques, radioresistant tumours are common and there exists an urgent need
to increase tumour responsiveness and sensitivity to radiation treatment [39].
1.3.3

Immunotherapy
The concept of cancer immunotherapy dates back to the late nineteenth century

when William B. Coley tested cancer treatments involving administration of live and
heat-killed bacteria and bacterial components systemically or directly into human
tumours [40]. Cancer immunotherapy attempts to harness the power of the immune
system to destroy cancer cells [41]. Cytokines such as interleukin-2 (IL-2) and interferon
α (IFNα) are already being used in clinic to treat melanoma patients [41]. IL-2 is
primarily involved in T cell proliferation and immune regulation [42]. IL-2 therapy is
approved for hematological malignancies as well as renal cell carcinoma [41]. IFNα is a
type I IFN with multiple functions including induction of apoptosis, as well as inhibition
of proliferation and angiogenesis in treated cells [43].
Monoclonal antibodies are currently also used in clinical practice. For example,
trastuzumab (Herceptin) is a monoclonal antibody that targets Her2 on the cell surface
and is often used to treat breast cancer. Rituximab is another antibody that targets the B
cell surface marker CD20. Rituximab is therefore approved for the treatment of B cell
lymphoma [44]. These antibodies can directly induce apoptosis [41], or inhibit the
proliferation of the tumour cells by blocking growth factor receptors [45]. Furthermore,
monoclonal antibodies can indirectly contribute to the destruction of the tumour by
6

recruiting cytotoxic cells of the immune system, such as macrophages, natural killer (NK)
cells and T cells to the tumour microenvironment [46, 47].
A recent advancement in the field of tumour immunotherapy is the reprograming of
T lymphocytes to target specific antigens (Ags) on the surface of tumour cells by
chimeric antigen receptors (CARs) [48]. CARs are genetically designed constructs
consisting of an Ag-specific antibody molecule that is linked to a T cell signaling domain
that can be accompanied by a co-stimulatory signal that significantly improves the
activation of CAR-expressing T cells [49]. Since CAR-expressing T cells recognize their
target cell in a major histocompatibility complex (MHC)-independent fashion, exploiting
the antigen-specific properties of the monoclonal antibody, they are not affected by MHC
downregulation at the surface of the tumour cells, a phenomenon common in most human
cancers [49].
Another common immunotherapy approach is to design vaccines that could either
increase tumour immune recognition or enhance T cell antitumour function [50]. Tumour
vaccines include whole tumour cell lysates [51], recombinant viral vectors that encoded
tumour Ags [52], dendritic cells (DCs) loaded with tumour Ags [53], DNA vectors
encoding tumour Ags [54], and synthetic peptides [55]. Most cancer vaccines have failed
to extend the overall survival of patients [56]. However, two new immune-based
treatments -- sipuleucel-T and ipilimumab have demonstrated the capacity to achieve this
endpoint – and have now been approved by the US Food and Drug Administration (FDA)
for the treatment of patients with metastatic prostate cancer and melanoma, respectively,
and have focused recent attention to cancer immunotherapy [57]. Sipuleucel-T is a
cellular immunotherapy that relies on the patient’s own antigen presenting cells (APCs)
that have been activated in vitro with recombinant human prostatic acid phosphatase
(PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [58]. PAP is
expressed in ∼95% of prostate cancers and is primarily limited to the prostate. GM-CSF,
on the other hand, is a major activator of immune cells, especially of the granulocyte and
macrophage lineage, and acts as an immune adjuvant [59]. Patients who received
sipuleucel-T showed a 4.1 month increase in their median overall survival compared to
patients receiving placebo [58]. Ipilimumab, on the other hand, is an anti-cytotoxic T
lymphocyte antigen 4 (CTLA-4)-blocking antibody approved by the FDA in 2011 for the
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treatment of metastatic melanoma [60]. CTLA-4 is expressed on T cells and when bound
to B7 ligands (CD80 and CD86) on APCs, induces inhibitory downstream T cell receptor
signaling which inhibits T cell function [61]. CTLA-4 is also expressed on the surface of
CD25+ FOXP3+ T regulatory cells (Tregs) and is important to their immune suppressive
function [60]. Ipilimumab-mediated blocking of CTLA-4 increases T cell function and
depletes Tregs [62]. Since ipilimumab’s mechanism of action is independent of the tumour
type and is specific to T cells, this drug is also being investigated for treatment of prostate,
lung, renal, and breast cancers [60].
1.3.4

Combination treatments of cancer
All three treatment modalities described above have the capacity, alone or in

combination, to inhibit tumour growth partially or completely or to ablate tumours
completely (temporarily or permanently). However, none is effective or curative in all
cases, and its effectivness depends on histologically and molecularly defined tumour type
and tissue origin. Because most human tumours develop resistance to individual
therapeutic agents [63-65], combining multiple treatment methods (applied concurrently
or sequentially) can at least partially reduce the risk of developing treatment resistance,
and the development of new treatment combinations is an important and promising
strategy to improve cancer therapy. Optimally-timed combination treatment of NSCLC
cells with low dose erlotinib and paclitaxel eliminated tumour populations that were
otherwise resistant to monotherapy with each drug at the same dose [66]. This is partially
because combination therapy can avoid or delay the evolution of drug resistance in a
given cancer cell. Moreover, applying high concentrations of a given drug to achieve fast
tumour reduction rate is not necessarily the best strategy in the long term, as this could
impose maximal selective pressure for evading mutations and acquiring resistance
phenotypes in cancer cells. Therefore, using a combination of lower doses of multiple
drugs can possibly delay the acquired resistance phenotype in a given tumour [66].
Until recently, combining chemotherapy and immunotherapy was considered
antagonistic [67] for two main reasons. First, chemotherapy reduces lymphocyte counts
to an abnormally low level (lymphocytopenia), which results in an overall reduction in
some forms of immune function due to the treatment imposed immunodeficiency [68].
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Second, it was widely accepted that most chemotherapies exert their effect by inducing
apoptosis in cancer cells [69], an event that avoids immune stimulation and promotes
immune quiescence and tolerance of tumour cell presence in host organisms [67]. This
could negatively impact tumour immune surveillance (i.e., the ability of the immune
system to recognize and eliminate neoplastic cells, thereby protecting the body from
cancer by functioning as an extrinsic immune suppressor) [70]. However, recent
advances in our understanding of the immune system make it clear that therapy-induced
inhibition and death of immune cells, and the nature of therapy-induced tumour cell death,
do not necessarily exclude combined chemo- and immunotherapy. In fact, chemotherapy
can, under some circumstances, both induce tumour cell death and induce strong immune
responses to cancer cells [67]. For example, chemotherapy-mediated lymphocytopenia
induced memory CD8+ T cell proliferation and decreased Tregs in the patients with a
positive clinical response to temozolomide (TMZ) [71]. Moreover, CD8+ T cell responses
against specific melanoma Ags were enhanced in patients after chemotherapy, while their
virus-specific T cell responses remained the same [71]. Thus, antitumour immune activity
can be maintained or even increased in the face of cytotoxic antitumour chemotherapy
[72]. Furthermore, low dose radiation enhances T cell tumour infiltration by normalizing
tumour vasculature in melanoma xenografts and mouse pancreatic carcinoma [73].
1.4

Cancer Treatment Resistance
Cancer cells within heterogeneous tumour cell populations harbour mutations that

can provide fitness advantages to those subpopulations [74]. Under selective pressure
imposed by growth conditions and/or administration of therapeutic agents in host
organisms, resistant subpopulations can be selected for preferential survival and growth
[74]. Some of the more common mechanisms mediating treatment resistance in cancer
cells are described below.
1.4.1

Resistance to Chemotherapy
The effectiveness of chemotherapy is often limited by undesirable, off-target

toxicities to normal cells, and by the ability of cancer cells to develop resistance to
therapies. There are multiple ways a cancer cell becomes resistant to a given
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chemotherapy drug. Here I describe some of the more common mechanisms of resistance
to chemotherapy. For example, some cancer cells express a drug efflux pump also known
as p-glycoprotein (P-gp), which is ATP-dependent [10]. P-gp is widely expressed among
human cancer cells and is coded by the MDR1 gene [10]. P-gp is capable of binding to a
wide variety of hydrophobic drugs and then releasing them out of the cell and into the
extracellular matrix. Multidrug resistance-associated protein-1 (MRP-1) is another drug
efflux pump and a member of the ATP-binding cassette (ABC) transmembrane
transporter superfamily that is composed of 9 proteins expressed by some cancer cells [75,
76]. Other proteins of this superfamily are all related to MRP-1 based on gene sequence.
These include, among others, MRP-4, MRP-5, MRP-6, MRP-7, MRP-8, and MRP-9.
MRP-7, for instance, is a lipophilic anion transporter that confers resistance to some
natural anticancer agents such as docetaxel, paclitaxel, vinblastine, and vincristine [77].
MRP-8 confers resistance to nucleoside-based analogs including 5FU and 5FUdR [78].
Another important ABC family member is breast cancer resistance protein (BCRP). Even
though this protein is expressed by most normal tissues including breast, lung, placenta,
small intestine, and liver [79], it was first isolated from a resistant breast cancer cell line,
hence its name [80]. In normal tissues, BCRP is involved in toxin and xenobiotic efflux
as a defensive mechanism [81]. BCRP is expressed in a wide range of hematopoietic and
solid tumours and its expression is frequently correlated with poor patient outcome and
chemotherapy-resistant disease [80]. In general, cancer cells expressing efflux pumps
exhibit reduced sensitivity to multiple drugs [10]. Mutations that alter cell surface
molecules, such as mutations in folate binding protein and/or reduced folate transporter,
reduce their ability to bind to chemotherapeutic drugs and this can also confer resistance
to drugs such as methotrexate [82].
Many other mechanisms of tumour cell drug resistance have been identified in
addition to those involved in drug efflux or influx. First, overexpression of glutathione
and glutathione s-transferases (GST) that are involved in thiol-mediated detoxification of
anticancer drugs is also a known drug resistant mechanism in many cancer cells,
especially against platinum-based drugs such as cisplatin [83, 84]. Second, chemotherapy
drugs exert their effects by induction of apoptosis [69]. However, some cancer cells can
become resistant to apoptosis mainly by downregulation or loss of pro-apoptotic
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molecules or by expressing anti-apoptotic proteins [85]. For example, increased
expression of the B cell lymphoma-2 (BCL-2) anti-apoptotic protein has been attributed
to resistance to many chemotherapy drugs and ionizing radiation [86]. Another major
resistance mechanism that is most relevant to this thesis is the ability of cancer cells to
repair their DNA after chemotherapy-induced DNA damage. DNA repair mechanisms
related to this thesis will be discussed in more detail later. In addition, most DNA repair
mechanisms in cancer cells also play major roles in conferring resistance to
chemotherapy drugs. For example, BER plays a vital role in tumour cell resistance to the
alkylating agent TMZ. DNA lesions that are induced by TMZ are mostly N-methylated
bases that are normally recognized by DNA glycosylase members involved in BER.
Therefore, TMZ therapeutic efficiency depends on the specific activity of BER in
targeted tumour cells [87].
1.4.2

Resistance to Radiation
Radiation causes single and double strand breaks (SSBs and DSBs), damaged

bases, and DNA abasic sites (i.e., sites where a base has been lost). Both normal and
cancer cells can repair these forms of DNA damage by BER [88, 89]. Ionizing radiation
enhances the activity of BER proteins at the G1 phase of the cell cycle. These proteins
help to repair the damaged bases and inhibit radiation-induced cell killing [90]. BER
proteins include human endonuclease III that removes damaged bases from DNA; DNA
glycosylase that recognizes deoxyguanosine lesions; and apurinic/apyrimidinic
endonuclease (APE1) that is involved in recognition and processing of abasic sites [90,
91]. A key protein in the BER pathway that is mainly involved in radioresistance is poly
ADP ribose polymerase-1 (PARP-1) [92]. Radiation-induced DNA damage increases the
activity of PARP-1 in cancer cells. Therefore, blocking PARP-1 activity or BER in
cancer cells by treating the cells with PARP inhibitors [93] or other drugs that can block
BER such as methoxyamine (MX) [94] is a strategy that enhances the radiation treatment
outcome [95]. Another DNA repair mechanism that is involved in radioresistance is HRR
[96]. For example, overexpression of Rad51 (an HRR protein) is associated with
radiation resistance in breast cancer type-2 susceptibility protein (BRCA2)-defective
cancer cells [97].
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All the aforementioned DNA repair mechanisms that are involved in resistance to
radiation were, in studies presented in this thesis, subjected to inhibition studies in order
to sensitize cancer cells to various treatment methods [98] and are discussed in more
detail below.
1.4.3

Resistance to Immunotherapy
Cancer immunotherapy, like other cancer treatment strategies, can lead to

emergence of resistant cancer cells that hinder treatment effectiveness [99]. There are
multiple barriers that could undermine effective immunotherapy, and the likelihood of
their development is based on the nature of the immunotherapeutic approach [41].
However, some of these barriers are more common; for example, the presence of Tregs in
the tumour microenvironment and tumour draining lymph nodes (TDLNs) [100] can
effectively suppress tumour-specific CD8+ T cells at TDLNs, thus suppressing the
mounting antitumour response even after adoptive transfer of tumour-primed CD4+ T
cells in mice [101]. Another common mechanism that contributes to the failure of cellular
immunotherapy or tumour vaccination is the loss of MHC class I on the surface of cancer
cells. CD8+ T cells recognize their targets by examining the MHC-peptide complex on
cell surfaces; however, cancer cells have evolved to lose their MHC molecules as a
common mechanism of immune evasion [101]. Fortunately, this phenomenon can be
avoided by using CAR-expressing T cells for adoptive transfer as described earlier [73].
Tumour cells also develop abnormal and hyperpermeable vasculature that hinders T cell
access to tumours. Furthermore, tumour release of vascular endothelial growth factor
(VEGF) inhibits T cell migration towards tumours from the vasculature [73].
Normalization of tumour vasculature by anti-VGEF therapy can significantly increase the
effectiveness of tumour immunotherapy [102].
1.5

Indoleamine 2,3-dioxygenase

The immunoregulatory molecule IDO is a 45 kDa hemoprotein that is essential for
oxidative catabolism of tryptophan in the kynurenine pathway [103]. IDO catalyzes this
step by the oxidative cleavage of the 2,3-double bond in the indole moiety of Ltryptophan, resulting in the production of the first kynurenine pathway metabolite, N12

formyl kynurenine (Figure 1.1) [104]. IDO has broad substrate specificity because of its
ability to degrade indoleamine derivatives, including L- and D-tryptophan, serotonin,
melatonin, and tryptanine [105]. IDO degradation of tryptophan in the kynurenine
pathway forms a series of biologically active metabolites such as quinolinic acid (QA),
kynurenic acid (KA), and 3-hydroxykynurenine [106]. QA acts as an agonist of Nmethyl-D-aspartate (NMDA) receptors, for glutamate. QA is also neurotoxic and induces
death in neurons through apoptosis and necrosis [107]. KA is another metabolite of the
kynurenine pathway and is an antagonist of NMDA and nicotinic acetylcholine receptors.
Both QA and KA are assumed to be active at peripheral sites outside the nervous system
because of the presence of NMDA receptors in the periphery [106]. In addition to the
above, 3-hydroxykynurenine is another neurotoxic byproduct of the kynurenine pathway
capable of generating free radicals [108]. QA produced from IDO catabolism of
tryptophan can be converted to NAD+ in monocytic cells including macrophages and
microglia. Therefore, IDO can provide a source of NAD+ to cells from tryptophan
catabolism [109]. In mice, IDO protein can be naturally found in various organs
including prostate, epididymis, uterus, colon, lung, spleen, and bladder [110]. In humans,
IDO can also be found in different tissues including lung, placenta, and small intestine
[111, 112]. However, IDO can be induced in most human cells, especially APCs by
inflammatory cytokines such as interferon gamma (IFNγ), tumour necrosis factor (TNF)α and infections [113, 114]. IDO expression in cells is tightly regulated at the
transcriptional and post-translational levels. IDO mRNA transcription is promoted by
factors such as interferon regulatory factor (IRF)-8 and the transcription factor Forkhead
box O3 (FOXO3) [115, 116]. DNAX-activation protein 12 (DAP12), on the other hand,
suppresses IDO mRNA transcription in cells [116]. The regulatory factor suppressor of
cytokine signaling 3 (SOCS3) binds to IDO protein and marks it for ubiquitinylation and
degradation [117]. The main function of IDO is to regulate the immune system and
suppress the inflammatory response of the immune cells that will be discussed below.
1.5.1

IDO and the Immune System

IDO promotes innate immunity during host-pathogen interactions, while it inhibits
adaptive immunity through suppressing pro-inflammatory responses [103]. Most
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intracellular pathogens such as Listeria monocytogens depend on host tryptophan for
replication [118]. As part of its role in innate immunity, IDO can directly suppress
pathogen replication by limiting the availability of tryptophan. IDO therefore plays a vital
antimicrobial role in suppressing the infection of Toxoplasma gondii [119], Listeria
monocytogens [118], and many other intracellular pathogens. However, IDO’s role in
adaptive immunity is mainly to suppress lymphocytes [103]. It mainly modifies immune
response by two means: first, by depleting tryptophan in the cellular environment that
would otherwise trigger amino acid-sensing signal transduction pathways in immune
cells. This depletion leads to an arrest of T cell proliferation [120]. Second, IDO produces
kynurenine products that are toxic for T cells and this induces their death via apoptosis
[103]. IDO’s rapid consumption of tryptophan from the local microenvironment triggers
a regulatory signal in T cells by inhibiting or activating molecular stress response
pathway mediators, such as the mammalian target of rapamycin (mTOR) and general
control non-repressed (GCN)-2 kinase, respectively [103]. The GCN2 molecule responds
to elevated levels of uncharged tRNA induced by tryptophan insufficiency [120]. GCN2
phosphorylates eukaryotic initiation factor (eIF2α). Phosphorylation of eIF2α results in
general inhibition of most mRNA translation in the cell, thus blocking protein synthesis
and arresting cell growth [121]. GCN2 activation in CD8+ T cells leads to cell cycle
arrest and anergy [120], but its role in CD4+ T cells is more complex. Activation of
GCN2 in CD4+ T cells blocks the differentiation of T helper (TH) 17 cells [122], but
promotes differentiation and enhances the function of Tregs. IDO, therefore, also appears
to suppress activated T cells by increasing the number and enhancing the function of Tregs
(Figure 1.1) [123, 124].
On the other hand, IDO-mediated production of kynurenine metabolites can
directly induce apoptosis in lymphocytes [125] and appears to suppress the activated T
cells in three major ways. First, kynurenine metabolites promote the differentiation of
Tregs by activating aryl hydrocarbon receptor (AHR), a central player in T cell
differentiation [126]. Second, kynurenine-mediated AHR activation can directly suppress
tumour-infiltrating CD8+ T cells [127]. Third, kynurenine metabolites negatively impact
the immunogenicity of DCs [128]. Moreover, IDO appears to have additional, nonenzymatic functions, including a signaling role in transforming growth factor (TGF) β14

induced tolerance in plasmacytoid DCs [129]. IDO was originally reported to prevent
allogeneic fetal rejection in mice, which is consistent with its expression in the placenta
[130]. It suppresses the alloresponse and attenuates allograft rejection [131, 132].
Furthermore, IDO expression by APCs prevents graft versus host disease (GVHD) [133].
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Figure 1. 1. IDO function. IDO is primarily involved in the breakdown of tryptophan in
the body. IDO also suppresses immune cells through its enzymatic and signaling
functions. Tryptophan depletion and production of kynurenine metabolites directly
induces anergy and apoptosis in T cells and NK cells. IDO also causes CD4+ T cells to
reprogram to Tregs that further suppress CD8+ T cells. IDO signaling also induces a stable
regulatory phenotype in plasmacytoid DCs that further suppresses T cells (Figure
modified from [108]).

17

18

Figure 1. 2. IDO suppression of immune cells. IDO decreases the activity of cytotoxic
T cells, NK cells, and mature DCs via tryptophan depletion, toxic tryptophan catabolites,
and induction of Tregs, MDSCs, immature DCs, and TAMs. Treg = T regulatory cell;
MDSC = myeloid-derived suppressor cell, TAM = tumour-associated macrophage,
immature DC = immature dendritic cell, mature DC = mature dendritic cell, NK cell =
natural killer cell, CD8+ T cell = cytotoxic CD8+ T cell, IDO = indoleamine 2,3dioxygenase (Figure modified from [134]).
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1.5.2

IDO and Cancer
Most human tumours express IDO [135], which contributes to tumour-induced

tolerance and suppression of the immune system (Figure 1.2 and Table 1.1). The tumour
suppressor BAR adapter-encoding gene Bin 1 is commonly mutated in cancers [136]. Bin
1 genetically controls IDO. Transient or stable downregulation of Bin 1 enhances the
basal and IFNγ-induced activity of the IDO promoter in cancer cells and macrophages.
Conversely, ectopic expression of Bin 1 cDNA reverses IDO promoter activity in the
same type of cells [136]. IDO induces a tolerogenic state in the tumour microenvironment
and tumour-draining lymph nodes [134]. Tumour-draining lymph nodes are sites vital for
T cell activation. Therefore, IDO expression by APCs at these sites effectively suppresses
naïve T cells before they can become fully activated. Furthermore, IDO-expressing APCs
induce Tregs at tumour-draining lymph nodes, thus enhancing the tolerogenic environment
against effector T cells [134].
In the majority of patient studies, IDO expression has been correlated with
decreased overall survival and decreased progression-free survival of the patients. For
example, in one study, IDO expression was evaluated in samples from 138 patients with
hepatocellular carcinoma. Lower IDO expression was correlated with high overall
survival in the studied cancer patients [137]. Moreover, IDO has been linked to increased
metastasis in various human cancers including NSCLC, breast cancer, and colorectal
cancer [138-140]. Colorectal cancer patients with high tumour IDO levels have a higher
rate of hepatic metastasis than patients with low IDO levels [140]. IDO was also
associated with distant metastases in patients with hepatocellular tumours [137].
Interestingly, high IDO expression was found in advanced stages of disease in patients
with ovarian cancer, nasopharyngeal carcinoma, and endometrial cancer [141-143].
IDO is also important in developing resistance to immunotherapy. The antiCTLA-4 antibody ipilimumab, described earlier, is effective only in a subset of
melanoma patients, suggesting that most melanoma cells are either intrinsically resistant
or develop resistance to this novel immunotherapy drug. It has been suggested that IDO
plays a major role in resistance to ipilimumab [144]. In fact, in two different mouse
tumour models (B16 melanoma and 4T1 mammary carcinoma) the anti-tumour effects of
ipilimumab were significantly greater in IDO knockout mice and wild type mice treated
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with the IDO inhibitor 1-methyl tryptophan (1-MT) than controls [144]. Melanoma
tumours overexpressing IDO were resistant to antibody blockage of CTLA-4. However,
the IDO inhibitor 1-MT could effectively reverse this phenomenon in vivo. The
protective role of IDO inhibition depended on the presence of both CD8+ T cells and
IFNγ in the same system [144].
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Table 1. 1. Many human tumours express IDO. Human tumour samples were analyzed
for IDO protein levels (table modified from [135]).
Tumour Type

IDO protein
(IDO+/total tumours assayed)

Prostatic carcinomas

11/11

Colorectal carcinomas

10/10

Pancreatic carcinomas

10/10

Cervical carcinomas

10/10

Endometrial carcinomas

5/5

Gastric carcinomas

9/10

Glioblastomas

9/10

NSCLC

9/11

Bladder carcinomas

8/10

Ovarian carcinomas

8/10

Head and Neck carcinomas

7/11

Esophageal carcinomas

7/10

Mesotheliomas

6/10

Renal cell carcinomas

5/10

Melanoma

11/25

Breast carcinomas

3/10

Thyroid carcinomas

2/10

Lymphomas

4/18

Small-cell lung carcinomas

2/10

Sarcomas

2/10

Hepatocarcinmas

2/5

Adrenal carcinomas

2/5

Choriocarcinomas

1/5

Cutaneous basocellular carcinomas

1/5

Testicular seminomas

0/5
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1.5.3

IDO Inhibitors
There is compelling evidence that IDO plays a major role in suppressing the

immune system during cancer progression [145]. Because IDO has been linked to higher
rates of metastasis and poor patient outcome, it is an attractive target for cancer treatment
[146]. Thus, the search for IDO inhibitors has become a very active area of research,
particularly since the seminal work of the Van den Eynde group in 2003 that showed IDO
could confer immunoresistance in tumours [135]. The best-known IDO inhibitor at that
time was 1-MT, discovered in 1991, which is a tryptophan derivative with an affinity in
the micromolar range (Ki ∼ 34 µM) [147]. The first IDO inhibitor to enter a phase I
clinical trial, in 2008, was the D-stereoisomer of 1-MT (D-1MT; NLG8189).
Unfortunately, the L-stereoisomer of 1-MT (L-1MT) was shown later to be an IDO
inhibitor while the D-1MT tested in the clinical trial is not [148, 149]. Regardless, D1MT is currently undergoing phase II clinical trial for treatment of prostate cancer and
metastatic breast cancer [150]. D-1MT can also bind and inhibit IDO2, a putative
paralogue of IDO1 (IDO), although the physiological relevance of IDO2 in cancer in not
well understood [150]. Another breakthrough in developing novel IDO inhibitors took
place in 2006, when the 3-dimensional structure of IDO complexed with 4phenylimidazole (PIM) and cyanide ion (CN-) was elucidated [104]. PIM was discovered
earlier as a modestly potent IDO inhibitor, which bound to the active site of IDO and
inhibited its enzymatic activity in a non-competitive manner [151]. The discovery of
three-dimensional structures of IDO, complexed with PIM and CN-, provided vital
information for the structure-based drug design of novel IDO inhibitors [104]. In fact, the
discovery of most newer IDO inhibitors originated from detailed analysis of the structural
interaction between IDO and PIM.
Three major companies have led in the discovery of IDO inhibitors in recent
years: 1) Newlink Genetics, focused mainly on phenyl-imidazole-derived compounds.
They produced a number of soluble IDO inhibitors with activities in the nanomolar range.
None of these compounds has yet progressed to clinical trials, 2) The Ludwig Institute for
Cancer Research (LICR) works mainly on PIM analogues such as phenyl-trizoles and a
series of amino-hydroxyquinolines, which have also not yet progressed to clinical trials,
and 3) Incyte Corp, which has discovered a number of active IDO inhibitors with activity
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in the nanomolar range. Their main focus is on a series of hydroxyamidines including
INCB24360 which is under phase II clinical testing [150]. INCB24360 effectiveness has
been assessed in comparison to tamoxifen treatment in recurrent ovarian cancer patients
[150]. Patients with myelodysplastic syndrome (MDS) were reported to have elevated
tryptophan metabolites in their sera. Incyte Corp, therefore, is planning to assess whether
INCB24360 is effective in MDS patients and whether it inhibits hematopoietic progenitor
amplification in these patients [152].
There are certain challenges to discovering IDO inhibitors. First, IDO’s active site
topology is resistant to a high degree of inhibition. This is because of the relatively small
size of IDO, which hinders the binding of large inhibitor molecules [153]. Second, IDO
inhibition kinetics are not completely understood. Some IDO inhibitors were reported to
bind IDO in a competitive manner and others in a non-competitive way [154]. Some
inhibitors have been shown to bind IDO based on a redox activity [155, 156]. Therefore,
designing better drug candidates requires a better understanding of IDO inhibition
kinetics. The third and major challenge in developing a promising IDO inhibitor is the
ability to translate the results of IDO inhibitors from preclinical studies into clinical
settings, which requires compounds with appropriate bioavailability and low toxicity
profile [157]. The encouraging aspect of blocking IDO is the mild nature of unfavorable
side effects [157]. Importantly, there is no sign of development of spontaneous
autoimmunity in IDO knockout mice [157]. Furthermore, the side effects of D-1MT
during phase I clinical trials were generally mild, including reports of easily managed
hypophysitis [150].
In addition to small molecule inhibitors, antisense targeting of IDO mRNA has
been investigated in a number of preclinical settings using small interfering RNA
(siRNA) and short hairpin RNA (shRNA). For example, siRNA knockdown of IDO
mRNA in B16F10 mouse melanoma cells in vitro inhibited the enzymatic function of
IDO and thus prevented tryptophan catabolism [158]. B16F10 cells cocultured with CD4+
and CD8+ T cells in vitro induced apoptosis in both T cell subsets. However, siRNA
downregulation of IDO significantly reduced apoptosis in T cells [158]. IDO
downregulation in B16F10 melanoma cells, before tumour inoculation into mice, slowed
tumour growth in vivo. Interestingly, siRNA knockdown of IDO was more protective
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than 1-MT in inhibiting IDO function in cancer cells [158]. Intratumoural administration
of IDO siRNA in established tumours significantly delayed growth and decreased tumour
size. These results were attributed to the effect of IDO inhibition in reinstalling an
antitumour immune response against melanoma in mice [158]. Skin delivery of IDO
siRNA in tumour-bearing mice inhibited IDO mRNA in DCs and effectively delayed
bladder tumour growth in syngeneic mice [159]. Animals treated with IDO siRNA had a
significant increase in their survival rate compared to the control group. Interestingly,
local IDO siRNA treatment was more effective than systemic administration of L-1MT in
IDO inhibition. The therapeutic effect of IDO siRNA in this model was attributed to
CD8+ T cells, since depletion of these cells abolished the protective effect of IDO siRNA
[159]. In another study, IDO shRNA was shown to be effective in impeding tumour
growth in three mouse models of liver cancer, including subcutaneous, orthotopic, and
metastatic disease [160]. The cytotoxic function of CD8+ T cells and NK cells was
improved following IDO shRNA skin delivery [160]. In addition, IDO shRNA treatment
of tumour-bearing animals increased the serum mRNA levels of proinflammatory
cytokines IL-12 and IFNγ (both important in anti-tumour immunity) and decreased IL-10
mRNA levels that suppresses anti-tumour responses [160].
1.5.4

IDO Inhibition to Improve Chemotherapy and Radiation

In a mouse transgenic model of breast cancer in which tumours were induced by
expression of the oncogene Neu under the control of the mouse mammary tumour virus
(MMTV) promoter, IDO inhibition with 1-MT has been combined with paclitaxel, a
chemotherapeutic agent commonly used to treat breast cancer [136]. The combination
resulted in tumour regression in tumour-bearing animals [136]. This effect was greater
than using 1-MT or paclitaxel alone. In addition, each agent was effective at a lower dose
than its maximally tolerated dose. Analysis of tumour sections showed evidence of higher
tumour cell death in the combination group. Strikingly, depletion of CD4+ T cells or the
use of T cell-deficient athymic mice instead of immunocompetent mice abolished the
effect of combined treatment, indicating that an immune-mediated effect was involved in
blocking IDO in the context of paclitaxel treatment [136]. In the same study, the effect of
combining 1-MT with other chemotherapy agents with broad mechanisms of action that
25

are used to treat breast cancer was examined. 1-MT improved the therapeutic effect of
cisplatin, cyclophosphamide, and doxorubicin (Table 1.2). The authors of the study
concluded that combining IDO inhibition with a diverse group of chemotherapeutic
agents could effectively increase their therapeutic activity in the treatment of breast
cancer [136].
Several clinical studies have suggested that high IDO levels during treatment
could be related to a poor response to chemotherapy and/or radiotherapy and perhaps
contribute to resistance to therapy. In a single arm phase II study in patients with stage III
NSCLC, serum kynurenine/tryptophan levels were measured as a surrogate marker for
IDO activity during treatment [161]. Patients were treated with induction gemcitabine
and carboplatin and then received concurrent carboplatin, paclitaxel, and 74 Gray (Gy)
thoracic radiation. Cancer patients showed high IDO activity compared to healthy
controls. This high IDO activity after chemotherapy was associated with poor patient
outcome. However, the power of this study was limited by the relatively low number of
patients and therefore low statistical power [161]. In another study, IDO was positively
associated with chemoresistance in a gene expression profiling study that aimed to
identify molecules associated with resistance to paclitaxel-based chemotherapy in ovarian
cancer cell lines and refractory surgical ovarian cancer specimens [162]. IDO was highly
expressed in both paclitaxel-resistant cell lines and refractory ovarian tumours but was
absent in paclitaxel-sensitive cell lines and tumours [162]. In a clinical study that
analyzed NSCLC patient response to platinum-based chemotherapy in a small cohort of
patients, IDO expression in monocytes and granulocytes was analyzed pre- and posttreatment. The patient population that benefited from the treatment showed lower IDO
expression in blood monocytes post-treatment [163]. All the aforementioned studies
provide a rationale for IDO inhibition in order to sensitize tumour cells to chemotherapy
and radiation.
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Table 1. 2. IDO inhibition increases the effectiveness of certain chemotherapeutic
drugs in the presence of the immune system in a mouse model of breast cancer.
Tumour-bearing MMTV-Neu mice were treated with or without the IDO inhibitor 1-MT
in combination with the indicated chemotherapy agents. IDO inhibition potentiated the
effect of cisplatin, cyclophosphamide, doxorubicin, and paclitaxel. (* p < 0.05) (Table
adapted from [136]).
Compound

Class

Mean Tumour
Volume ± SEM
(+ 1-MT)

Mean Tumour
Volume ± SEM
( - 1-MT)

Cisplatin

Alkylating agent

0.77 ± 0.18

1.7 ± 0.33

Cyclophosphamide

Alkylating agent

0.81 ± 0.12

1.4 ± 0.18

0.79 ± 0.07

1.5 ± 0.25

Doxorubicin

Antineoplastic
antibiotic agent

5FU

Antimetabolite

1.2 ± 0.20

1.1 ± 0.25

Methotrexate

Antimetabolite

1.7 ± 0.28

1.7 ± 038

Paclitaxel

Mitotic inhibitor

0.68 ± 0.11

2.4 ± 0.43

Vinblastine

Mitotic inhibitor

1.3 ± 0.19

1.2 ± 0.18

0.67 ± 0.11

1.0 ± 0.16

0.97 ± 0.07

0.99 ± 0.25

FTI
Rapamycin
Tetrathiomolybdate
Vehicle

Signal transduction
inhibitor
Signal transduction
inhibitor
Antiangiogenic

1.9 ± 0.52
1.7 ± 0.17

2.0 ± 0.42
3.0 ± 0.44
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1.6

DNA Repair
DNA is the source of all genetic information in cells and its integrity is vital to life

[164]. DNA integrity, however, can be reduced by the action of damaging environmental
agents (e.g., ultraviolet [UV] light) and/or reduced cellular capacity for high fidelity
DNA replication. The resulting DNA damage, whether it be caused directly or indirectly
from faulty DNA repair, if not corrected, will result in mutation and possible
development of genetically-based diseases such as cancer [164]. Cells have evolved
various DNA repair mechanisms that are responsible for detection and repair of DNA
damage, independent of the damage source but related to the type of lesion [164]. At a
minimum, mammalian cells utilize five forms of DNA repair to cope with various types
of DNA lesions: BER, mismatch repair (MMR), NER, and double-strand break repair,
which includes both HRR and non-homologous end joining (NHEJ) [165]. This section
contains a brief description of DNA repair mechanisms relevant to this thesis and specific
molecules relevant to those mechanisms, including PARP, TS, and NAD+.
1.7

Base Excision Repair
The BER pathway repairs base lesions and SSBs induced by deaminating,

alkylating, and oxidative agents [166]. BER starts with identification of damaged bases
by a DNA glycosylase. The glycosylase catalyzes the cleavage of an N-glycosidic bond
to remove the damaged base to create an apurinic or apyrmidinic site (AP site) in the
DNA strand [167]. A DNA AP endonuclease or DNA AP lyase then cleaves the DNA
backbone resulting in a SSD nick 5’ or 3’, respectively, to the AP site. The processing
activity of the AP endonuclease converts the newly-formed nick into a single-nucleotide
gap. DNA polymerase β (PolB) uses the correct nucleotide to fill in the gap; polymerase
activity is facilitated by the 3’-hydroxyl and a 5’-phosphate groups of bases flanking the
gap. A DNA ligase completes the final repair process by sealing the nick (Figure 1.3)
[167].
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There are two forms of BER: short-patch and long-patch. The difference between
them lies mainly in the enzymes that are involved in the repair process [167]. Cells
choose to proceed with either repair process based on the relative ATP concentration
adjacent to the AP site and the effectiveness of the AP lyase activity of PolB [168] .
Short-patch BER occurs more frequently at high ATP concentrations, whereas long-patch
BER is the preferred mechanism at low ATP levels [168]. The second determining factor
for cells to choose between short and long patch repair is the presence or absence of the
5’-terminal deoxyribophosphate (dRP) intermediate that is produced by the AP
endonuclease. Efficient removal of the dRP by PolB lyase activity leads to short-patch
BER. However, failure to successfully remove the dRP results in long-patch BER,
forming nicks that are refractory to DNA ligase action [168-170]. X-ray repair crosscomplementing protein 1 (XRCC1) is among the first proteins to be recruited to the nick
generated by the activity of either glycosylase and/or AP endonuclease. This scaffold
protein modulates the ATP concentration near the nick and coordinates short-patch BER
[171]. Moreover, it interacts with ligase III and PolB [171, 172]. Long-patch BER, on the
other hand, requires proliferating cell nuclear antigen (PCNA). This abundant nuclear
protein coordinates the long-patch BER process by interacting with DNA polymerases δ
and ε (PolD and PloE) and flap structure-specific endonuclease 1 (FEN1). Resistance of
dRP to cleavage by PolB results in a switch to PolD or PolE. These DNA polymerases
add 2-8 extra nucleotides into the repair gap, which generates a flap structure. This
structure is then removed by FEN1 in a PCNA-dependent manner. Eventually, DNA
ligase I seals the nick and completes the repair process [170, 173].
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Figure 1. 3. The BER pathway. DNA glycosylase identifies and removes damaged
bases, leaving an AP site. The AP site is then cleaved by DNA AP endonuclease leaving
a gap in the DNA backbone. PolB then fills the gap with the correct nucleotide, based on
its complementarity with the bound DNA strand. Finally, DNA ligase seals the nick and
completes the repair (Figure adapted from [167]).
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1.7.1

Base Excision Repair and Cancer
Cancer cells are highly dependent on DNA repair for survival. Many alkylating

agents create DNA adducts. Cancer cells need to excise and repair these adducts before
DNA replication can occur [174]. BER executes this vital function in cancer cells. BER,
therefore, plays a crucial role in mediating resistance to many DNA-damaging cytotoxic
drugs in cancer cells [174]. In fact, many BER proteins are overexpressed in human
cancers and increased resistance to therapy has been attributed to their action [175]. For
example, AP endonuclease levels are elevated in ovarian cancer, prostate cancer, and
osteosarcoma [175]. However, all enzymes involved in BER are also essential for normal
cells, making therapeutic targeting of BER enzymes problematic. For example, AP1
knockout is an embryonic lethal event in mice and AP1 is essential for the viability of
cultured cells [176]. On the other hand, knocking down PolB, the major DNA polymerase
in BER, increases sensitivity to chemical mutagens and irradiation, but multiple DNA
polymerases in human cells can compensate for the lack of BER PolB [175]. Therefore,
targeting BER proteins efficiently and specifically could be challenging.
1.7.2

Base Excision Repair Inhibition in Cancer Treatment

BER can be effectively blocked by the alkoxyamine derivative MX, which
specifically reacts with the aldehyde group in the sugar moiety formed in the DNA abasic
site following the glycosylase removal of the damaged base. This forms a stable MXbound AP site that is refractory to the AP endonuclease lyase activity and PolB function
necessary for completion of repair [177]. MX has been shown to be active in sensitizing
various forms of human tumours to chemotherapy and radiation. For example, MX
combined with the alkylating agent TMZ induced more DNA damage in T98G
glioblastoma cells than treatment with TMZ alone. MX also sensitized TMZ-resistant
T98G cells to the TMZ [178]. Moreover, MX combination treatment with pemetrexed
resensitized pemetrexed-resistance lung cancer cell lines to this drug [179]. The
sensitizing effect of MX in this study was attributed to the dual inactivation of uracil
DNA glycosylase (UDG) and topoisomerase IIα (topo IIα) in cancer cells. MX stably
bound to the AP site effectively trapped UDG and topo IIα at the AP site. Since tumour
cells express higher levels of these enzymes than normal bone marrow (BM) cells, it was
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suggested that MX potentiated the pemetrexed effect with minimal hematopoietic toxicity
[179]. In another study, combination treatment with MX and TMZ sensitized platinumresistant ovarian cancer cells to TMZ cytotoxicity, increased DNA damage in tumour
cells, and enhanced apoptosis [180]. A phase I study of combined MX and TMZ in
patients with advanced solid tumours is currently under way [181]. In another phase I
study that is currently recruiting patients, combined MX and fludarabine phosphate is
being tested in patients with hematological malignancies [182]. A phase I study of
combined MX and pemetrexed is already completed and several phase II studies in
multiple indications including NSCLC are planned [179].
1.8

Homologous Recombination Repair
HRR is a DNA repair process conserved across all species [183]. It serves as a

high fidelity template-dependent repair mechanism for double-strand breaks (DSBs),
DNA gaps, and DNA interstrand crosslinks (ICLs)(Figure 1.4). HRR is essential to
preserve genomic integrity and avoid tumour progression. The first step in HRR starts
with Rad51, a protein with DNA binding and ATPase properties, which positions the
invading 3’ end on a DNA strand and forms a nucleoprotein filament. Rad51 recruitment
to the DNA damage site is facilitated by BRCA1, which is also involved in processing
DSBs. Another central protein to HRR is the tumour suppressor protein BRCA2 [179,
184]. BRCA1 and BRCA2 mutations predispose women to ovarian and breast cancers
[185]. BRCA2 is also involved in recruiting Rad51 to DSBs through the eight BRC
repeats of BRCA2 protein that bind to Rad51. Upon binding to RAD51, BRCA2 binds to
single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) through its DNAbinding domain. Cells lacking BRCA2 are defective in HRR. In fact, BRCA2-deficient
cells cannot recruit Rad51 to DSBs [186]. Therefore, targeting BRCA2 in cancer cells is
of great interest as a therapeutic strategy [187]. SiRNA-mediated reduction of BRCA2
decreased the proliferation rate of A549 adenocarcinoma cells, even in the absence of
drug treatment, likely because of increased DNA damage due to genomic instability
mediated by decreased DNA repair [187]. Moreover, the cytotoxic effect of the alkylating
agents cisplatin and melphalan was significantly enhanced after siRNA downregulation
of BRCA2 in A549 and Hela cells [187].
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Figure 1. 4. Homologous recombination repair of DSB. 1-2: Radiation induces DSBs.
3: Efficient 5’ to 3’ resection of DSB ends allows recruitment of the single-stranded
DNA-binding complex and Rad51. The complex begins HRR by positioning the invading
3’ end on a DNA strand and forming a nucleoprotein filament. BRCA1 facilitates RAD51
recruitment to the damaged site. BRCA1 association with histones near sites of DNA
damage depends on histone γH2AX. 4: Strand invasion of 3’ ssDNA overhangs into a
homologous sequence allows the completion of DNA synthesis at the invading end. This
is followed by the second DSB end capture and formation of an intermediate. 5: DNA
synthesis to the gap and ligation to form a crossover. DSBs = double strand breaks.
ssDNA = single strand DNA (Figure adapted from [188]).

35

1.9

PARPs and DNA Repair
PARP-1 is the most studied member of the PARP superfamily. PARP-1 is a

molecular sensor of DNA breaks and plays a crucial role in organizing their repair
(Figure 1.5). The catalytic activity of PARP-1 increases dramatically (over 500-fold) on
binding to DNA breaks [189]. It catalyzes the covalent transfer of ADP-ribose units from
the NAD+ substrate to the γ-carboxyl group of glutamic acid residues on a variety of
acceptor proteins, a process called heteromodification [189]. These acceptor proteins are
normally associated with DNA regulation and modification. PARP-1 can also poly-ADPribosylate itself (automodification). Through poly-ADP-ribosylation of its partner
proteins, PARP-1 regulates chromatin structure and DNA metabolism [189]. PARP-1
partner proteins include high mobility group (HMG) proteins, histones, DNA helicases,
topoisomerases I and II, BER and single-strand break repair (SSBR) factors, and different
transcription factors. PARP-1 is important in genomic integrity [190-192] and the
induction of cell death in injured tissues [193]. PARP-2, the second member of the PARP
family, is also activated by DNA breaks [194]. PARP-2 is required for efficient repair of
SSBs in DNA and for genomic integrity [195, 196]. Although there are other PARP
family members, they are less important in DNA repair. Both PARP-1 and PARP-2
regulate multiple DNA repair mechanisms in cells. Therefore, they are vital for the
survival of cancer cells, particularly those affected by chemotherapy and radiation [197].
Some of the interactions between PARP molecules and DNA repair mechanisms that are
relevant to this thesis are described next.
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Figure 1. 5. PARP function during DNA damage and repair. PARP proteins use
NAD+ molecules as substrates for mono- and/or poly-ADP ribosylation of acceptor
proteins such as XRCC1. PARP function is crucial for the recruitment of acceptor
proteins to the site of DNA damage. PARP = poly(adenosine diphosphate-ribose)
polymerase. NAD+ = nicotinamide adenine dinucleotide. NAM = nicotinamide (Figure
adapted from [198]).
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1.9.1

PARP-1 and XRCC1
Poly-ADP-ribosylated PARP-1 preferentially interacts with XRCC1, the

BER/SSBR scaffold protein [199]. In vivo, in the context of locally induced SSBs or
DSBs, recruitment of XRCC1 to the damaged area of DNA is strictly dependent on polyADP-ribosylation [200]. Chemical inhibition of polymer of ADP-ribose (PAR) formation
abolishes XRCC1 recruitment to the damaged site [200], consistent with observations
made in irradiated PARP-1-/- cells [189]. Inhibition of XRCC1 recruitment to the
damaged area of DNA subsequently affects DNA repair processes such as BER and
SSBR, because XRCC1 mediates DNA repair by stimulating DNA repair enzymes [201].
In response to base damage, PARP-1 and XRCC1 also interact with the chromosomeorganizing complex condensin I to allow efficient BER through modifying the local
chromatin and organizing the structure of DNA [202].
1.9.2

PARP-2 and XRCC1
PARP-2 also interacts with XRCC1 and other BER/SSBR proteins including

DNA ligase III and DNA polymerase β [196]. Cells lacking PARP-2 have enhanced
sensitivity to genotoxic agents and have delayed SSB rejoining [190, 196]. However,
unlike PARP-1, XRCC1 recruitment to the site of DNA damage and recognition of SSBs
does not require PARP-2, suggesting that PARP-2 functions at later stages of DNA repair
[189].
1.9.3

PARP-1 and Homologous Recombination Repair
A direct role for PARP-1 in DSB repair has not yet been demonstrated. PARP-1

appears not to be required for HRR-mediated DNA DSB repair [203]. Indeed, Rad51 foci
are still generated in the absence of PARP-1. More importantly, DSB repair is functional
in PARP-1 inhibited cells [203]. Furthermore, PARP-1 does not colocalize to RAD51
foci [204]. However, inhibition of PARP-1 results in increased HRR, suggesting an
important role for PARP-1 in genomic instability [203]. This provides further rationale
for blocking HRR in the context of PARP-1 inhibition in cancer cells, which could
overwhelm the DNA repair machinery of cancer cells and induce apoptosis.
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1.9.4

Inhibiting PARP in Cancer Treatment
PARP-1 is overexpressed in many human cancers and has been linked to poor

prognosis [205]. Through the BER pathway, PARP plays a vital role in the repair of the
SSBs, and blocking PARP leads to DSBs in DNA. Tumour cells with impaired or low
level PARP activity depend heavily on HRR to survive. Thus, tumours with mutated
BRCA1/2 genes (important in HRR) have elevated sensitivity to PARP inhibitors [206,
207]. A randomized, phase II clinical study in high grade serous ovarian cancer patients
with HRR deficiency showed that blocking PARP increased progression-free survival
compared to treatment with placebo [208]. Olaparib is a potent oral PARP inhibitor [209,
210]. Olaparib has antitumour activity at non-toxic doses in phase I/II monotherapy
studies in ovarian cancer patients with BRCA1/2 mutations [211, 212]. PARP inhibition
enhanced the effect of DNA-damaging cytotoxic drugs such as cisplatin and
cyclophosphamide, presumably due to inhibition of BER [213]. This effect could also be
observed in human tumour cells with PTEN deficiency: PTEN plays a role in the
expression of Rad51 and, therefore, PTEN-deficient cells lack HRR [214].
1.10 Nicotinamide Adenine Dinucleotide
NAD+ plays a vital role in many biological and biochemical functions in cells.
NAD+ biosynthesis proceeds through both de novo and salvage pathways. De novo
biosynthesis of NAD+ is linked to IDO [215]. NAD+ is also important for DNA repair
and contributes to cancer cell survival and drug resistance [215]. NAD+ biosynthesis and
function in DNA repair are described below.
1.10.1 De Novo NAD+ Biosynthesis
Cells depend highly on NAD+ for many biological processes [215]. In most
eukaryotic cells, tryptophan is the NAD+ precursor in the de novo pathway, where
tryptophan is converted to QA via kynurenine (Figure 1.6). The tryptophan-catabolizing
enzymes IDO and tryptophan 2,3-dioxygenase (TDO) catalyze the first step in NAD+
production in all eukaryotic cells. IDO is expressed in most tissues, whereas TDO is
primarily a liver enzyme [215]. The first step in the kynurenine pathway is oxidation of
tryptophan to N-formylkynurenine by IDO or TDO (Figure 1.6.) [216]. Kynurenine
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formidase (KFase) then removes the formyl group by catalyzing N-formylkynurenine
hydrolysis to produce kynurenine [217]. The hydroxylase enzyme 3-monooxygenase
(KMO) then hydroxylases kynurenine to generte 3-hydroxykynurenine [218]. In the next
step, kynureninase cleaves the amino acid side chain of 3-hydroxyhynurenine to form 3hydroxyanthranilate. In the last step of kynurenine pathway, QA is generated by complex
oxidative rearrangement of 3-hydroxyanthranilate by 3-hydroxyanthranilate-3,4dioxygenase (HAD) [219-221]. QA is the NAD+ building block through the de novo
pathway. QA phosphoribosyltransferase (QAPRT) uses QA to produce nicotinic acid
mononucleotide (NAMN), which is subsequently converted to NA adenine dinucleotide
(NAAD). Finally, NAD synthase (NADS) converts NAAD to NAD+ (Figure 1.6) [222].
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Figure 1. 6. De novo NAD+ production. In the first step of the kynurenine pathway,
IDO or TDO catabolize tryptophan to generate N-formylkynurenine. Kynurenine
formidase (KFase) then produces kynurenine from N-formylkynurenine. In the next step,
hydroxylase enzyme 3-monooxygenase (KMO) hydroxylyses kynurenine to make 3hydroxykynurenine.

Kynureninase

then

forms

3-hydroxyanthranilate

from

3-

hydroxykynurenine. In the last step of the kynurenine pathway, oxidative rearrangement
of 3-hydroxyanthranilate by 3-hydroxyanthranilate-3,4-dioxygenase (HAD) yields
quinolinic acid (QA), which is then converted into nicotinic acid mononucleotide
(NAMN) by QA phosphoribosyltransferase (QAPRT). Next, NAM mononucleotide
adenylyltransferase (NMNAT) produces NAAD from NAMN. Finally, NAD synthase
uses NAAD to produce NAD+ as the final product of this pathway (Figure adapted from
[198]).
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1.10.2 Salvage Pathway of NAD+ Biosynthesis
The building blocks of NAD+ in the salvage pathway are nicotinamide (NAM),
nicotinic acid (NA), and nicotinamide riboside (NR) [223, 224]. NAM and NA are used
by two different phosphoribosyltransferases for production of NAM mononucleotides
(NMN) and NA mononucleotides (NAMN), respectively. These molecules are used in
two distinct salvage pathways to produce NAD+ [215]. NMN adenylyltransferase
subsequently converts NMN into NAD+. NAMN, on the other hand, is converted to
NAAD by NMN adenylyltransferase (NMNAT) and finally NAD+ is produced from
NAAD by NAD synthase [222]. Finally, in a third salvage pathway, NR can be used as a
NAD+ precursor. NR kinase (NRK) phosphorylates NR to make NMN, which can be
then directly converted to NAD+ [215].
1.11 NAD+ and DNA Repair
NAD+ is the substrate for mono- and poly-ADP-ribosylation in cells [189]. In this
reaction, breakage of the glycosidic bond between NAM and ribose consumes parent
NAD+ and donates ADP-ribose to an acceptor molecule. As described above, poly-ADP
ribosylation is essential for DNA repair and genomic stability in cells [215]. This
phenomenon was first reported by Chambon et al., who described how liver nuclear
extracts synthesized poly-ADP-ribose upon addition of NAD+ [225]. This finding led to
the understanding of how ADP-ribose is linked to an amino acid acceptor and not
transferred to an acetyl group, which takes place with most sirtuins [226]. In cells, PARP
enzymes are responsible for building ADP-ribosyl groups into polymers from NAD+
[189]. The PARP family of proteins may have as many as 17 members and is the most
abundant of the ADP-ribosyl transferases. All these enzymes share a similar active site in
their structures [227]. PARP-1 is the most studied member of PARP family and is
responsible for most PARP activity in cells [198]. As previously described, PARP-1 is a
ubiquitous nuclear protein that responds to DNA damage. Moreover, DNA damage
stimulates NAD+ biosynthesis because of the need to cleave more NAD+ for poly-ADPribosylation by PARPs [228]. In fact, NAD+ availability has been shown to affect the
length of poly-ADP-ribosyl polymer synthesis by PARP-1 [228]. In addition, DNA repair
occurs faster in the presence of higher NAD+ levels or in cells with active NAD+
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biosynthesis [228]. Some studies suggest that PARP activation might not depend on
NAD+, due to the low Km of PARP-NAD+ association (20-80 µM) [198]. Furthermore,
PARP binding to DNA breaks via its DNA-binding domain seems to regulate PARP
catalytic activity [229]. However, despite possible limitations on the role of NAD+ on
PARP activity, PARP function has an important impact on NAD+ metabolism. PARP
activity is the main mediator of NAD+ catabolism in cells, and high PARP activity
reduces intracellular NAD+ [230, 231]. Since cells depend highly on NAD+ for survival,
PARP activity induces cells to produce NAD+ through de novo and/or salvage pathways
[198, 232]. Treatment of cells with genotoxic agents that damage DNA leads to sustained
PARP activity in a short period of time and decreases NAD+ by 10-20%. This can be
detrimental to cells since NAD+ depletion decreases ATP production [230, 231, 233]. It is
conceivable that cancer cells possess increased NAD+ production to overcome constant
depletion of NAD+ consumed in the course of PARP-mediated DNA repair necessitated
by genomic instability and concomitant accumulation of DNA damage [234, 235].
Interestingly, NMPRTase, a key enzyme in the NAD+ salvage pathway, is upregulated in
human colorectal cancers. This suggests that human tumours increase their production of
NAD+ as a survival mechanism [236, 237].
1.12 NAD+ Inhibition as a Strategy for Cancer Treatment
As mentioned above, tumours depend highly on NAD+ and possess high NAD+
turnover due to high PARP activity [189, 227, 235, 238, 239]. Therefore, blocking NAD+
production is an attractive approach to sensitize cancer cells to PARP-mediated depletion
of NAD+ and induction of apoptosis [240]. The NAD+ precursors NM and NA in most
human tissues are obtained from the diet. Tryptophan, on the other hand, is not a major
source of tissue NAD+ in humans [241]. These data provide a rationale for targeting the
NAD+ salvage pathway in cancer cells. FK866 is an effective small-molecule inhibitor of
that pathway. It non-competitively blocks NMPRTase and consequently decreases
cellular levels of NAD+, and induces apoptosis in cancer cells with little side effects on
healthy cells because of their lower rate of catabolic depletion of NAD+ by PARP [242].
FK866 administered in vitro begins to reduce intracellular NAD+ by ∼50% in HepG2
liver carcinoma cells as early as 8 hours after addition [242]. As mentioned above, NAD+
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is a necessary coenzyme for ATP production and blocking NAD+ production by FK866
treatment drops ATP production in HepG2 cells after 3 days of drug treatment [242].
This is important, since ATP enables cells to undergo apoptosis which requires sufficient
energy

for

nuclear

condensation

and

subsequent

DNA

degradation

and

phosphatidylserine transfer to the cell surface to facilitate phagocytic removal of dead
cell particles [242, 243]. FK866 selectively blocks NAD+ synthesis by blocking the NAM
pathway of NAD production. However, a high concentration of NAM (10 mM) is able to
reverse the inhibitory effect of FK866 in HepG2 cells. Moreover, 1mM NA also
antagonizes the antiproliferative activity of FK866. Thus, increased amounts of NAD+
precursors could antagonize FK866 function [242].
1.13 Thymidylate Synthase
BER induces resistance to pemetrexed, a thymidylate synthase (TS)-targeting
drug [179]. TS is a key rate-limiting enzyme in DNA synthesis and is responsible for de
novo synthesis of deoxythymidine-5’-monophosphate (dTMP) through methylation of
dUMP by a methyl donor [244]. Since DNA replication and repair is largely dependent
on the dTMP pool, cell proliferation depends on TS [245]. Intriguingly, most human
tumours have elevated levels of TS mRNA and protein. Ectopic expression of TS in
normal cells can lead to a variety of malignant phenotypes in cells including: anchorage
independent

growth,

hyperplasia,

foci

formation,

and

tumour

formation

in

immunodeficient mice [246, 247].
1.13.1 TS Inhibition in Cancer
TS has been a target in cancer treatment since the late 1950s [248]. The TS
inhibitor 5FU remains the drug of choice for colorectal cancer patients in both adjuvant
and palliative care since its initial application in the 1950s [249]. In recent years a
combination of 5FU with other chemotherapeutic anticancer drugs and biological agents,
including bevacizumab and cetuximab, have successfully increased the response of
patients with metastatic colorectal cancer to treatment [249]. TS-targeting drugs have
anti-tumour activity against other types of cancers including NSCLC, and the TStargeting drug pemetrexed, in combination with cisplatin, is now administered in the first
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line to treat advanced non-squamous NSCLC [250]. A common mechanism of resistance
to TS-targeting drugs is through increased TS mRNA translation after binding of TS
inhibitors to TS protein both in vitro and in patients [251, 252]. The underlying
mechanism of this phenomenon is the ability of TS protein to bind to its own mRNA at
two different sequences to repress translation [253]. However, binding of TS-targeting
drugs to TS protein reduces TS interaction with TS mRNA. This leads to decreased TS
protein-mediated translational repression, increased TS mRNA translation, increased
amounts of TS protein and, ultimately, resistance to TS protein-targeting drugs due to
target overproduction [245]. To overcome this common problem, antisense targeting of
TS mRNA in conjunction with TS-inhibitors has been shown to sensitize a variety of
human tumour cell lines to TS-targeting drugs including raltitrexed, 5FU, and 5FUdR
[254]. Moreover, concurrent targeting of TS mRNA and BRCA2 or TK mRNA with
antisense oligodeoxynucleotides (ODNs) or siRNA sensitizes cancer cells to a number of
chemotherapy drugs in vitro [187, 255].
1.14 Targeting mRNA with RNA Interference
Silencing RNA through RNA interference (RNAi) is a post-transcriptional
process that results in sequence-specific gene silencing. Double-stranded RNA (dsRNA)
molecules are first introduced into target cells. Dicer, an RNase III family member, then
cleaves the dsRNA molecules into 19-23 nucleotide fragments (siRNAs) that contain a 5’
phosphorylated end and an unphosphorylated 3’ end with two unpaired nucleotide
overhangs. The unwindase activity of Argonaute (Ago)-2 unwinds the siRNA duplex into
two single strands: the guide and passenger strands. The guide strand is incorporated into
the RNA-induced silencing complex (RISC) and the passenger strand is degraded. The
RISC complex then finds endogenous RNA complementary to the guide strand and
cleaves the target RNA through the separate endonuclease activity of Ago-2 [256].
RNAi is a powerful tool to regulate gene expression. Hence, it is emerging as a
form of treatment for many human diseases including cancer [257]. Antisense molecules
combined with conventional treatments can be used to induce synthetic or
complementary lethality in human cancers [187]. Preclinical studies have revealed the
effectiveness of RNAi in silencing cancer-related genes [258]. RNAi targeting of many
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RNAs regulating critical characteristics of tumour cells in vivo (including tumour growth,
metastasis, chemoresistance, and angiogenesis) has resulted in favorable outcomes [258].
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Chapter 2
2

Thesis Hypotheses:

1- IDO confers resistance to the chemotherapeutic anticancer drugs cisplatin, 5FUdR,
pemetrexed, gemcitabine, olaparib, methoxyamine, and FK866 and γ radiation in cancer
cells.
2- IDO downregulation sensitizes cancer cells to the chemotherapeutic anticancer drugs
cisplatin, 5FUdR, pemetrexed, gemcitabine, olaparib, methoxyamine, and FK866 and γ
radiation.
2.1

Thesis Objectives

A) To reduce IDO mRNA levels using an antisense shRNA expression vector in human
lung adenocarcinoma A549 cells, human cervical adenocarcinoma HeLa cells, and
human lung adenocarcinoma H441 cells, in order to generate clonal human tumour cell
populations with: a) cytokine-inducible IDO (A549 and HeLa), b) cytokine-inducible
IDO downregulated by antisense IDO shRNA (A549 and HeLa), and c) basal IDO
expression downregulated by antisense IDO shRNA (H441).
B) To assess the effect of IDO downregulation on human tumour cell sensitivity to the
chemotherapeutic

drugs

cisplatin,

olaparib,

5FUdR,

pemetrexed,

gemcitabine,

methoxyamine, and FK866; or ionizing radiation; in the clonal human tumour cell
populations.
C) To assess the effect of combined downregulation of IDO and TS on human tumour
cell sensitivity to chemotherapeutic drugs 5FUdR and pemetrexed.
D) To assess the effect of combined downregulation of IDO and BRCA2 on human
tumour cell sensitivity to chemotherapeutic drugs olaparib and cisplatin.
E) To assess the effect of IDO downregulation on human tumour cell sensitivity to
combined treatments of pemetrexed and methoxyamine.
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F) To assess the effect of IDO downregulation on human tumour cell sensitivity to
combined treatments of γ radiation and olaparib.
2.2

Thesis Overview
The immune regulatory molecule IDO plays an important and still largely

unexplored immune-independent role in the tumour cell response to some common forms
of cancer treatment including chemotherapy (cisplatin, olaparib, 5FUdR, pemetrexed,
gemcitabine, methoxyamine, and FK866) and therapeutic ionizing γ radiation. The
importance of IDO in immune evasion and metastasis of cancer cells is well established
[135]. Moreover, targeting IDO with 1-MT improves the effectiveness of some
chemotherapy drugs in the context of an intact immune system in mouse models [136].
Here, for the first time, I show the importance of targeting IDO in human cancer cell
resistance to the chemotherapy drugs cisplatin, olaparib, pemetrexed, gemcitabine,
methoxyamine, and FK866 and γ radiation in vitro and in the absence of immune cells.
Conventional IDO inhibitors target IDO’s enzymatic function and not its
signaling function. The approach I have employed to target IDO has been to use RNAi: a
strategy to block IDO expression prior to protein synthesis (i.e., by reducing IDO mRNA
levels) that has certain advantages over conventional inhibition of the enzymatic function
of IDO protein. For example, targeting IDO mRNA will, by reducing the amount of IDO
protein, reduce both its well-described enzymatic function (tryptophan degradation) and
putative, but poorly explored signaling and other function(s).
To assay these, the first step was to stably transfect human adenocarcinoma A549
and HeLa cells with vectors directing expression of anti-IDO shRNA (capable of
mediating degradation of IDO mRNA) or scrambled shRNA (scr shRNA, incapable of
downregulating any known human RNA sequences). Next, and because A549 and HeLa
cells express IDO in vitro only after cytokine induction [259, 260], 44 and 6 stably
transfected A549 and HeLa clones, respectively, were treated with IFNγ to determine
whether anti-IDO shRNA incorporation altered IDO mRNA and/or protein levels
compared to control, non-targeting, scrambled shRNA (scr-shRNA) incorporation.
Because IDO expression is causally associated with reduced proliferation [145], the
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functionality of IFNγ-induced IDO was determined by assessing the proliferation rate of
cells after IFNγ induction of IDO in cells harbouring: a) anti-IDO shRNA or, b) scr
shRNA). The prediction was that IFNγ treatment would reduce proliferation more
effectively in cells with scr shRNA (and unimpeded induction of IDO) than in cells with
anti-IDO shRNA (and specific reduction in capacity to synthesize IDO). Moreover,
differences in proliferation associated with changes in IDO level (and not IFNγ
treatment) would be evidence that the critical factor was IDO and not other effects of
IFNγ treatment. We also determined whether IDO expression affected cell cycle
progression in A549 cells. We found that IDO induced cell cycle arrest at G1, and that
anti-IDO shRNA abolished this effect in A549 cells.
Since IDO is responsible for de novo synthesis of NAD+ as a product of
enzymatic degradation of tryptophan in mammalian cells, the level of NAD+ levels in
A549 cells expressing high levels of IDO after IFNγ induction (scr shRNA-transfected
cells) and those with reduced IDO expression (anti-IDO shRNA-transfected cells) was
assessed. On the basis of evidence presented in the Results section, we concluded that
anti-IDO shRNA reduced NAD+ levels in A549 cells.
Because NAD+ is required for PARP activity, we assessed the effect of antisensemediated knockdown of IDO on the sensitivity of A549 and HeLa cells to the PARP
inhibitor olaparib. IDO-producing A549 human tumour cells exhibited elevated
resistance to olaparib while anti-IDO shRNA ablated that resistance in that cell line.
However, IDO-producing HeLa cells did not show the same phenomenon.
PARP activity is essential for some DNA repair pathways including BER. In light
of results revealing the involvement of IDO in mediating resistance to olaparib in A549
cells, we assessed the effect of IDO upregulation and antisense-mediated IDO reduction
on the capacity of the BER inhibitor FK866 to reduce A549 cell proliferation. IDO
conferred resistance to FK866, an effect that was abolished by anti-IDO shRNA in A549
cells. Overall, IDO expression mediated resistance to PARP inhibition by olaparib and
BER inhibition by FK866, both important processes in repair of DNA damage to tumour
cells induced by chemotherapy or radiation.
To expand observations beyond chemotherapy, the effect of IDO upregulation
and downregulation on A549 and HeLa cell sensitivity to γ radiation was assessed. IDO
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conferred resistance to γ radiation in IDO-expressing cells and anti-IDO shRNA reversed
that resistance. Since γ radiation induces double strand breaks in DNA, we examined the
effect of IDO on sensitivity to cisplatin (an alkylating agent that causes DNA DSBs).
IDO downregulation sensitized cancer cells to cisplatin. Moreover, IDO conferred
resistance to cisplatin similar to γ radiation. Because olaparib has been reported to
sensitize human tumour cells to ionizing radiation [261], the capacity of IDO
upregulation or downregulation to alter sensitivity to combined treatment with γ radiation
and olaparib was examined. As described below (Results), IDO induced resistance to the
combined treatment in A549 cells and IDO downregulation decreased this phenomenon.
Since BER is involved in resistance to the TS-targeting drug pemetrexed, and
IDO conferred resistance to BER inhibition in cancer cells, we assessed whether
upregulation or downregulation of IDO prior to monotherapy or combined treatment with
pemetrexed and the BER inhibitor methoxyamine affected cancer cells sensitivity to
these drugs. IDO increased cell resistance to both monotherapy and combined treatment
with the two drugs. IDO downregulation reduced this phenomenon.
IDO downregulation sensitized cancer cells to monotherapy with the TS-targeting
drug pemetrexed or gemcitabine, but not to another TS-targeting drug 5FUdR. On the
other hand, concurrent reduction of IDO and TS using antisense shRNA and siRNA,
respectively, sensitized A549 cells to both drugs. These data implicate IDO as a mediator
of resistance to TS-targeting drugs in general, and particularly in the context of antisensereduced TS.
Lastly, we examined the effect of concurrent antisense-mediated reduction of IDO
and BRCA2 on A549 cell sensitivity to either olaparib or cisplatin. Concurrent BRCA2
and IDO downregulation sensitized cancer cells to each of these drugs to a greater degree
than expected based on the sensitizing effect of knockdown of either target alone (i.e.,
more than additive).
In an additional series of experiments, human H441 epithelial adenocarcinomaderived cells, which naturally express IDO without the need for cytokine induction [262],
were assessed for sensitivity to cisplatin. They were stably transfected with anti-IDO
shRNA or control scr-shRNA. IDO mRNA levels were measured in clonal populations
and cells with low IDO levels were compared to populations with high IDO levels with
52

respect to cisplatin sensitivity, and compared with data obtained after IFNγ-induced IDO
expression in human A549 lung tumour-derived and human HeLa cervical tumourderived cells with respect to drug sensitivity. Similar to A549 and HeLa cells, IDO
downregulation sensitized H441 cells to cisplatin.
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Chapter 3
3

Materials and Methods

3.1

Cell Culture
Human lung adenocarcinoma A549 cells, human cervical adenocarcinoma HeLa

cells, and human lung papillary adenocarcinoma H441 cells were obtained from the
American Type Culture Collection (ATCC), and maintained in Minimal Essential
Medium α (MEMα), Dulbecco’s Modified Eagle Medium (DMEM), and Roswell Park
Memorial Institute medium (RPMI)-1640, respectively. Cultured media were
supplemented with 10% fetal bovine serum (FBS)(Gibco, Life Technologies, Carlsbad,
California, USA, catalogue # 325-043-EL), 100 units/ml penicillin and 100 µg
streptomycin (pen/strep)(Gibco, Life Technologies, Carlsbad, California, USA, catalogue
# 15140-122) in 70 cm2 flasks (Sigma-Aldrich, St. Louis, Missouri, USA). Cells were
maintained in an incubator and kept at 37°C in 5% CO2. For most experiments, cells were
allowed to proliferate to no more than 70-80% of maximum occupancy on tissue culture
plastic (i.e., 70-80% confluent). Trypsin/EDTA (Wisent, Inc., Quebec, Canada) was used
to detach cells from flasks. To detach cells, they were first rinsed with sterile Dulbecco’s
phosphate buffered saline (PBS)(Wisent, Inc., Quebec, Canada) to remove residual FBS.
PBS was then aspirated and 1 ml of trypsin/EDTA was added to the cells. Cells were
returned to the incubator for 2-3 minutes then 9 ml of growth medium was added to the
cells to neutralize the trypsin/EDTA. Harvested cells were then analyzed as described
below.
3.2

Cytotoxic Drugs
Olaparib (AZD2281) was purchased from Selleckchem (Houston, Texas, USA).

5FUdR was purchased from Sigma Chemical Co. (St. Louis, Missouri, USA).
Pemetrexed (Alimta, manufactured by Eli Lilly and Co., Toronto, Ontario, Canada) and
cisplatin (Platinol, manufactured by Bristol-Myers Squibb, Montreal, Quebec, Canada)
were obtained from the pharmacy at London Health Sciences Centre (London, Ontario,
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Canada). Methoxyamine and FK866 were purchased from Sigma-Aldrich (St. Louis,
Missouri, USA).
3.3
3.3.1

Stable IDO Downregulation
Bacterial Strain, Growth, and Preparation of Competent Cells
The Escherichia coli (E.coli) strain DH5α was used for plasmid amplification.

Bacteria were grown in Luria-Bertani (LB) broth, Miller (Bioshop Canada Inc,
Burlington, ON) overnight in a shaking incubator at 37°C. To transform bacterial cells
with foreign DNA (plasmid), they were first rendered competent as follows: An
overnight bacterial culture (4 ml) was transferred into fresh LB broth (70 ml) in a 250 ml
Erlenmeyer flask and incubated in a shaking incubator at 37°C for 2 hours. The optical
density (OD) of the bacterial culture at 600 nm was measured relative to sterile LB
medium (blank control). When OD600 nm reached 0.354 the bacteria were transformed
with plasmid as follows. The bacterial culture was centrifuged at 4000 g for 10 minutes at
4°C. The supernatant was discarded and the cell pellet gently suspended (vortexing was
avoided) in 25 ml of sterile, ice-cold transformation solution (10 mM morpholinopropane
sulfonic acid (MOPS), pH 7.0; 10 mM rubidium chloride (RbCl). The bacteria were then
centrifuged (4000 X g, 10 min, 4°C). The supernatant was discarded and the cell pellet
was resuspended in 25 ml of filtered sterile, cold transformation solution II (MOPS, pH
6.5; 50 mM CaCl2; 10 mM RbCl). The bacterial suspension was left on ice for 1 h and
cells were then recovered by centrifugation (4000 X g, 10 min, 4°C). The supernatant
was aspirated without disturbing the bacterial pellet. Transformation solution II (5 ml)
was then added to the pellet, resulting in competent cells ready for transformation.
Competent bacteria were used immediately, after up to 2 weeks after storage at 4o C, or
after storage at -20o C in 10% glycerol.
3.3.1.1 Bacterial Transformation with Plasmids
Anti-IDO shRNA (1 µg) and non-targeting scrambled control shRNA [Qiagen
KH01328P SureSilencingTM Puromycin vector (human IDO1, catalogue # 336314)] were
added to separate tubes of competent bacteria (150 µl) and mixed gently. The puromycin
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vector pGeneClipTM (Figure 3.1) contains a beta-lactamase (ampicillin resistance) region
that allows transformed bacteria to become resistant to ampicillin. This vector also
contains a puromycin-N-acetyltransferase coding region that confers puromycin
resistance to successfully-transfected mammalian cells, to allow clonal selection. There
were four different anti-IDO shRNA sequences and one non-targeting scrambled control
shRNA (Table 3.1). Each shRNA sequence was individually inserted into the plasmid
vector as part of an insert sequence. The loop structure of the shRNA consists of the
sequence CTTCCTGTCA. The insert sequence containing each shRNA was inserted
between positions 438 and 439 in the plasmid vector. Each shRNA inserted into the
plasmid vector targets a different exon on the IDO1 gene. The plasmid vectors were used
to transform E.coli strain DH5α before plasmid purification. The plasmid- DH5α mixture
was kept on ice for 25 min, then heat-shocked (2.5 min, 42°C) followed by incubation at
4o C for 2 min. LB broth (1 ml) was then added to the bacteria, followed by incubation at
37°C for 1 hour in a shaking incubator. Bacteria were centrifuged at 6000 X g for 2 min
and the majority of the supernatant was removed leaving 50-100 µl. The bacterial pellet
was resuspended in the remaining supernatant and spread on LB agar plates (containing
50 µg/ml ampicillin to select for transformed cells). Transformed cells were grown
overnight at 37° C. Non-transformed bacteria were cultured on agar plates with and
without ampicillin as a control experiment to confirm the activity of ampicillin.

56

Table 3. 1. SureSilencing shRNA plasmid sequences. Each anti-IDO shRNA sequence
targets a specific exon on the IDO gene. Each shRNA sequence was inserted into a
plasmid vector. Those vectors were propagated in bacteria then purified and used to
stably transfect cancer cells.
shRNA ID

Insert Sequence

1

AGACTGCAGTAAAGGATTCTT

2

GTGACTAAGTACATCCTGATT

3

CAGTGTTCTTCGCATATATTT

4

TCCTCCAGGACATGAGAAGAT

NC (control)

GGAATCTCATTCGATGCATAC
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Figure 3. 1. The puromycin-resistant vector pGeneClipTM. Anti-IDO shRNA
sequences or non-targeting scrambled shRNA control sequence were separately inserted
into this vector prior to stable transfection of mammalian cells. The vector contains an
ampicillin resistance region to allow the transformed bacteria to grow in the presence of
ampicillin in order to propagate the plasmid, and a puromycin-N-acetyltransferase coding
region that allows stably transfected cells to grow in the presence of puromycin.
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3.3.1.2 Plasmid Purification
After growing bacteria on plates overnight, single colonies were inoculated by
sterile pipette into 2.5 ml of LB medium containing 50 µg/ml ampicillin. The bacterial
culture was incubated in a shaking incubator at 37° C for 5 hours, inoculated into 250 ml
of LB medium containing 50 µg/ml ampicillin, and then grown overnight at 37° C with
shaking. Plasmids were purified from these bacterial cultures using Qiagen HiSpeed
plasmid maxi kits (Qiagen, catalog # 12662) according to the following protocol that was
described by the manufacturer:
Bacterial cells were harvested by centrifugation at 6000 X g for 15 minutes at 4°
C. The supernatant was discarded and the bacterial pellet suspended in 10 ml of buffer P1
containing RNase A (100 µg/ml), Tris base (50 mM, pH 8.0), and EDTA (10 mM) that
was provided in the kit (added immediately prior to use) to lyse bacteria. Buffer P2 (10
ml) containing NaOH (200 mM) and 1% SDS (w/v) was then added (without vortexing,
to avoid shearing genomic DNA), mixed, and incubated for 5 min at 25o C. After
incubation, 10 ml of chilled buffer P3 containing potassium acetate (3.0 mM, pH 5.5) was
added to the lysate and mixed immediately by inverting 4-6 times. The lysate was then
poured into the barrel of QIAfilter Maxi cartridges, incubated for 10 minutes, and then
allowed to empty by gravity flow after adding 10 ml of QBT buffer [750 mM NaCl, 50
mM MOPS (pH 7.0), 15% isopropanol (v/v), and 0.15% Triton X-100 (v/v)]. Nonplasmid DNA material remaining in the cartridge was eluted using the supplied syringe
plunger, the cartridge contents were washed with 60 ml of QC buffer [1.0 M NaCl, 50
mM MOPS (pH 7.0), and 15% isopropanol (v/v)] by gravity flow, and plasmid DNA was
eluted in 15 ml of QF buffer [1.25 M NaCl, 50 mM Tris-base (pH 8.5), and 15%
isopropanol v/v]. The eluted DNA was precipitated by adding 10.5 ml room temperature
isopropanol followed by incubation for 5 min. The elute/isopropanol mixture was then
filtered to immobilize plasmid DNA on a QIA filter membrane, washed with 2 ml of 70%
ethanol, air dried, and dissolved in 0.5 ml of Tris-EDTA (TE) buffer (pH 8.0).
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3.3.2

Plasmid Quality Control and Diagnostic Restriction Digest
To verify that purified plasmids contained the desired shRNA inserts, a plasmid

quality control by Pst I restriction enzyme digestion was carried out. Plasmids containing
shRNA inserts were expected to generate two diagnostic bands 3209 bp and 1402 bp
upon digestion. All 5 plasmid samples described in section 3.4.2 were used for this
experiment (anti-IDO shRNA plasmids 1-4 and scrambled control shRNA plasmid). Each
reaction contained 1.2 µg plasmid DNA, 2 µl of the 10x reaction mix, 0.5 µl Pst I enzyme,
and sufficient sterile water to achieve a final volume of 20 µl. Restriction digestion
proceeded at 37° C for one hour before separating the digestion products on the basis of
electrophoretic mobility through a 1% agarose gel. As a negative control for each sample,
1 µg of each supercoiled plasmid (uncleaved) was assessed by gel electrophoresis.
3.3.2.1 Ethanol Precipitation of DNA
To maximize plasmid concentrations before transfection of cancer cells, plasmids
were precipitated in ethanol and resuspended in 100-200 µl of TE buffer to obtain a final
concentration of a 1 µg/µl for each plasmid.
3.3.2.2

Linearization of shRNA Plasmids for A549 Stable Transfection
To increase the efficiency of plasmid integration into the genomic DNA, plasmid

linearization was performed as described below:
Anti-IDO shRNA 2 and scrambled shRNA plasmids (40 µg) were linearized using Sca I
restriction enzyme (Fermentas, 10 U/µl, Hanover, MD) using the protocol and buffers
supplied by the manufacturer. The reaction mix was: 5 µl Buffer (10x concentration), 40
µl DNA, 6 µl Sca I enzyme, 4 µl dH2O. Restriction cleavage proceeded at 37°C for 3 h,
followed by ethanol precipitation. Precipitated plasmids were dissolved in dH2O to a final
concentration of 1 µg/µl.
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3.3.2.3 Stable Transfection of A549, HeLa, and H441 Cells with anti-IDO shRNA
or Scrambled shRNA Plasmids
Human A549, HeLa, and H441 cells were stably transfected with a vector
expressing short hairpin RNA (shRNA) antisense to human IDO1, or a scrambled, nontargeting control shRNA (SuperArray, Mississauga, ON), using Lipofectamine 2000
(LFA2K)(Invitrogen, Burlington, ON, Canada) according to the manufacturer's
instructions. Anti-IDO shRNA 2 exerts the most robust IDO downregulation in human
SW480 colorectal adenocarcinoma cells (Dr. M.D. Andersen, Center for Cancer
Immunotherapy, Herlev University hospital, Denmark, personal communication).
Therefore, we used plasmid shRNA 2 and scrambled control shRNA to stably transfect
A549 and HeLa cells. We stably tranfected H441 cells with each plasmid shRNAs (1, 2,
3 and 4) and scrambled control shRNA. H441 (1 x 106) were cultured overnight in 25
cm2 flasks in 2 ml of AMEM supplemented with 10% FBS. On the day of transfection
with shRNA, cells were approximately 70% confluent. For transfection, 10 µg of antiIDO gene-specific plasmid expressing shRNA or scrambled control shRNA was mixed
with 10 µl LFA2K and 125 µl serum-free MEMα. The mixture was then incubated for 20
minutes in room temperature to allow shRNA:LFA2K complex formation. After
incubation, 250 µl of the mixture was added to each flask of cells. At 4 h after
transfection, culture medium was exchanged for fresh MEMα containing 10% fetal
bovine serum. Cells were washed with PBS (1x) and trypsinized 24 h later, and seeded
into a 14 cm mammalian tissue culture dish in 30 ml MEMα supplemented with 10%
FBS. Cells were allowed to proliferate in culture for 72 h, followed by replacement with
fresh medium containing 2 µg/ml puromycin (Bioshop, Burlington, ON). Medium was
replaced every 3 days with fresh medium containing 2 µg/ml puromycin. Stablytransfected cells formed colonies, and single colonies (approximately 30 transfected with
each of the shRNA-expressing plasmids) were selected and grown in 48-well plates in 0.8
ml MEMα supplemented with 10% FBS and 2 µg/ml puromycin. When confluent, cells
were transferred to 6-well plates and were cultured in triplicate. A549 and HeLa cells
were then treated with IFNγ (25 ng/ml) and IDO mRNA and protein levels were
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measured by qPCR and immunoblotting, respectively. Since H441 cells express IDO
endogenously, IDO mRNA was directly measured in the selected clones by qPCR.
3.4

Transient Transfection of A549 Cells with anti-IDO shRNA or Scrambled
shRNA Plasmids
To test the capability of each shRNA to transiently downregulate IDO, A549 cells

were transfected with 8 µg of each plasmid using a modification of established protocols
(Plasmid DNA transfection LipofectamineTM 2000 transfection guideline, Invitrogen,
Burlington, ON, Canada). A549 cells (7 x 105) were cultured in 25 cm2 flasks in 2 ml of
MEMα supplemented with 10% FBS. Each plasmid (8 µg) was added to 20 µl of LFA2K
for 20 min at 25o C to allow shRNA: LFA2K complex formation. Cells were transfected
by adding a mixture of plasmids and LFA2K (250 µl total volume) and incubating for 4 h
at 37° C. Fresh medium containing IFNγ (16 ng/ml, R&D Systems, Minneapolis, MN)(4
ml) was added to each flask. Total RNA was isolated 24 h after transfection and cDNA
generated from those isolated RNAs. Semi-quantitative PCR analysis of IDO and
GAPDH cDNAs in each sample was performed to assess IDO downregulation by each
plasmid.
3.5

RNA Isolation
A549 and HeLa cells were cultured overnight and then the growth medium was

replaced with medium containing IFNγ (25, 50 or 100 ng/ml). RNA was isolated from
A549 and HeLa cells 20 h after IFNγ treatment. Cells were washed with PBS twice.
Trizol reagent (1 ml, Invitrogen) was added to each flask to lyse cells directly. The cell
lysate was pipetted up and down several times and then transferred to 1.5 ml
microcentrifuge tubes. Chloroform (200 µl) was added to each cell lysate and vortexed
for 10 sec, followed by incubation for 5 min at 25o C. Samples were centrifuged at 20000
X g at 4° C. The top aqueous phase (450-500 µl, containing RNA) was transferred into a
new microcentrifuge tube. Isopropyl alcohol (600 µl) was added to precipitate the RNA.
Samples were vortexed and incubated at room temperature for 10 min, centrifuged at
20000 X g for 20 min at 4°C. The supernatant was discarded and the RNA pellet was
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washed twice with 1 ml of 70% ethanol, air dried, and dissolved in 20 µl of DEPCtreated water measurement of RNA concentration by NanoDrop® analysis.

3.6

IDO mRNA Detection via Conventional PCR

Isolated mRNA (1 µg) was used to synthesize cDNA by reverse transcription using
MMLV-RT (Invitrogen). PCR amplification of IDO cDNA proceeded as follows: 95°C,
5 min; 95°C, 30 s; 57°C, 30 s; 72°C, 30 s; 95°C, 30 (39 times); 72°C, 10 min; 4°C
GAPDH cDNA was similarly amplified except for 24 rather than 39 amplifications at
step 5. The reverse and forward primer sequences for IDO and GAPDH are shown in
Table 3.2. To visualize PCR amplification products, 25 µl of PCR product was added to 6
µl of Orange-G loading dye in glycerol, mixed, and separated by electrophoresis through
a 1.5% non-denaturing agarose gel. A sample (1 µg) of the RNA used to generate cDNA
was similarly separated by gel electrophoresis to visually determine RNA integrity.
3.7

IDO mRNA Quantitation by Real-Time PCR
A549 and HeLa clonally-selected populations stably-transfected with anti-IDO

shRNA or non-targeting scrambled control shRNA were collected 24 h after treatment
with IFNγ (25 ng/ml, R&D Systems, Minneapolis, MN). H441 clonal populations, stably
transfected with anti-IDO shRNA or non-targeting scrambled control shRNA were
collected 24-36 h post cell culture without IFNγ treatment. Cells were lysed (Trizol
reagent, Invitrogen) and total RNA isolated according to the manufacturer's instructions.
cDNA was synthesized by reverse transcription (MMLV-RT) using 1 µg of purified
RNA. IDO and 18S rRNA or GAPDH (control housekeeping genes) levels were
measured simultaneously by multiplex real-time PCR amplification using a TaqMan
IDO1 gene expression assay kit (Applied Biosystems, Carlsbad, CA).
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Table 3. 2. IDO and GAPDH PCR primer sequences.

IDO Forward primer

5'-TAATGGCACACGCTATGGAA-3'

IDO Reverse primer

3'-GGAAGGACAAACTCACGGACT-5'

GAPDH Forward primer

5'-TATTGGGCGCCTGGTCACCA-3'

GAPDH Reverse primer

3'-CCACCTTCTTGATGTCATCA-5'
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3.8

IDO, BRCA2 and TS Protein Detection and Measurement
A549 and HeLa cells were cultured in 75 cm2 flasks and treated with IFNγ (25

ng/ml). Cells were incubated for 48 h, washed twice with ice-cold PBS, harvested, and
sonicated. Lysed cells were centrifuged at 20,000 X g for 15 min at 4° C and the
supernatant collected and stored at -80° C for future use. Protein extracts (20 µg) were
quantified by BioRad protein assay, separated by electrophoresis through a 12%
polyacrylamide gel, and then electro-transferred to a nitrocellulose membrane. Primary
monoclonal antibodies against IDO (Abcam, Cambridge, UK) and actin (Sigma, St.
Louis, MO) were used to detect and quantify these proteins. Secondary anti-mouse and
anti-rabbit IgG (peroxidase-linked whole antibodies; GE Healthcare Life Sciences), were
bound to primary IDO and actin antibodies, respectively. The antibody-protein
complexes were visualized using a Storm scanner (GE Healthcare Life Sciences).
BRCA2 protein was assessed in A549 cells similar to the method to detect IDO
protein except that BRCA2 monoclonal rabbit antibody (Cell Signaling Technology #
90125, Danvers, MA, USA) was used to detect and quantify BRCA2 protein. A Ready
Gel Tris-HCL gradient gel 4-15% (Cat # 161-1158, BioRad) was used to separate the
proteins. Trans-blot Turbo transfer pack (Mini format) 0.2 µM PVDF (cat # 170-4150,
BioRad) was used for the transfer of proteins from the gel to the PVDF membrane.
TS protein was assessed in A549 cells similar to the method to detect IDO and
BRCA2 protein except that TS monoclonal antibody (Taiho Pharmaceutical, Hanno-City,
Japan) was kindly provided by Dr. Masakazu Fukushima (Taiho Pharmaceuticals, Hanno
Research Center, Hanno-City, Japan). Protein samples were isolated at 96 h post-siRNA
transfection of A549 cells.
3.9

NAD+ Quantification
NAD+ levels were measured in A549 clonal populations stably transfected with

plasmids directing expression of anti-IDO shRNA or scrambled shRNA, using a
NAD+/NADH quantification Kit (BioVision, Milpitas, CA; Catalog#K337- 100). Briefly,
2 x 105 cells were seeded into 25 cm2 flasks and grown overnight. Medium was replaced
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16-24 h later with 3 ml of fresh growth medium containing IFNγ (25 ng/ml). Cells were
washed 48 h later with ice-cold PBS, pelleted by centrifugation, and extracted using 2
freeze/thaw cycles and NADH/NAD extraction buffer (400 µl). NADt (total NAD
including NADH and NAD) was detected in 50 µl of extracted samples after addition of
NAD cycling buffer and NAD cycling enzyme mix to a total volume of 100 µl. NADH
levels were measured in a similar fashion in aliquots where NAD+ was degraded
beforehand by heating the samples to 60° C for 30 min. NAD+ levels were calculated by
subtracting NADH levels from NADt levels. Samples were read at OD 450 nm using a
Wallac Victor2 plate reader (Perkin Elmer Life Sciences, Waltham, MA).
3.10 Cell Cycle Analysis
A549 cells (2x105) were cultured overnight and then IFNγ (25 ng/ml) was added
(vehicle only was added to control cells). After 48 h, cells were washed with PBS,
trypsinized, and fixed in 70% ice-cold ethanol. Cells were washed with PBS 24 h after
fixation and resuspended in 1 ml of propidium iodide (20 µg/ml) (Sigma Aldrich, St.
Louis, MO) and 0.1% Triton X-100 (BDH Chemicals, Poole, UK) staining solution with
RNAse A (Bioshop, Burlington, ON, Canada) for 15 minutes at 37o C. The stage of cell
cycle was analyzed using a BD FACSCalibur flow cytometer (BD Biosciences, Franklin
Lakes, NJ) and FlowJo software (Tree Star, Inc., Ashland, OR, USA).
3.11 Olaparib Treatment
A549 and HeLa cells (5x104) were seeded into 25 cm2 flasks in 2 ml of MEMα and
DMEM supplemented with 10% FBS plus pen/strep, respectively. Medium was replaced
with fresh growth medium with or without IFNγ (25 ng/ml) 16-24 h after seeding.
Twenty-four or 48 h after addition of IFNγ, medium was replaced with fresh medium
containing olaparib (1, 1.5 or 5 µM). Three days after addition of olaparib, cells were
washed to remove the dead cells and particles and adherent cells were trypsinized and
enumerated using a Coulter counter (Beckman, Mississauga, ON). Viability of the
counted cells was confirmed by trypan blue exclusion.
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3.12 γ Radiation Treatment
A549 and HeLa cells (5x104) were seeded into 25 cm2 flasks in 2 ml of growth
medium. Culture media was replaced with medium with or without IFNγ (25 ng/ml) 1624 h later. Cells were exposed to γ radiation (4 Gy) using a
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Co irradiator (London,

Ontario, Canada) or a Varian Clinical 21EX Linear accelerator (Varian Medical System,
Palo Alto, CA) using a 6 MV X ray beam (40 x 40 cm with 1.5 cm water equivalent
buildup material) 48 h after addition of IFNγ. After irradiation, medium was replaced
with fresh growth medium without IFNγ and cells were allowed to proliferate for 72 h.
Cells were then trypsinized and live cells were enumerated using a Coulter counter.
3.13 Combined Treatment with Radiation and Olaparib
A549 and HeLa cells (5x104) were grown and irradiated as described above.
Immediately after irradiation, medium was replaced with fresh medium containing
olaparib (5 µM) and cells were allowed to proliferate in culture for 72 h. Cells were then
trypsinized and live cells were enumerated using a Coulter counter.
3.14 Cisplatin, Gemcitabine, Pemetrexed, and 5FUdR Treatment
A549 cells (5x104) were seeded into 25 cm2 flasks in 2 ml of MEMα supplemented
with 10% FBS containing pen/strep. Medium was replaced with fresh growth medium
with or without IFNγ (25 ng/ml) 16-24 h after seeding. Twenty-four or 48 h after addition
of IFNγ, medium was replaced with fresh medium containing either cisplatin (4 or 8 µM),
gemcitabine (10 nM), pemetrexed (200 nM), or 5FUdR (40 nM). Three days after
addition of drugs, cells were washed to remove the dead cells and particles. Adherent
cells were trypsinized and enumerated using a Coulter counter (Beckman, Mississauga,
ON). Viability of the counted cells was confirmed by trypan blue exclusion. H441 cells
(5x104) were seeded into 6-well plates in 3 ml of RPMI-1640 supplemented with 20%
FBS plus pen/strep and grown overnight. Medium was replaced the next day with 4 ml of
fresh growth medium containing cisplatin (5 or 10 µM). Cells were allowed to proliferate
for 8 days. On day 5 after initial culture, 2 ml fresh medium was added to each well. At
the end of the experiment cells were washed to remove the dead cells and particles.
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Adherent cells were trypsinized and enumerated using a Coulter counter (Beckman,
Mississauga, ON).
3.15 Blocking NAD+ Synthesis by FK866 Treatment
A549 cells (5x104) were seeded into 25 cm2 flasks in 2 ml of MEMα supplemented
with 10% FBS plus pen/strep. Medium was replaced with fresh growth medium with or
without IFNγ (25 ng/ml) 16-24 h after seeding. Forty-eight h after addition of IFNγ,
medium was replaced with fresh medium containing FK866 (5 nM). Three days after
addition of FK866, cells were washed to remove the dead cells and particles and adherent
cells were trypsinized and enumerated using a Coulter counter (Beckman, Mississauga,
ON). Viability of the counted cells was confirmed by trypan blue exclusion.
3.16 Blocking BER by Methoxyamine Treatment
A549 cells (5x104) were seeded into 25 cm2 flasks in 2 ml of MEMα supplemented
with 10% FBS plus pen/strep. Medium was replaced with fresh growth medium with or
without IFNγ (25 ng/ml) 16-24 h after seeding. Forty-eight h after addition of IFNγ,
medium was replaced with fresh medium containing methoxyamine (MX)(3 mM). Three
days after addition of MX, cells were washed to remove the dead cells and particles and
adherent cells were trypsinized and enumerated using a Coulter counter (Beckman,
Mississauga, ON). Viability of the counted cells was confirmed by trypan blue exclusion.
3.17 Combined Treatment with Pemetrexed and MX
A549 cells (5x104) were grown and co-treated with pemetrexed (30 nM) and MX (3 mM)
as described above. Cells were allowed to proliferate in culture for 72 h. Cells were then
trypsinized and live cells were enumerated using a Coulter counter.
3.18

IDO siRNA Transfection
Human IDO siRNA [OnTarget Plus SMARTPool IDO (Dharmacon RNAi

Technologies)] was used to transfect A549 and H441 cells (Table 3.3). IDO siRNA (10
nM) and control non-targeting siRNA (2.5 nM) in serum-free MEMα and LFA2K (2.5
µg/ml) were incubated together for 20 min. The siRNA:LFA2K mix was then added to
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A549 and H441 cells that had been seeded, in triplicate, at 2 x105 cells per 25 cm2 flask
24 h beforehand. In case of A549 cells, at 4 h after addition of siRNA:LFA2K, media
were exchanged for fresh growth medium containing IFNγ (16 ng/ml). In another method,
A549 cells were treated with IFNγ (50 ng/ml) 6 h before siRNA transfection.
Transfection was conducted as above. At 4 h post transfection fresh medium containing
IFNγ (50 ng/ml) was added to the A549 cells. H441 cells that endogenously express IDO,
without induction with added cytokines, were similarly transfected with IDO siRNA as
above, without IFNγ induction. RNA was isolated from the cells 24 h post-siRNA
transfection. cDNA was synthesized and IDO and GAPDH cDNAs amplified by PCR.
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Table 3. 3. ON-Target Plus® IDO1, TS and BRCA2 siRNA target mRNA sequences.
Target
siRNA ID

Targeted RNA

Target mRNA Sequence

Position in
mRNA
Transcript

IDO A

IDO1 mRNA

5’-UCACCAAAUCCACGAUCAU-3’

1281-1299

IDO B

IDO1 mRNA

5’-UUUCAGUGUUCUUCGCAUA-3’

422-440

IDO C

IDO1 mRNA

5’-GUAUGAAGGGUUCUGGGAA-3’

1383-1401

IDO D

IDO1 mRNA

5’- GAACGGGACACUUUGCUAA-3’

1213-1231

TS #3

TS mRNA

5′-ACAGAGAUAUGGAAUCAGA-3′

576-594

TS #4

TS mRNA

5′-GGACUUGGGCCCAGUUUAU-3′

526-544

BRCA2

BRCA2 mRNA

5′-GAAACGGACUUGCUAUUUA-3′

4285-4303

BRCA2

BRCA2 mRNA

5′-GGUAUCAGAUGCUUCAUUA-3′

558-576

BRCA2

BRCA2 mRNA

5′-GAAGAAUGCAGGUUUAAUA-3′

1949-1967

BRCA2

BRCA2 mRNA

5′-UAAGGAACGUCAAGAGAUA-3′

7242-7260

Control

No Target

5’-UGGUUUACAUGUUGUGUGA-3’
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3.19 BRCA2 siRNA Transfection and Drug Treatment
Concentrations of siRNAs targeting human BRCA2 [OnTarget Plus SMARTPool
BRCA2 (Dharmacon RNAi Technologies)] (Table 3.3) that reduced target mRNAs by
approximately 70% by 24 h after transfection were determined (10 nM). BRCA2 siRNA
(10 nM) and control non-targeting siRNA (2.5 nM) in serum-free MEMα and LFA2K
(2.5 µg/ml) were incubated together for 20 min. The siRNA:LFA2K mix was then added
to A549 cells that had been seeded, in triplicate, at 2 x105 cells per 25 cm2 flask 24 h
beforehand. At 4 h after addition of siRNA:LFA2K, medium was exchanged for fresh
growth medium containing IFNγ (25 ng/ml). Medium was replaced with fresh medium
containing olaparib or cisplatin 16-24 h later. Tumour cell proliferation was enumerated
72 h later using a Coulter counter.
3.20

TS siRNA Transfection and Drug Treatment
TS siRNA number 3 or TS siRNA number 4 (Table 3.3) (targeting different regions

of human TS mRNA)[OnTarget Plus (Dharmacon RNAi Technologies, Lafayette, CO,
USA)] that reduced target mRNAs by approximately 70% by 24 h after transfection, were
used to downregulate TS mRNA in A549 cancer cells. TS siRNA (5 nM) and control
non-targeting siRNA (5 nM) in serum-free MEMα and LFA2K (2.5 µg/ml) were
incubated together for 20 min. The siRNA:LFA2K mix was then added to A549 cells that
had been seeded, in triplicate, at 2 x105 cells per 25 cm2 flask 24 h beforehand. At 4 h
after addition of siRNA:LFA2K, media was exchanged for fresh growth medium
containing IFNγ (25 ng/ml). Medium was replaced with fresh medium containing
pemetrexed, 5FUdR, or gemcitabine 48 h later. Tumour cell proliferation was enumerated
72 h later using a Coulter counter.
A549 cells were transiently transfected with either control siRNA or TS siRNA for 4 h.
Cultured medium was then replaced with growth medium containing IFNγ (16 ng/ml).
RNA was isolated from cells 24 h post-transfection and IDO and TS mRNA were
measured by PCR.
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3.21

Puromycin Treatment of A549 Cells
A549, HeLa, and H441 cells (5 x 105) were seeded in a 10 cm2 plastic tissue culture

dish in 5 ml of growth medium overnight. Puromycin (0, 1, 2, 4, 6, or 8 µg/ml) was added
to the cells. Cell growth was monitored by visual microscopy daily. The lowest
concentration that killed all cells was chosen to maintain the stably-transfected A549,
HeLa and H441 cells.
3.22 Colony Forming Assay after Irradiation
A549 clonal populations were seeded in 25 cm2 flasks in 2 ml of growth medium
overnight. Cultured medium was replaced by fresh medium with or without IFNγ (25
ng/ml) and maintained for 48 h. Cells were then irradiated (4 Gy) or not (control cells).
All cells were trypsinized and 300 cells were seeded in 6 well plates in 4 ml of growth
medium. Medium was replaced with fresh medium 72 h later. Cells were allowed to
proliferate for a total 7 days. Medium was aspirated and cells were washed with PBS and
stained with 0.5% crystal violet for 45 min at 20o C. Cells were washed twice with dH2O
and colonies were counted. The number of colonies in each treatment group was divided
by the number of colonies in the control and multiplied by 100 to estimate % colony
formation.
3.23 Statistical Analysis
Student’s t test (2-tailed) was used to determine differences between two means.
One-way ANOVA was used to assess differences among multiple means. A p value of
0.05 was selected a priori to indicate significant differences. In some analyses, data were
pooled from A549 and HeLa clonal populations that expressed anti-IDO shRNA and
compared to the pooled measurements of multiple clones expressing scrambled control
shRNA. Tumours are heterogenous populations and each clonal population, although
relatively similar to other clones because of their derivation from a common parent,
potentially has differences due to variation induced by ongoing genomic instability.
Combining tumour clones allows examinination of the role of IDO in drug sensitivity and
resistance in a heterogenous cancer population originating from the same parental cell
line. Observing meaningful statistical differences in radiation and drug sensitivity in
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examined clones provides clear evidence for the importance of IDO downregulation in
cancer cells despite other differences among cells.
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Chapter 4
4

Results

4.1

IDO Induction in A549 and HeLa Cells

IDO plays a major role in suppressing the immune response during tumour progression.
Most human tumours express IDO in vivo [135], but IDO protein is undetectable in A549
and HeLa cells in vitro until induced by IFNγ. Therefore, IFNγ was used to induce IDO
in A549 and HeLa cells in these studies as described in chapter 3, section 3.5. RNA
quality was tested from representative samples (Figure 4.1), cDNA was synthesized, and
IDO and GAPDH mRNA levels determined using the synthesized cDNA (Table 3.2
shows primer sequences). IFNγ strongly induced IDO mRNA in both A549 and HeLa
adenocarcinoma cells (Figures 4.2 and 4.3). Since all IFNγ concentrations induced IDO
mRNA in cancer cells, and to limit non-IDO related effects of IFNγ, 25 ng/ml IFNγ was
used to induce IDO in subsequent experiments unless otherwise noted. This strongly
induced IDO mRNA and protein in both A549 and HeLa cells. In the next step, we
measured A549 IDO protein levels after IFNγ treatment as described (Chapter 3, section
3.8). IFNγ (25 ng/ml) induced IDO protein in A549 cells (Figure 4.4).
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Figure 4. 1. Quality of RNA isolated from A549 cells ± IFNγ (50 ng/ml). A549 cells
were cultured overnight then treated with or without IFNγ (50 ng/ml). RNA was isolated
20 h post-IFNγ treatment. RNA samples were separated on a 1.5% agarose gel to confirm
RNA integrity. Top bands are 25S rRNA and the lower bands are 18s rRNA. Lanes 1-2:
A549 cells without IFNγ treatment. Lanes 3-5, A549 cells with IFNγ treatment.
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Figure 4. 2. IDO mRNA levels in A549 cells ± IFNγ (25, 50 or 100 ng/ml). A549 cells
were treated with or without IFNγ (25, 50 or 100 ng/ml) and RNA was isolated 20 h later.
cDNA was synthesized from the isolated RNA (1 µg) and then used as the template for
IDO and GAPDH cDNA amplification by PCR. Top bands represent IDO and the lower
bands represent the housekeeping gene GAPDH. PCR amplification products were
separated by electrophoresis through a 1.5% non-denaturing agarose gel. Lane 1:
Molecular weight ladder for GAPDH. Lane 2-4: A549 cells without IFNγ treatment. Lane
5-7: A549 cells with IFNγ treatment (25 ng/ml). Lane 8-10: A549 cells with IFNγ
treatment (50 ng/ml). Lane 11-13: A549 cells with IFNγ treatment (100 ng/ml). Lane 14:
non-template control. Lane 15: Molecular weight ladder for IDO. The GAPDH PCR
product is 750 bp and IDO PCR product is 800 bp.
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Figure 4. 3. IDO mRNA levels in HeLa cells ± IFNγ (25, 50 or 100 ng/ml). HeLa cells
were treated with or without IFNγ (25, 50 or 100 ng/ml) and RNA was isolated 20 h later.
cDNA was synthesized from the isolated RNA (1 µg) and then used as the template for
IDO and GAPDH cDNA amplification by PCR. Top bands represent IDO and the lower
bands represent the housekeeping gene GAPDH. PCR amplification products were
separated by electrophoresis through a 1.5% non-denaturing agarose gel. Lane 1-3: HeLa
cells without IFNγ treatment. Lane 4-6: HeLa cells with IFNγ treatment (25 ng/ml). Lane
7-9: HeLa cells with IFNγ treatment (50 ng/ml). Lane 10-12: HeLa cells with IFNγ
treatment (100 ng/ml). Lane 13: non-template control. Lane 14: Molecular weight ladder
for GAPDH. Lane 15: Molecular weight ladder for IDO. The GAPDH PCR product is
750 bp and IDO PCR product is 800 bp.
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Figure 4. 4. IDO protein levels in A549 cells ± IFNγ (25 ng/ml). A549 cells were
treated with or without IFNγ (25 ng/ml) and lysed 48 h later. Immunoblots were probed
for IDO and α actin. The top bands represent IDO and the lower bands represent α actin.
Lane 1: A549 cells with IFNγ treatment. Lane 2: A549 cells without IFNγ treatment.
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4.2

IDO mRNA Levels in H441 Cells
H441 human lung adenocarcinoma cells endogenously express IDO [262][personal

communication, Dr. Vios Karanikas (Cancer Immunology unit, department of
Immunology, University of Thessaly, Greece)]. IDO mRNA levels were measured in
H441 cells 24 h after culture (without IFNγ treatment). H441 cells endogenously express
IDO mRNA and do not require IFNγ induction (Figure 4.5).
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Figure 4. 5. IDO mRNA levels in H441 cells. H441 cells were cultured for 24 h
(without IFNγ treatment) and RNA isolated. cDNA was synthesized from the isolated
RNA (1 µg) and then used as the template for IDO and GAPDH cDNA amplification by
PCR. Top bands represent IDO and the lower bands represent the housekeeping gene
GAPDH. PCR amplification products were separated by electrophoresis through a 1.5%
non-denaturing agarose gel. Lane 1: Molecular weight ladder for GAPDH. Lane 2-4:
H441 cells without IFNγ treatment (three replicates). Lane 5: non-template control. Lane
6: Molecular weight ladder for IDO. GAPDH PCR product is 750 bp and IDO PCR
product is 800 bp.
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4.3

IDO siRNA Downregulation in A549 and H441 Cells
In order to study the effect of IDO on tumour cell response to chemotherapy and

radiation, we reduced IDO mRNA in A549 cells by siRNA transfection. We transfected
A549 cells with 4 different IDO siRNAs (siRNAs A, B, C, and D) using two different
methods (described in Chapter 3, Section 3.18). IDO-expressing H441 cells were
similarly transfected with 4 different IDO siRNAs but without IFNγ induction. As shown,
siRNA did not appreciably reduce IDO mRNA in tumour cells (Figures 4.6 A-B, 4.7, 4.8).
The numerical reductions in IDO mRNA observed after siRNA transfection (PCRgenerated bands quantified using GelEval 1.37 software), were:
A549 cells: IDO siRNA A: 20% reduction, IDO siRNA B: 4% reduction, IDO siRNA C:
14% reduction, IDO siRNA D: 30% reduction.
H441 cells: IDO siRNA A: no reduction, IDO siRNA B 0%, IDO siRNA C 50%, IDO
siRNA D 10% downregulation.
Note that these did not achieve statistical significance.
The minimal capacity of IDO siRNA to reduce IDO mRNA was confirmed by qPCR
(Figure 4.8 and Figure 4.9).
4.4

Plasmid Quality Control and Diagnostic Restriction Digest (anti-IDO shRNA
Stable Transfection)
To analyze the purified plasmids isolated from bacteria, we digested plasmid

DNA with Pst I (described in Chapter 3, Section 3.3.2). The undigested plasmid was used
as negative control. Plasmids containing the desired shRNA generated 2 diagnostic bands
(3200 bp and 1400 bp) when separated by gel electrophoresis (Figure 4.10).
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Figure 4. 6. IDO mRNA levels in A549 cells after transfection with IDO siRNA. A,
A549 cells were treated with IFNγ (50 ng/ml) 6 h before transfection. A549 cells were
transfected with IDO siRNA. Growth medium containing IFNγ (25 ng/ml) was added to
the cells 4 h after transfection. RNA was isolated from cells 24 h post transfection and
cDNA was synthesized. Generated cDNA was used for PCR amplification of IDO and
GAPDH cDNA. B, A549 cells were transfected with IDO siRNA. Growth medium
containing IFNγ (25 ng/ml) was added to the cells 4 h after transfection. RNA was
isolated from cells 24 h post-transfection and cDNA was synthesized using that RNA as
template. Generated cDNA was used for PCR amplification of IDO and GAPDH cDNA
to quantitate relative IDO mRNA. Lanes 1-3: A549 cells treated with medium (no
transfection). Lanes 4-6: A549 cells transfected with LFA2K only. Lanes 7-9: A549 cells
transfected with control (ctl) 2 siRNA. Lanes 10-12: A549 cells transfected with IDO
siRNA A. Lanes 13-15: A549 cells transfected with siRNA B. Lanes 16-18: A549 cells
transfected with siRNA C. Lanes 19-21: A549 cells transfected with siRNA D. Lane 22:
non-template control (ntc) for PCR. The top bands represent IDO and lower bands
represent GAPDH.
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Figure 4. 7. IDO mRNA levels in H441 cells after transfection with IDO siRNA.
H441 cells were transfected with IDO siRNA. Growth medium was added to the cells 4 h
after transfection. RNA was isolated from cells 24 h post transfection and cDNA was
synthesized. Generated cDNA was used for PCR amplification of IDO and GAPDH
cDNA. Lanes 1-3: H441 cells treated with medium (no transfection). Lanes 4-6: H441
cells transfected with LFA2K only. Lanes 7-9: H441 cells transfected with control (ctl) 2
siRNA. Lanes 10-12: H441 cells transfected with IDO siRNA A. Lanes 13-15: H441
cells transfected with siRNA B. Lanes 16-18: H441 cells transfected with siRNA C.
Lanes 19-21: H441 cells transfected with siRNA D. The top bands represent IDO and
lower bands represent GAPDH.
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Figure 4. 8. qPCR analysis of IDO mRNA in A549 cells following siRNA
transfection. A549 cells were transfected with IDO siRNA. Growth medium containing
IFNγ (25 ng/ml) was added to the cells 4 h after transfection. RNA was isolated from
cells 24 h post transfection and cDNA was synthesized. Generated cDNA was used for
qPCR analysis of IDO and GAPDH mRNA. Results from all groups were normalized to
control siRNA. Medium, treated with cultured medium only. LFA2K, treated with
Lipofectamine 2000 only. Control siRNA, transfected with control siRNA. IDO siRNA A,
transfected with IDO siRNA A. IDO siRNA B, transfected with IDO siRNA B. IDO
siRNA C, transfected with IDO siRNA C. IDO siRNA D, transfected with IDO siRNA D.
Each bar represents the mean of 3 values (n=3 for determination of each value from 3
independent experiments) ± SEM.
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Figure 4. 9. qPCR analysis of IDO mRNA in H441 cells following siRNA
transfection. H441 cells were transfected with IDO siRNA. Growth medium containing
was added to the cells 4 h after transfection. RNA was isolated from cells 24 h post
transfection and cDNA was synthesized. Generated cDNA was used for qPCR analysis of
IDO and GAPDH mRNA. Results from all groups were normalized to control siRNA.
Medium, cells were treated with cultured medium only. LFA2K, treated with
Lipofectamine 2000 only. Control siRNA, transfected with control siRNA. IDO siRNA A,
transfected with IDO siRNA A. IDO siRNA B, transfected with IDO siRNA B. IDO
siRNA C, transfected with IDO siRNA C. IDO siRNA D, transfected with IDO siRNA D.
Each bar represents the mean of 3 values (n=3 for determination of each value from 3
independent experiments) ± SEM.
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Figure 4. 10. Pst 1 digestion to confirm the presence of IDO shRNA in the
expression vector. Pst I cleavage generates two DNA bands diagnostic for IDO shRNA
(3200 bp and 1400 bp). Purified plasmids were digested with the restriction enzyme Pst I
for one hour at 37° C to confirm the presence of desired shRNA. The final products of
digestion along with undigested supercoiled plasmids were separated on a 1% agarose gel.
Lane 1: Molecular weight ladder. Lane 2, Pst I-digested plasmid containing shRNA 1.
Lane 3: undigested supercoiled plasmid containing shRNA 1. Lane 4: Pst I-digested
plasmid containing shRNA 2. Lane 5: undigested supercoiled plasmid containing shRNA
2. Lane 6: Pst I-digested plasmid containing shRNA 3. Lane 7: undigested supercoiled
plasmid containing shRNA 3. Lane 8: Pst I-digested plasmid containing shRNA 4. Lane
9: undigested supercoiled plasmid containing shRNA 4. Lane 10: Pst I-digested plasmid
containing scrambled shRNA. Lane 11: undigested supercoiled plasmid containing
scrambled shRNA.
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4.5

IDO mRNA Quantification in A549 and H441 Clonal Population
To measure IDO mRNA levels in the stable cell lines, RNA was isolated from

stably-transfected A549 and H441 clonally-selected populations as described (Chapter 3,
Section 3.5). IDO mRNA and 18S rRNA levels were measured simultaneously by
multiplex real-time PCR amplification (Figure 4.11) as described (Chapter 3, Section 3.7).
Several A549 clonal cell lines, which are NC-3, NC-10, NC-30, 2-4, 2-6, and 2-18 were
selected for further analysis based on the degree of shRNA-associated reduction in IDO
mRNA levels after IFNγ induction (Figure 4.12). Similarly, several H441 clonal
populations were selected for analysis based on IDO mRNA reduction in these naturallyIDO expressing clones (Figure 4.13).
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Figure 4. 11. IDO mRNA quantification in A549 clonal populations. A549 clonal
populations were treated with IFNγ (25 ng/ml) for 24 h. RNA was isolated and used to
generate cDNA. IDO mRNA and 18S rRNA levels were assessed simultaneously by
multiplex qPCR amplification. A, white bars, A549 clonal cells transfected with
scrambled control shRNA and B, black bars A549 clonal cells transfected with anti-IDO
shRNA. Each bar represents the mean of 3 values (n=3 for determination of each value) ±
SEM.
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Figure 4. 12. IDO mRNA levels in selected A549 clonal cell lines. A549 cell lines
stably-transfected with anti-IDO shRNA (2-4, 2-6, and 2-18) or scrambled shRNA (NC-3,
NC-10, and NC-30) were treated with IFNγ (25 ng/ml) for 24 h. IDO mRNA and 18S
rRNA were quantified 24 h post-IFNγ treatment by qPCR. White bars: A549 clonal cells
transfected with scrambled control shRNA. Black bars: A549 clonal cells transfected
with anti-IDO shRNA. The selected clones were used for future experiments. Each bar
represents the mean of 3 values (n=3 for determination of each value) ± SEM (*P < 0.05).

102

103

Figure 4. 13. IDO mRNA quantification in H441 clonal populations. H441 clonal
populations stably transfected with scrambled shRNA or anti-IDO shRNA were cultured
for 24 h without IFNγ treatmen). RNA was isolated from cells and used to generate
cDNA. IDO mRNA and 18S rRNA levels were measured simultaneously by multiplex
qPCR amplification. From left to right: Scrambled shRNA, H441 cells transfected with
scrambled shRNA. Anti-IDO shRNA #1, H441 cells transfected with anti-IDO
shRNA#1. Anti-IDO shRNA #2, H441 cells transfected with anti-IDO shRNA #2. AntiIDO shRNA #3, H441 cells transfected with anti-IDO shRNA #3. Anti-IDO shRNA #4,
H441 cells transfected with anti-IDO shRNA #4. All clones are normalized to clone 2-16,
which exhibited the lowest IDO mRNA level. Each bar represents the mean of 3 values
(n=3 for determination of each value) ± SEM.
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4.6

IDO Protein Levels in A549 and HeLa Clonal Populations
IDO protein levels were measured in A549 and HeLa selected clonal populations

as described (Chapter 3, Section 3.8). Anti-IDO shRNA decreased IDO protein levels in
A549 and HeLa clonal populations compared to non-targeting control shRNA,
respectively (Figures 4.14 and 4.15).
4.7

IDO Levels are Inversely Correlated with Tumour Cell Proliferation
IDO expression is correlated with decreased proliferation [135]. Therefore, the

effect of anti-IDO shRNA on IDO-mediated slow growth was examined. A549 and HeLa
cell clonal populations were treated with IFNγ (25 ng/ml) and allowed to proliferate for
72 h. High IDO levels were associated with reduced proliferation of A549 and HeLa
clonal cells, and the presence of anti-IDO shRNA attenuated IFNγ-induced reduction in
proliferation (Figures 4.16 and 4.17). These data suggest that IFNγ-induced IDO protein
is functional in these cells and that anti-IDO shRNA reduces IDO function.
4.8

IDO Effect on A549 Cell Cycle
IDO-mediated depletion of tryptophan induces cell cycle arrest in T cells at the G1

phase of the cell cycle [263]. We therefore determined whether IDO-induced reduction in
growth of cancer cells was associated with altered cell cycle. A549 cells were cultured
with and without IFNγ for 48 h. The cell cycle was then measured as described in section
3.12. IFNγ induction of IDO increased the number of cells in G1 by 10% and decreased
the numbers in G2/M in cells expressing scrambled control shRNA by the same amount.
The presence of anti-IDO shRNA in cells treated with IFNγ abolished the increase in the
number of cells in G1 and the decrease in the number of cells in G2/M (Figure 4.18).
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Figure 4. 14. IDO protein levels in A549 clonal cell populations with and without
IFNγ (25 ng/ml) treatment. IDO was induced in A549 clonal populations by IFNγ
treatment (25 ng/ml) for 48 h. Non-treated A549 clonal cells were used to determine the
basal level of IDO without IFNγ induction by immunoblot. A549 cells untransfected with
plasmids harbouring shRNA were used as controls (WT).
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Figure 4. 15. IDO protein levels in HeLa clonal cells with and without IFNγ (25
ng/ml) treatment. IDO was induced in HeLa clonal populations by IFNγ treatment (25
ng/ml) for 48 h and assessed by immunoblot. Untreated HeLa clonal cell populations
were used to determine the basal level of IDO without IFNγ induction.
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Figure 4. 16. IDO slows proliferation of A549 cells and anti-IDO shRNA attenuates
the IDO-mediated reduction in proliferation. A549 clonal populations were cultured
with and without IFNγ (25 ng/ml) for 72 h. Tumour cells were washed with PBS and
trypsinized. Tumour cell proliferation was enumerated by cell counting. Each bar
represents the mean of 3 independent experiments (n=3 for determination of each value)
± SEM (*P < 0.05).
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Figure 4. 17. IDO slows proliferation of HeLa cells and anti-IDO shRNA attenuates
IDO-mediated reduction in proliferation. HeLa clonal cell populations were cultured
with and without IFNγ (25 ng/ml) for 72 h. Tumour cells were washed with PBS and
trypsinized. Tumour cell proliferation was enumerated by cell counting. Each bar
represents the mean of 3 independent experiments (n=3 for determination of each value)
± SEM (*P < 0.05).
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Figure 4. 18. IDO mediated the increased accumulation of cells in G1 and decreased
accumulation in G2/M in A549 cells. Tumour cells were cultured overnight, treated with
or without IFNγ (25 ng/ml) for 48 h, and analyzed for cell cycle compartmentalization as
described in Materials and Methods. Each bar represents pooled data to generate mean
values from 3 independent clonal populations harbouring scrambled control shRNA or
anti-IDO shRNA, and each bar represents the mean of those 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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4.9

IDO Downregulation Decreases Intracellular NAD+
IDO is responsible for de novo synthesis of NAD+ from tryptophan. Whether or

not anti-IDO shRNA decreased NAD+ levels in A549 cells (as described in Chapter 3,
Section 3.9) was examined. Anti-IDO shRNA decreased NAD+ levels in A549 clonal
populations by 60% (Figure 4.19).
4.10 IDO Mediates Resistance to the NAD+ Inhibitor FK866
FK866 is a pharmacological inhibitor of NAD+ synthesis from the salvage
pathway and is being evaluated for clinical anticancer efficacy [264]. IDO inhibition
decreased NAD+ levels in A549 cells by approximately 60% (Figure 4.19), similar to the
degree of reduction of NAD+ induced in human tumour cells by FK866 [242]. I
hypothesized that the IDO-mediated increase in NAD+ had the potential to counter the
therapeutic effect of FK866. To test this hypothesis, I induced IDO in A549 clonal
populations with IFNγ (25 ng/ml) for 48 h and then treated the cells with FK866 as
described (Chapter 3, Section 3.15). IDO increased the resistance of A549 clonal cells to
FK866 and anti-IDO shRNA partially decreased this effect (Figure 4.20). Clone 2-4
(containing anti-IDO shRNA) has a greater amount of IDO than clones 2-6 and 2-18
(Figures 4.14 and 4.20) and was also more resistant than those clones to the effect of
FK866 (Figure 4.20). There was a relatively modest positive linear correlation (R2=0.54)
between IDO protein levels and resistance to FK866 (Figure 4.20, Panel C).
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Figure 4. 19. IDO downregulation decreased NAD+ in A549 cells. A549 clonal cell
populations were treated with IFNγ (25 ng/ml) for 48 h. Lysates were prepared from
treated cells and total NAD (NADt) and NADH were measured. NAD+ levels were
calculated by subtracting NADH from NADt. Each bar represents the mean of 3 values
(n=3 for determination of each value) ± SEM (*P < 0.05).
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Figure 4. 20. A549 clonal cell population sensitivity to FK866 (5 nM) before and
after IDO induction. Panels A-B present data for each of 6 individual clonal
populations before and after IDO induction. A549 clonal cell populations were cultured
with or without IFNγ (25 ng/ml) for 48 h. Medium was then replaced with fresh growth
medium containing FK866 (5 nM) and cells were allowed to proliferate for 72 h. Cells
were then trypsinized and live cells were enumerated. White bars: A549 clones
transfected with scrambled shRNA. Gray bars: A549 cells transfected with anti-IDO
shRNA. Each bar represents the mean of 3 values (n=3 for determination of each value) ±
SD. Panel C: Correlation analysis of the relationship between IDO protein content
(relative to actin) and clonal population resistance to FK866 (proliferation relative to
untreated control cells).
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4.11 IDO in Tumour Cells Mediates Resistance to Olaparib
NAD+ is necessary for PARP activity [215] and anti-IDO shRNA decreased NAD+
levels in A549 cells. Therefore, the capacity of IDO to increase tumour cell resistance to
olaparib, and the capacity of anti-IDO shRNA to reverse this effect, was assessed. A549
and HeLa clonal cell populations were treated with olaparib as described (Chapter 3,
Section 3.11). IDO downregulation sensitized A549 cells to low dose olaparib by 16%
(p= 4 x 10-4)(Figures 4.21 and 4.22). Similarly, IDO downregulation sensitized A549
cells to high doses of olaparib by 18% (p= 1 x 10-3)(Figures 4.23 and 4.24). Cells with
unimpeded IDO expression after IFNγ induction had increased resistance to olaparib (i.e.,
increased IDO was associated with reduced drug effectiveness), while antisensedownregulation of IDO during and after IFNγ induction resulted in sensitivity to olaparib
equal to that of cells untreated with IFNγ (Figure 4.25). Some HeLa clonal cells showed a
similar pattern of sensitivity to olaparib in the absence of IDO. However, their sensitivity
was less potent compared to A549 cells (Figure 4.26 and 4.27). These results show that
IDO expression in tumour cells confers resistance to olaparib and, since all clonal
populations were treated identically with IFNγ, the observed resistance to olaparib was
due solely to the presence of shRNA (and, by extension, IDO knockdown) and not effects
of IFNγ unrelated to IDO.
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Figure 4. 21. A549 clonal cell population sensitivity to low dose olaparib (1.5 µM)
before and after IDO induction. Panels A-B present data for each of 6 individual clonal
populations before and after IDO induction. A549 clonal populations were cultured with
or without IFNγ (25 ng/ml) for 48 h. Cultured medium was then replaced with fresh
growth medium containing olaparib (1.5 µM) and cells were allowed to proliferate for 72
h. Cells were then trypsinized and live cells were enumerated using a Coulter counter.
White bars represent A549 clones transfected with scrambled shRNA and gray bars
represent A549 cells transfected with anti-IDO shRNA. Each bar represents the mean of
3 values (n=3 for determination of each value) ± SD. Significant changes are shown in
pooled results (Figure 4.22).

123

124

Figure 4. 22. Sensitivity of clonal A549 populations to low dose olaparib (1.5 µM)
before (A) and after (B) IDO induction. Data shown in Figure 4.21 were pooled to
generate mean values from 3 independent clonal populations harbouring scrambled
control shRNA or anti-IDO shRNA, and each bar represents the mean of those 3 values
(n=3 for determination of each value) ± SEM (*P < 0.05).
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Figure 4. 23. A549 clone sensitivity to high dose olaparib (5 µM) before and after
IDO induction. Panels A-B present data for each of 6 individual clonal populations
before and after IDO induction. A549 clonal populations were cultured with or without
IFNγ (25 ng/ml) for 48 h. Cultured medium was then replaced with fresh growth medium
containing olaparib (5 µM) and cells were allowed to proliferate for 72 h. Cells were then
trypsinized and live cells were enumerated using a Coulter counter. White bars represent
A549 clones transfected with scrambled shRNA and gray bars represent A549 cells
transfected with anti-IDO shRNA. Each bar represents the mean of 3 values (n=3 for
determination of each value) ± SD. Significant changes are shown in pooled results
(Figure 4.24).

127

128

Figure 4. 24. Sensitivity of clonal A549 populations to high dose olaparib (5 µM)
before (A) and after (B) IDO induction. Data shown in Figure 4.23 were pooled to
generate mean values from 3 independent clonal populations harbouring scrambled
control shRNA or anti-IDO shRNA, and each bar represents the mean of the 3 values
(n=3 for determination of each value) ± SEM (*P < 0.05).
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Figure 4. 25. Induction of IDO in A549 clonal cell populations decreases the
effectiveness of olaparib. Results were obtained from 3 independent clonal cell
populations with scrambled control shRNA or anti-IDO shRNA, and each bar represents
the mean of the 3 values (n=3 for determination of each value) ± SEM (*p < 0.05).
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Figure 4. 26. HeLa clone sensitivity to high dose olaparib (5 µM) before and after
IDO induction. Panels A-B present data for each of 6 individual clonal populations
before and after IDO induction. HeLa clonal populations were cultured with or without
IFNγ (25 ng/ml) for 48 h. Cultured medium was then replaced with fresh growth medium
containing olaparib (5 µM) and cells were allowed to proliferate for 72 h. Cells were then
trypsinized and live cells were enumerated using a Coulter counter. White bars represent
HeLa clones transfected with scrambled shRNA and gray bars represent HeLa cells
transfected with anti-IDO shRNA. Each bar represents the mean of 3 values (n=3 for
determination of each value) ± SD. Significant changes are shown in pooled results
(Figure 4.27).
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Figure 4. 27. Sensitivity of clonal HeLa populations to high dose olaparib (5 µM)
before (A) and after (B) IDO induction. Data shown in Figure 4.26 were pooled to
generate mean values from 3 independent clonal populations harbouring scrambled
control shRNA or anti-IDO shRNA, and each bar represents the mean of the 3 values
(n=3 for determination of each value) ± SEM (*P < 0.05).

135

4.12

IDO Mediates Resistance to γ Radiation in Cancer Cells
In view of the potential for IDO to modulate PARP activity, it was hypothesized

that human tumour cell IDO mediates resistance to ionizing γ radiation. We irradiated
A549 and HeLa clonal cell lines as described (Chapter 3, Section 3.12). IDO
downregulation sensitized A549 and HeLa cells to radiation by approximately 20%
(P=2.6 x 10-7) and 10% (P=0.021), respectively (Figures 4.28, 4.29, 4.31, 4.32, and 4.33).
A549 and HeLa clones untreated with IFNγ (i.e., lacking IDO) were equally sensitive to
radiation regardless of whether or not they harboured anti-IDO shRNA. In addition, IDO
induced by IFNγ treatment of A549 clones lacking anti-IDO shRNA (i.e., stably
expressing only control scrambled shRNA) increased resistance to γ radiation by
approximately 15%, compared with no change in clones harbouring anti-IDO shRNA
(Figures 4.30). A trend toward a similar response was observed in HeLa cells, but did not
achieve statistical significance (Figure 4.34).
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Figure 4. 28. A549 clone sensitivity to γ radiation (4 Gy) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. A549 clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h. Cultured cells were then irradiated (4 Gy) then the medium was then
replaced with fresh growth medium and cells were allowed to proliferate for 72 h. Cells
were then trypsinized and live cells were enumerated using a Coulter counter. White bars
represent A549 clones transfected with scrambled shRNA and gray bars represent A549
cells transfected with anti-IDO shRNA. Each bar represents the mean of the 3 values
(n=3 for determination of each value) ± SD. Significant changes are shown in pooled
results (Figure 4.29).
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Figure 4. 29. Sensitivity of clonal A549 populations to γ radiation (4 Gy) before (A)
and after (B) IDO induction. Data shown in Figure 4.28 were pooled to generate mean
values from 3 independent clonal populations harbouring scrambled control shRNA or
anti-IDO shRNA, and each bar represents the mean of the 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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Figure 4. 30. Induction of IDO in A549 clonal cell induces resistance to γ radiation.
Results were obtained from 3 independent clonal cell populations with scrambled control
shRNA or anti-IDO shRNA, and each bar represents the mean of those 3 values (n=3 for
determination of each value) ± SEM (*P<0.05).
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Figure 4. 31. Induction of IDO in A549 clonal cell induces resistance to γ radiation.
A549 cells were induced with IFNγ (25 ng/ml) for 48 h. Cells were then γ irradiated (4
Gy), trypsinized and 300 cells were seeded in 6-well plates. Colonies were stained with
0.5% crystal violet 7 days later. Each bar represents the mean of 3 values (n=3 for
determination of each value) ± SEM (* P < 0.05).
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Figure 4. 32. HeLa clone sensitivity to γ radiation (4 Gy) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. HeLa clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h. Cultured cells were then irradiated (4 Gy) then the medium was then
replaced with fresh growth medium and cells were allowed to proliferate for 72 h. Cells
were then trypsinized and live cells were enumerated using a Coulter counter. White bars
represent HeLa clones transfected with scrambled shRNA and gray bars represent HeLa
cells transfected with anti-IDO shRNA. Each bar represents the mean of the 3 values
(n=3 for determination of each value) ± SD. Significant changes are shown in pooled
results (Figure 4.33).
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Figure 4. 33. Sensitivity of clonal HeLa populations to γ radiation (4 Gy) before (A)
and after (B) IDO induction. Data shown in Figure 4.32 were pooled to generate mean
values from 3 independent clonal populations harbouring scrambled control shRNA or
anti-IDO shRNA, and each bar represents the mean of the 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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Figure 4. 34. Induction of IDO in HeLa clonal cell populations and association with
resistance to γ radiation. Results were obtained from 3 independent clonal cell
populations with scrambled control shRNA or anti-IDO shRNA, and each bar represents
the mean of those 3 values (n=3 for determination of each value) ± SEM (p = 0.06). A
trend toward increased resistance to γ radiation with increased IDO was observed but did
not achieve statistical significance.
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4.13 IDO in Human Tumour Cells Mediates Resistance to Combined γ Radiation
and PARP Inhibition
In light of the common clinical use of combination therapies and the common goal
of causing DNA damage and subsequently inhibiting DNA repair through the use of γ
radiation and PARP inhibitors, respectively, it was of interest to determine the effect of
IDO on cancer cell sensitivity to the combination of these treatments. We tested this
questions by inducing IDO in A549 and HeLa clones as described (Chapter 3, Section
3.13). Prior to treatment with IFNγ, all clonal A549 populations harbouring either antiIDO shRNA or control scrambled shRNA were equally sensitive to combined treatment
(Figures 4.35 and 4.36). In the case of HeLa clonal cell populations, those harbouring
scrambled shRNA were more sensitive to combination treatment than clonal cells with
anti-IDO shRNA (Figures 4.38 and 4.39). After IDO induction by IFNγ, A549 and HeLa
clones harbouring anti-IDO shRNA were approximately 30% and 20% more sensitive to
combined treatment with γ radiation and olaparib, respectively, than similarly-treated
clones harbouring control scrambled shRNA (p<0.05)(Figures 4.35 and 4.38). In addition,
in A549 clonal cell populations, IFNγ induced IDO-mediated resistance to the
antiproliferative effects of combined olaparib and γ radiation, but anti-IDO shRNA
abolished that resistance (Figure 4.37). HeLa clonal populations showed a similar trend
but that trend did not achieve statistical significance (Figure 4.40).
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Figure 4. 35. A549 sensitivity to combined γ irradiation (4 Gy) and olaparib (5 µM)
treatment before (A) and after (B) IDO induction. A549 cells were induced with with
or without IFNγ (25 ng/ml) for 48 h. Cells were then treated with γ radiation (4 Gy) and
the medium was immediately replaced with fresh growth medium with olaparib (5 µM).
Cells were allowed to proliferate for 72 h. Results were obtained from independent
measurements of proliferation of three A549 clonal populations (2 independent
experiments for each population) with control scrambled shRNA and 3 with anti-IDO
shRNA. Bars represent the means of those 3 independent measurements (n=3 for each
measurement) ± SEM (*p<0.05). White bars represent A549 clones transfected with
scrambled shRNA and gray bars represent A549 cells transfected with anti-IDO shRNA.
Each bar represents the mean of the 3 values (n=3 for determination of each value) ± SD.
Significant changes are shown in pooled results (Figure 4.36).
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Figure 4. 36. Sensitivity of clonal A549 populations to combined γ radiation (4 Gy)
and olaparib (5 µM) treatment before (A) and after (B) IDO induction. Data shown
in Figure 4.35 were pooled to generate mean values from 3 independent clonal
populations harbouring scrambled control shRNA or anti-IDO shRNA, and each bar
represents the mean of those 3 values (n=3 for determination of each value) ± SEM (*P <
0.05).
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Figure 4. 37. Induction of IDO in A549 clonal cell induces resistance to combined γ
radiation and olaparib treatment. Results were obtained from 3 independent clonal cell
populations with scrambled control shRNA or anti-IDO shRNA, and each bar represents
the mean of those 3 values (n=3 for determination of each value) ± SEM (*p<0.05).

157

158

Figure 4. 38. HeLa sensitivity to combined γ irradiation (4 Gy) and olaparib (5 µM)
treatment before (A) and after (B) IDO induction. HeLa cells were induced with with
or without IFNγ (25 ng/ml) for 48 h. Then the cells were treated with γ radiation (4 Gy)
and the medium was immediately replaced with fresh growth medium harbouring
olaparib (5 µM). Cells were allowed to proliferate for 72 h. Results were obtained from
independent measurements of proliferation of 3 HeLa clonal populations (2 independent
experiments for each population) with control scrambled shRNA and 3 with anti-IDO
shRNA. Bars represent the means of those 3 independent measurements (n=3 for each
measurement) ± SEM (*p<0.05). White bars represent HeLa clones transfected with
scrambled shRNA and gray bars represent HeLa cells transfected with anti-IDO shRNA.
Each bar represents the mean of the 3 values (n=3 for determination of each value) ± SD.
Significant changes are shown in pooled results (Figure 4.39).
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Figure 4. 39. Sensitivity of clonal HeLa populations to combined γ radiation (4 Gy)
and olaparib (5 µM) treatment before (A) and after (B) IDO induction. Data shown
in Figure 4.38 were pooled to generate mean values from 3 independent clonal
populations harbouring scrambled control shRNA or anti-IDO shRNA, and each bar
represents the mean of those 3 values (n=3 for determination of each value) ± SEM (*P <
0.05).
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Figure 4. 40. Antisense reduction of IDO in A549 clonal cell reduces resistance to
combined γ radiation and olaparib treatment. Results were obtained from 3
independent clonal cell populations with scrambled control shRNA or anti-IDO shRNA,
and each bar represents the mean of those 3 values (n=3 for determination of each value)
± SEM (*p<0.05). Increased IDO in these cells induced a trend toward increased cell
survival in the presence of olaparib but that trend did not achieve statistical significance
(p=0.07).
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4.14 IDO in Human Tumour Cells Mediates Resistance to the Base Excision Repair
Inhibitor Methoxyamine
NAD+ is required for PARP function and PARP is essential for recruitment of the
BER scaffold protein XRCC1 to damaged DNA [200]. In light of our observation that
IDO plays a role in mediating resistance to the PARP inhibitor olaparib, the capacity of
IDO to mediate resistance to the BER inhibitor methoxyamine was examined. A549 cells
were treated with or without IFNγ (25 ng/ml) for 48 h to induce IDO. Tumour cells were
then treated with methoxyamine as described (Chapter 3, Section 3.16). IDO
downregulation sensitized cancer cells to methoxyamine (Figures 4.41 and 4.42). Of
particular note, A549 clone 2-4, although it is stably transfected with anti-IDO shRNA,
had a higher level of IDO than anti-IDO shRNA-containing clones 2-6 and 2-18 (Figure
4.12) and showed a higher degree of methoxyamine resistance than shRNA-transfected
clones with lower levels of IDO (Figure 4.41, Panel C, showing a moderate correlation
between IDO level and methoxyamine resistance [R2 = 0.83]). In addition, IFNγ induced
IDO-mediated resistance to the antiproliferative effects of methoxyamine, and anti-IDO
shRNA abolished that resistance (Figure 4.43).
4.15 IDO in Human Tumour Cells Mediates Resistance to the TS-targeting Drug
Pemetrexed
Thymidylate synthase (TS) is important in DNA repair and DNA synthesis and is
overexpressed in most human cancers [245]. The TS-targeting drug pemetrexed is
commonly used to treat multiple types of human cancer including NSCLC and colorectal
cancer [179]. BER is reported to be important in cancer cell resistance to this drug. The
sensitivity of A549 clonal populations to pemetrexed in the presence of IDO was
therefore tested. Clonal A549 cell populations were treated with pemetrexed as described
in chapter 3, section 3.14. IDO downregulation sensitized cancer cells to pemetrexed
(Figures 4.44 and 4.45). Furthermore, IFNγ-induced IDO decreased the effectiveness of
pemetrexed in IDO-expressing cancer cells but the IDO-mediated decrease in pemetrexed
effectiveness was reduced in A549 clonal cell populations harbouring anti-IDO shRNA
(Figure 4.46).
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Figure 4. 41. A549 clone sensitivity to methoxyamine (3 mM) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. A549 clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h. Cultured medium was then replaced with fresh growth medium
containing methoxyamine (3 mM) and cells were allowed to proliferate for 72 h. Cells
were then trypsinized and live cells were enumerated. White bars represent A549 clones
transfected with scrambled shRNA and gray bars represent A549 cells transfected with
anti-IDO shRNA. Each bar represents the mean of 3 values (n=3 for determination of
each value) ± SD. Significant changes are shown in pooled results (Figure 4.42). Panel
C: relationship between IDO protein level (relative to actin) and resistance to
methpxyamine (MX) (proliferation relative to untreated control cells). The R2 value of
0.83 represents a moderate positive relationship.
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Figure 4. 42. Sensitivity of clonal A549 populations to methoxyamine (3 mM) before
(A) and after (B) IDO induction. Data shown in Figure 4.41 were pooled to generate
mean values from 3 independent clonal populations harbouring scrambled control shRNA
or anti-IDO shRNA, and each bar represents the mean of those 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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Figure 4. 43. Induction of IDO in A549 clonal cell induces resistance to
methoxyamine (3 mM). Results were obtained from 3 independent clonal cell
populations with scrambled control shRNA or anti-IDO shRNA, and each bar represents
the mean of those 3 values (n=3 for determination of each value) ± SEM (*p < 0.05).
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Figure 4. 44. A549 clone sensitivity to pemetrexed (200 nM) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. A549 clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h, then with pemetrexed (200 nM), and enumerated 72 h later. White bars
represent A549 clones transfected with scrambled shRNA and gray bars represent A549
cells transfected with anti-IDO shRNA. Each bar represents the mean of 3 values (n=3
for determination of each value) ± SD. Significant changes are shown in pooled results
(Figure 4.45).
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Figure 4. 45. Sensitivity of clonal A549 populations to pemetrexed (200 nM) before
(A) and after (B) IDO induction. Data shown in Figure 4.44 were pooled to generate
mean values from 3 independent clonal populations harbouring scrambled control shRNA
or anti-IDO shRNA, and each bar represents the mean of those 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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Figure 4. 46. Induction of IDO in A549 clonal cell induces resistance to pemetrexed
(200 nM). Results were obtained from 3 independent clonal cell populations with
scrambled control shRNA or anti-IDO shRNA, and each bar represents the mean of those
3 values (n=3 for determination of each value) ± SEM (*p < 0.05).
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4.16 IDO in Human Tumour Cells Mediates Resistance to Combined Treatment of
Pemetrexed and Methoxyamine
A phase I clinical trial of combined methoxyamine and pemetrexed has been
completed and phase II clinical trials of that drug combination in multiple indications
including NSCLC are planned [179]. In view of our observation of IDO-mediated
resistance to both pemetrexed and methoxyamine, it was hypothesized that IDO could
induce resistance to combined methoxyamine and pemetrexed treatment. To test this
hypothesis, IDO was induced in A549 clonal cell populations and then those populations
were treated with a combination of pemetrexed (30 nM) and methoxyamine (3 mM) as
described in chapter 3, section 3.17. IDO downregulation sensitized cancer cells to
combined treatment (Figures 4.47 and 4.48). Moreover, IFNγ-induced IDO mediated
resistance to the combined pemetrexed and methoxyamine treatment and resistance was
reduced in the presence of anti-IDO shRNA (Figure 4.49). It should be noted that,
although it is stably transfected with anti-IDO shRNA, clone 2-4 has a higher level of
IDO than other clonal A549 populations containing anti-IDO shRNA (clones 2-6 and 218)(Figure 4. 12). Clone 2-4 was more resistant to combined pemetrexed and
methoxyamine treatment than clones 2-6 and 2-18, consistent with the existence of a
relationship between the amount of IDO in tumour cells and their resistance to combined
treatment with these two drugs (Figure 4.47, Panel C, R2=0.70).

177

Proliferation	
  
(%	
  control)	
  

C)
150	
  
100	
  
50	
  
0	
  
0	
  

0.2	
  

0.4	
  

0.6	
  

0.8	
  

1	
  

IDO	
  Protein	
  	
  
(Relative	
  to	
  actin	
  Protein)	
  
R²	
  =	
  0.70	
  

178

Figure 4. 47. A549 clone sensitivity to combined pemetrexed (30 nM) and
methoxyamine (3 mM) treatment before and after IDO induction. Panels A-B
present data for each of 6 individual clonal populations before and after IDO induction.
A549 clonal populations were cultured with or without IFNγ (25 ng/ml) for 48 h.
Cultured medium was then replaced with fresh growth medium containing pemetrexed
(30 nM) and methoxyamine. Tumour cells were then allowed to proliferate for 72 h.
Finally, cells were trypsinized and live cells were enumerated using a Coulter counter.
White bars represent A549 clones transfected with scrambled shRNA and gray bars
represent A549 cells transfected with anti-IDO shRNA. Each bar represents the mean of
3 values (n=3 for determination of each value) ± SD. Significant changes are shown in
pooled results (Figure 4.48). Panel C: relationship between IDO protein (relative to
actin) and clonal population resistance to combined pemetrexed and methoxyamine (MX)
treatment proliferation relative to untreated control cells). The R2 value of 0.7 represents a
moderate positive relationship.
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Figure 4. 48. Sensitivity of clonal A549 populations to combined pemetrexed (30
nM) and methoxyamine (3 mM) treatment before (A) and after (B) IDO induction.
Data shown in Figure 4.47 were pooled to generate mean values from 3 independent
clonal populations harbouring scrambled control shRNA or anti-IDO shRNA, and each
bar represents the mean of those 3 values (n=3 for determination of each value) ± SEM
(*P< 0.05).
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Figure 4. 49. Induction of IDO in A549 clonal cell induces resistance to combined
pemetrexed (30 nM) and methoxyamine (3 mM) treatment. Results were obtained
from 3 independent clonal cell populations with scrambled control shRNA or anti-IDO
shRNA, and each bar represents the mean of those 3 values (n=3 for determination of
each value) ± SEM (*p<0.05).
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4.17 The Effect of IDO Downregulation in Human Tumour Cells Sensitivity to
other TS-targeting Drugs (5FUdR and Gemcitabine)
Because IDO downregulation sensitized cancer cells to the TS-targeting drug
pemetrexed (Figure 4.44 and 4.45), we hypothesized that IDO downregulation could
sensitize cancer cells to other TS-targeting drugs commonly used in clinic, including
5FUdR and gemcitabine. Cancer cells were treated with IFNγ (25 ng/ml) for 48 h and
then 5FUdR or gemcitabine as described in chapter 3, section 3.14. IDO downregulation
did not sensitize cancer cells to 5FUdR (Figures 4.50 and 4.51), but did increase
sensitivity to gemcitabine (Figure 4.52 and 4.53). I should note that 5FUdR treatment
equally reduced proliferation in both scrambled control shRNA and anti-IDO shRNA
harbouring clonal populations before and after IFNγ treatment (Figures 4.50 and 4.51).
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Figure 4. 50. A549 clone sensitivity to 5FUdR (200 nM) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. A549 clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h and then 5FUdR (200 nM) for 72 h at which time live cells were
enumerated by Coulter counting. White bars represent A549 clones transfected with
scrambled shRNA and gray bars represent A549 cells transfected with anti-IDO shRNA.
Each bar represents the mean of 3 values (n=3 for determination of each value) ± SD.
Significant changes are shown in pooled results (Figure 4.51).
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Figure 4. 51. Sensitivity of clonal A549 populations to 5FUdR (200 nM) before (A)
and after (B) IDO induction. Data shown in Figure 4.50 were pooled to generate mean
values from 3 independent clonal populations harbouring scrambled control shRNA or
anti-IDO shRNA, and each bar represents the mean of the 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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Figure 4. 52. A549 clone sensitivity to gemcitabine (10 nM) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. A549 clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h, then treated with gemcitabine (10 nM) for 72 h, at which time live cells
were enumerated by Coulter counting. White bars represent A549 clones transfected with
scrambled shRNA and gray bars represent A549 cells transfected with anti-IDO shRNA.
Each bar represents the mean of 3 values (n=3 for determination of each value) ± SD.
Significant changes are shown in pooled results (Figure 4.53).
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Figure 4. 53. Sensitivity of clonal A549 populations to gemcitabine (10 nM) before
(A) and after (B) IDO induction. Data shown in Figure 4.52 were pooled to generate
mean values from 3 independent clonal populations harbouring scrambled control shRNA
or anti-IDO shRNA, and each bar represents the mean of those 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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4.18

The Effect of IDO Downregulation in Human Tumour Cells' Sensitivity to

Cisplatin
Since IDO downregulation sensitized cancer cells to γ radiation, it was also
determined whether IDO knockdown sensitized A549, HeLa and H441 cells to the DNA
cross-linking agent cisplatin. We induced IDO in A549 and HeLa cells by treatment with
IFNγ and then exposed cells to cisplatin for 72 h to determine the effect on proliferation.
We treated H441 cells with cisplatin as described (Chapter 3, Section 3.14). IDO
downregulation sensitized both A549 and HeLa cells to cisplatin treatment by 18%
compared to cells without IDO reduction (p<0.05)(Figures 4.54, 4.55, 4.57, and 4.58).
IFNγ-induced IDO mediated cancer cell resistance to cisplatin. In addition, the effect of
IFNγ-induced IDO was reduced by anti-IDO shRNA in A549 and HeLa cells by 25% and
18% (p<0.05), respectively (Figure 4.56 and Figure 4.59). IDO downregulation also
sensitized natural IDO expressers (H441 cells) to cisplatin in the absence of IFNγ
treatment (Figure 4.60).
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Figure 4. 54. A549 clone sensitivity to cisplatin (8 µM) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. A549 clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h, then cisplatin (8 µM) for 72 h, at which time live cells were enumerated.
White bars represent A549 clones transfected with scrambled shRNA and gray bars
represent A549 cells transfected with anti-IDO shRNA. Each bar represents the mean of
3 values (n=3 for determination of each value) ± SD. Significant changes are shown in
pooled results (Figure 4.55).
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Figure 4. 55. Sensitivity of clonal A549 populations to cisplatin (8 µM) before (A)
and after (B) IDO induction. Data shown in Figure 4.54 were pooled to generate mean
values from 3 independent clonal populations harbouring scrambled control shRNA or
anti-IDO shRNA, and each bar represents the mean of those 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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Figure 4. 56. Induction of IDO in A549 clonal cell induces resistance to cisplatin (8
µM). Results were obtained from 3 independent clonal cell populations with scrambled
control shRNA or anti-IDO shRNA, and each bar represents the mean of those 3 values
(n=3 for determination of each value) ± SEM (*p<0.05).
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Figure 4. 57. HeLa clone sensitivity to cisplatin (4 µM) before and after IDO
induction. Panels A-B present data for each of 6 individual clonal populations before
and after IDO induction. HeLa clonal populations were cultured with or without IFNγ (25
ng/ml) for 48 h, then treated with cisplatin (8 µM) for 72 h, at which time live cells were
enumerated. White bars represent HeLa clones transfected with scrambled shRNA and
gray bars represent HeLa cells transfected with anti-IDO shRNA. Each bar represents the
mean of 3 values (n=3 for determination of each value) ± SD. Significant changes are
shown in pooled results (Figure 4.58).
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Figure 4. 58. Sensitivity of clonal HeLa populations to cisplatin (4 µM) before (A)
and after (B) IDO induction. Data shown in Figure 4.57 were pooled to generate mean
values from 3 independent clonal populations harbouring scrambled control shRNA or
anti-IDO shRNA, and each bar represents the mean of those 3 values (n=3 for
determination of each value) ± SEM (*P < 0.05).
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Figure 4. 59. Induction of IDO in HeLa clonal cell induces resistance to cisplatin (4
µM). Results were obtained from 3 independent clonal cell populations with scrambled
control shRNA or anti-IDO shRNA, and each bar represents the mean of those 3 values
(n=3 for determination of each value) ± SEM (*p < 0.05).
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Figure 4. 60. H441 clone sensitivity to cisplatin (5 and 10 µM). Data represents one
H441 clone with scrambled shRNA (white bar) and 5 H441 clones cells with anti-IDO
shRNA (black bars). H441 clonal populations were cultured overnight, then treated with
cisplatin (5 and 10 µM) for 8 days, at which time live cells were enumerated. Each bar
represents the mean of 3 values (n=3 for determination of each value) ± SD (*P<0.05).
Each bar represents the mean of 3 values (n=3 for determination of each value) ± SD.
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4.19 Thymidylate Synthase siRNA Downregulation in A549 Clonal Populations
TS-targeting drugs have anti-tumour activity against multiple types of cancers.
However, increased TS mRNA levels upon treatment with TS-targeting drugs is a
common mechanism of resistance to these agents [254] and knockdown of TS mRNA
using anti-TS siRNA or antisense oligonucleotides sensitizes tumour cells to TS-targeting
drugs [187, 254, 255, 265]. In view of the observation that IDO can at least partially
mediate resistance to some TS-targeting drugs, it was hypothesized that concurrent
downregulation of IDO and TS in cancer cells will sensitize cancer cells to these drugs to
a greater degree than knockdown of TS alone. To test the hypothesis, A549 tumour cells
were transfected with TS siRNA to confirm TS mRNA downregulation using this
strategy, as described (Chapter 3, Section 3.20). TS mRNA was downregulated in A549
cells upon TS siRNA transfection (Figure 4.61).
4.20 Thymidylate Synthase siRNA Downregulation in A549 Clonal Populations
after IFNγ Induction
Since we ultimately wished to simultaneously downregulate TS and IDO in A549
cells, it was necessary to determine whether siRNA transfection of A549 clones affected
IFNγ induction of IDO and/or whether IFNγ treatment altered siRNA-mediated
knockdown of TS. To test this, A549 cells were transiently transfected with either control
siRNA or TS siRNA and then treated with IFNγ as described in chapter 3, section 3.20.
IFNγ treatment did not interfere with siRNA transfection, and siRNA transfection did not
alter IFNγ induction of IDO induction in A549 cells (Figure 4.62).
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Figure 4. 61. TS siRNA transfection of A549 cells. A549 cells (untransfected with antiIDO shRNA plasmid) were transfected with control or TS siRNA. After 24 h, RNA was
isolated and used to generate cDNA. TS and GAPDH cDNA were amplified by PCR
from the cDNA. A: PCR products were separated by electrophoresis through a 1.5%
agarose gel. B: PCR-generated bands were quantified using Alpha Ease FC software.
Lanes 1 and 15: MW ladder. Lanes 2-4: control cells treated with medium alone. Lanes
5-7: cells treated with liposomal transfection reagent (LFA2K). Lanes 8-10: cells
transfected with control siRNA (all groups were normalized to this group). Lanes 11-13:
cells transfected with TS siRNA. Lane 14: PCR products from reaction without template
cDNA. Each bar represents the mean of 3 values (n=3 for determination of each value) ±
SEM.
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Figure 4. 62. TS siRNA downregulation in A549 cells after IFNγ (16 ng/ml)
treatment. A549 cells were treated with IFNγ (16 ng/ml) and then transfected with either
control or TS siRNA for 4 h. Cultured medium was then replaced with growth medium
containing IFNγ (16 ng/ml). RNA was isolated 24 h post transfection and used to
synthesize cDNA. IDO, TS and GAPDH cDNAs were amplified by PCR. Lanes 1-3:
cells treated with medium alone (control). Lanes 4-6: cells treated with liposomal
transfection reagent (LFA2K). Lanes 7-9: cells transfected with control siRNA. Lanes
10-12: cells transfected with TS siRNA. Lane 13: PCR products from reaction without
template cDNA.
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4.21 TS siRNA Downregulation in A549 Clonal Populations
TS siRNA downregulation in A549 clonal populations was assessed after
transfection of two different TS siRNAs targeting different regions of TS mRNA (TS
siRNA # 3 and TS siRNA #4). All A549 clonal populations were transfected as described
(Chapter 3, Section 3.20). TS siRNA downregulated TS protein in A549 clonal
populations harbouring either control, non-targeting shRNA or anti-IDO shRNA at 96 h
post-transfection (Figure 4.63).
4.22 TS Downregulation Enhances the Capacity of IDO Downregulation to
Sensitize A549 Cells to Pemetrexed
TS mRNA downregulation sensitizes A549 cells to the TS-targeting drug 5FUdR
[266]. IDO downregulation sensitized A549 cells to the TS-targeting drugs pemetrexed
and gemcitabine (Figures 4.44 and 4.52) but not 5FUdR (Figure 4.50). To test whether
concurrent knockdown of both TS and IDO sensitized A549 cells to anti-TS drugs more
effectively than knockdown of IDO alone, A549 clonal populations (stably transfected
with anti-IDO shRNA or control shRNA) were transiently transfected with TS siRNAs
numbers 3 or 4 as described (Chapter 3, Section 3.20). Concurrent IDO and TS
downregulation sensitized cancer cells to pemetrexed more effectively than knockdown
of IDO alone (Figure 4.64, A-C).
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Figure 4. 63. TS siRNA downregulation in A549 clonal populations. A549 clonal cells
were seeded and grown overnight. TS siRNA number 3 or 4 or control siRNA was then
used to transfect all clonal cells. Cells were lysed and protein was harvested 96 h later.
TS protein levels were determined using antibodies against TS and actin. Results were
quantified for each clone separately. A) TS siRNA transfection in A549 clone NC-3 (with
control, non-targeting shRNA). (B) TS siRNA transfection of clone 2-4 (with anti-IDO
shRNA). C) TS protein quantification results for all clonal populations. Each bar
represents the mean of 3 values (n=3 for determination of each value) ± SEM.
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Figure 4. 64. Concurrent IDO and TS downregulation sensitizes A549 cells to
pemetrexed more effectively than knockdown of IDO alone. A549 cells were
transfected with control or TS siRNA, then treated with IFNγ (25 ng/ml) for 48 h.
Pemetrexed (30 nM) was then added and cell number enumerated after 72 h drug
treatment. Bars indicate the mean relative number of cells (n=3 ± SD).
A) Proliferation of clonal A549 cell populations induced with IFNγ and then treated with
pemetrexed, but untransfected with siRNA of any kind. Gray bars indicate clones
containing anti-IDO shRNA and white bars indicate clones containing non-targeting
control shRNA.
B) Proliferation of the same clonal A549 cell populations transfected with control nontargeting siRNA, TS siRNA #3, or TS siRNA #4, induced with IFNγ, and then treated
with pemetrexed. The bars represent values normalized to values obtained from clones
treated with IFNγ but untreated with pemetrexed or siRNA; those cells were each
considered to have a proliferation value of 100% after IFNγ treatment. Gray bars
indicate clones containing anti-IDO shRNA and white bars indicate clones containing
non-targeting control shRNA.
C) Data for 3 individual A549 clones with anti-IDO shRNA and 3 clones with control,
non-targeting shRNA (from panels A and B) were pooled and mean values (n=3) are
show ± SEM (*p<0.05). Black bars indicate clones containing anti-IDO shRNA and
white bars indicate clones containing non-targeting control shRNA.
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4.23 IDO Downregulation Enhances the Capacity of TS Downregulation to
Sensitize A549 Cells to 5FUdR
Combined antisense downregulation of IDO and TS sensitized A549 cells to the
TS-targeting drug pemetrexed to a greater degree than antisense downregulation of TS
alone (Figure 4.64). In addition, IDO downregulation alone did not alter A549 cell
sensitivity to 5FUdR (Figure 4.50). Therefore, the capacity of combined, concurrent
downregulation of both IDO and TS downregulation to sensitize human tumour cells to
5FUdR to a greater degree than TS downregulation alone was assessed. Concurrent IDO
and TS downregulation using TS siRNAs numbers 3 or 4, combined with shRNAmediated reduction of IDO in response to induction with IFNγ, sensitized cancer cells to
5FUdR to a greater degree than TS downregulation alone (30% for TS siRNA number 3
and 15% for TS siRNA number 4 (Figure 4.65, A-C).
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Figure 4. 65. Concurrent IDO and TS downregulation sensitizes A549 cells to
5FUdR more effectively than knockdown of TS alone. A549 cells were transfected
with control or TS siRNA, treated with IFNγ (25 ng/ml) for 48 h, and then with 5FUdR
(40 nM) for 72 h, at which time the number of live cells was assessed as a measure of
proliferation. Bars indicate mean proliferation relative to appropriate controls ± SD (n=3).
A) Proliferation of clonal A549 cell populations induced with IFNγ and then treated with
5FUdR, but untransfected with siRNA of any kind. Gray bars indicate clones containing
anti-IDO shRNA and white bars indicate clones containing non-targeting control shRNA.
B) Proliferation of the same clonal A549 cell populations transfected with control nontargeting siRNA, TS siRNA #3, or TS siRNA #4, induced with IFNγ, and then treated
with 5FUdR. Bars represent values normalized to values obtained from clones treated
with IFNγ but untreated with pemetrexed or siRNA; those cells were considered to have a
proliferation value of 100% after IFNγ treatment. Gray bars indicate clones containing
anti-IDO shRNA and white bars indicate clones containing non-targeting control shRNA.
C) Data for 3 individual A549 clones with anti-IDO shRNA and 3 clones with control,
non-targeting shRNA (from panels A and B) were pooled and mean values (n=3) are
show ± SEM (*p < 0.05). Black bars indicate clones containing anti-IDO shRNA and
white bars indicate clones containing non-targeting control shRNA.
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4.24 BRCA2 Downregulation in A549 Clonal Populations
BRCA2 is important in homologous recombination repair. Cancer cells lacking
BRCA2 are more sensitive to olaparib and alkylating agents [208]. IDO downregulation
sensitized cancer cells to olaparib (Figures 4.24 and 4.27) and cisplatin (Figures 4.54,
4.57, and 4.60). It therefore hypothesized that concurrent IDO and BRCA2
downregulation in cancer cells would further sensitize A549 tumour cells to the PARP
inhibitor olaparib and the DNA cross-linking agent cisplatin. To test this hypothesis,
A549 clonal cell populations were first transiently transfected with BRCA2 siRNA to
assess the capacity to reduce BRCA2 protein. BRCA2 siRNA downregulated BRCA2
protein in A549 cells by approximately 50% at 48 h post-transfection (Figure 4.66).
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Figure 4. 66. siRNA downregulation of BRCA2 in A549 clones NC-3 and 2-18. A549
cells were transiently transfected with either control siRNA or BRCA2 siRNA smart pool.
Cell lysates were prepared and protein extracts were prepared at 48 h post-transfection.
BRCA2 and actin antibodies were used to probe membranes. BRCA2 protein content
relative to actin protein was reduced by 50% in clone NC-3 (control, non-targeting
shRNA) and by 50% in clone 2-18 (anti-IDO shRNA).
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4.25 Concurrent IDO and BRCA2 Downregulation Sensitizes A549 Cells to the
PARP Inhibitor Olaparib More than Knockdown of Either Gene Alone
Cancer cells harbouring BRCA2 mutations have increased sensitivity to the PARP
inhibitor olaparib [208]. As IDO downregulation sensitized A549 adenocarcinoma cells
to olaparib (Figure 4.24), we therefore determined whether simultaneous knockdown of
IDO and BRCA2 would sensitize A549 cells to olaparib with a greater degree than the
knockdown of either gene alone. Concurrent downregulation of IDO and BRCA2
sensitized A549 cells to olaparib (75%) to a greater degree than either IDO
downregulation (35%) or BRCA2 downregulation (30%)(Figure 4.67). These results
suggest that combining IDO downregulation with the knockdown of the DNA repair
molecule BRCA2 had a greater than additive effect on A549 cells.
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Figure 4. 67. Concurrent IDO and BRCA2 downregulation sensitized cancer cells to
olaparib to a greater degree than the knockdown of either gene alone. A549 clonal
cells transfected with either scrambled shRNA (NC-3) or anti-IDO shRNA (2-18) were
transiently transfected with BRCA2 siRNA, induced with IFNγ (25 ng/ml) and 24 h later,
treated with low dose olaparib (1 µM) for 72 h. Live cells enumerated at the end of that
time. Bars indicate the mean proliferation of cells from a representative experiment (n=3)
± SD, relative to appropriate controls. Values were normalized to those obtained from
clones treated with IFNγ but untreated with olaparib or siRNA; those cells were
considered to proliferate at a 100% level after IFNγ treatment. **Different from treatment
with either siRNA alone (* p ≤ 0.05).
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4.26

Concurrent IDO and BRCA2 Downregulation Sensitizes A549 Cells to the

DNA Cross-linking Agent Cisplatin More than Knockdown of Either Gene Alone
BRCA2 is vital for repair of DNA double stranded breaks (DDSBs) [187]. As
cisplatin cytotoxicity results in DDSBs in cancer cells [267] and IDO downregulation
sensitized A549 cells to cisplatin (Figure 4.54), we hypothesized that concurrent
downregulation of IDO and BRCA2 would enhance cisplatin toxicity in A549 cells
compared to knockdown of either IDO or BRCA2 alone. A549 clonal populations (with
and without anti-IDO shRNA) were transfected with BRCA2 siRNA to inhibit DNA
repair, treated with IFNγ to induce IDO, and then exposed to cisplatin for 72 h to assess
the effect on proliferation. Simultaneous knockdown of both IDO and BRCA2 sensitized
A549 cells to cisplatin to a greater degree (70%) than either IDO knockdown alone (47%)
or BRCA2 knockdown alone (20%) (Figure 4.68).
4.27 Concurrent IDO and BRCA2 Downregulation does not Sensitize A549 Cells to
5FUdR
In view of the observation that antisense knockdown of IDO enhanced the capacity of
antisense knockdown of TS to sensitize human tumour cells to 5FUdR (Figure 4.65), the
capacity of antisense knockdown of IDO combined with BRCA2 knockdown to sensitize
human tumour cells to 5FUdR was evaluated. Antisense reduction of IDO alone did not
sensitize A549 cells to 5FUdR (Figure 4.69, lane 3 vs. lane 4), but antisense
downregulation of BRCA2 sensitized A549 cells to 5FUdR (Figure 4.69, lane 3 vs. lane
5). Concurrent downregulation of IDO and BRCA2 did not sensitize cancer cells to
5FUdR to any greater degree than knockdown of BRCA2 alone (Figure 4.69, lane 5 vs.
lane 6). These results suggest that knockdown of IDO does not contribute to sensitization
to the TS-targeting drug 5FUdR, either alone or in combination with knockdown of
BRCA2.
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Figure 4. 68. Concurrent downregulation of IDO and BRCA2 sensitizes A549 to
cisplatin in an additive fashion. A549 clonal cells transfected with either scrambled
shRNA (NC-3) or anti-IDO shRNA (2-18) were transiently transfected with BRCA2
siRNA, induced with IFNγ (25 ng/ml), treated with low dose cisplatin (2.3 µM), and live
cells enumerated after 72 of drug treatment. Bars represent the means of 3 independent
measurements of cells (with or without downregulation of IDO) after BRCA2 siRNA
transfection + cisplatin treatment (n=3 for each measurement) ± SEM. Bars were
normalized to values obtained from clones treated with IFNγ but untreated with cisplatin
or siRNA; those cells were considered to proliferate at a 100% level after IFNγ treatment.
**Different from treatment with either siRNA in combination with cisplatin (* p ≤ 0.05).
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Figure 4. 69. Concurrent downregulation of IDO and BRCA2 did not sensitize A549
to the TS-targeting drug 5FUdR to a greater degree than the knockdown of either
gene alone. A549 clonal cells transfected with either scrambled shRNA (NC-3) or antiIDO shRNA (2-18) were transiently transfected with BRCA2 siRNA, induced with IFNγ
(25 ng/ml) for 24 h, and then treated with 5FUdR (40 nM) for 72 h, at which time live
cells were enumerated. Bars represent the means of 3 independent measurements of cells
(with or without downregulation of IDO) after BRCA2 siRNA transfection + 5FUdR
treatment (n=3 for each measurement) ± SD. Bars were normalized to values obtained
from clones treated with IFNγ but untreated with 5FUdR or siRNA; those cells were
considered to proliferate at a 100% level after IFNγ treatment (*p ≤ 0.05).
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Chapter 5

Discussion
5.1

IDO Induction in A549 and HeLa Cells
Most human tumours express IDO in vivo [135]. Various situations including

inflammation and infection can also induce IDO in the body [268, 269]. The proinflammatory cytokine IFNγ is a potent inducer of IDO in a variety of human cells
including cancer cells [270]. A549 and HeLa cells were therefore treated in vitro with
IFNγ and IDO mRNA and protein levels were examined. IDO is normally expressed in
human lung [108,109] and is expressed in human lung adenocarcinomas and cervical
cancer [68,71]. We therefore chose human cancer cell lines arising from the same organs
and induced IDO in them with IFNγ. IFNγ-mediated IDO mRNA induction was
measured at various times (12, 24, 48 and 72 h). IFNγ treatment induced IDO mRNA, 24
h (Figure 4.2 and Figure 4.3) and protein, 48 h (Figure 4.4) post-treatment in both A549
and HeLa adenocarcinoma cells (Figure 4.4 and Figure 4.15). IFNγ-mediated IDO
mRNA is at its highest level at 24 h and begins to reduce at later time points.
H441 adenocarcinoma cells were also examined for IDO mRNA expression without
IFNγ treatment. H441 cells expressed IDO mRNA in the absence of IFNγ (Figure 4.5).
These results show that IDO mRNA and protein can be induced in A549 and HeLa cells,
and that H441 cells are available as endogenous constitutive IDO expressers. We have
have also tested other human cancer cell lines for IDO induction including SW480 and
Caco-2 colorectal cancer cell line. However, IFNγ treatment did not induce IDO in these
cell lines.
Induction of IDO with IFNγ, followed by IDO downregulation in cancer cells,
provides

a

more

physiologically

relevant

model

to

study

IDO

in

cancer

thanoverexpression of IDO mediated by stable cDNA transfection. Moreover, IFNγ
provides the necessary post-translational modification of IDO protein that makes a fully
functional protein [114]. We therefore chose IFNγ to induce IDO in A549 and HeLa cells.
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5.2

IDO siRNA Downregulation in A549 and H441 Cells
To examine IDO’s effect on drug sensitivity independent of the immune system,

antisense siRNA was used in an attempt to first knockdown IDO in human cancer cells
and then expose them to chemotherapy drugs. Successful transient siRNA knockdown of
IDO mRNA has been previously demonstrated in multiple murine cancer models. In
those models, IDO was downregulated in murine DCs and not in tumour cells [158, 159].
On the other hand, Mobergslien and Sioud have reported successful knockdown of IDO
in human monocytes and DCs with an electroporation method [271], suggesting that
siRNA could be effective in human tumour cells. I transiently transfected A549 and H441
cells with a human IDO siRNA SMARTpool® (a commercially-available combination of
4 different siRNAs that target different regions of human IDO mRNA)(Table 3.3). IDO
siRNA was not capable of inhibiting IFNγ-induced IDO in A549 cells or naturallyoccurring elevated IDO mRNA in H441 cells (Figure 4.6-4.9). SiRNA downregulation of
human IDO has been, for the most part, reported in APCs and not tumour cells. Lack of
effectiveness in human tumour cells could be attributed to multiple factors, including
inefficiency of transient downregulation of IDO due to a high rate of IDO gene
transcription capable of constantly replenishing the IDO mRNA pool, induction of RNAi
repressors, or unknown factors suppressing Argonaute endonuclease effectiveness [56].
A high rate of IDO gene transcription would be expected to increase IDO mRNA levels
and reduce the effectiveness of transiently-transfected anti-IDO siRNA. Constant
production of antisense molecules (as would be produced by stably-incorporated shRNA)
was next considered as an approach to effectively reduce IDO in human tumour cells.
Regardless, it was apparent that the siRNA approaches tested here were insufficiently
effective at reducing IDO mRNA to be useful in assessing the role of IDO in mediating
treatment sensitivity in human tumour cells. However, using only siRNA is a limitation
to our antisense approach for transient IDO downregulation in cancer cells since we have
not tested ribonuclease (RNase) H-dependent ODNs to downregulate IDO.Antisense
ODNs, because they invoke a different RNAse pathway and are more stable both in vivo
and in vitro, may be more effective agents to reduce IDO than siRNAs.
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5.3

Stable Transfection of A549, HeLa and H441 Cells with anti-IDO shRNA
A number of studies have successfully used shRNA to create stable knockdown of

IDO and IDO2 in human cancer cells [272-274]. Since siRNA downregulation of IDO
was ineffective, I used anti-IDO shRNA to stably knock down IDO in A549, HeLa and
H441 cells. I transfected all three tumour cell lines with either anti-IDO shRNA or
scrambled control shRNA and picked multiple clones with reduced IDO mRNA (Figure
4.11-4.13) and protein (Figure 4.14 and Figure 4.15) for investigation. Measuring
kynurenine/tryptophan levels in culture medium before and after IDO induction [144] or
measuring cancer cell proliferation can assess IDO functionality in cancer cells. Since
IDO decreases cancer cell proliferation [145], and this can be examined as a one step
process, I tested the functionality of anti-IDO shRNA in clonal populations by assessing
its ability to counteract IDO-mediated decreases in tumour cell proliferation. A549 and
HeLa clonal populations with scrambled control shRNA showed decreased proliferation
compared to clonal cells with anti-IDO shRNA (Figure 4.16 and Figure 4.17).
Interestingly, A549 clone 2-4 with anti-IDO shRNA that was still capable of producing
some IDO protein (Figure 4.14) showed decreased proliferation compared to other A549
clonal populations with anti-IDO shRNA (Figure 4.16). It should be noted that IFNγ has
some anti-proliferative effects on all cells that are independent of IDO. However, since
all clonal populations were similarly treated with IFNγ, the observed difference in
proliferation is solely due to IDO expression in cancer cells and not IFNγ. These results
confirm that anti-IDO shRNA is functional in inhibiting both IDO levels and effects on
cancer cells.
5.4 The Effects of IDO on the A549 Cell Cycle
Published investigation of the characteristics of IDO is primarily in the context of the
immune system because of the clear immune regulatory roles described for IDO. IDOmediated tryptophan depletion induces cell cycle arrest in T cells in G1 [275]. I
determined whether IDO-induced reduction in growth of cancer cells was associated with
altered cell cycle. IFNγ induction of IDO increased the number of cells in G1 and
decreased the numbers in G2/M when cells were stably transfected with scrambled
control shRNA. The presence of anti-IDO shRNA in cells treated with IFNγ abolished
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the increase and decrease, respectively (Figure 4.18). To confirm these observations one
could serum-starve the A549 tumour cells to synchronize them before IFNγ treatment.
The increased time in G1 is important to increase the ability of tumour cells to
undergo complete, error-free DNA repair capable of removing basal and therapy-induced
DNA damage [276]. The increase in the number of cells in G1 seen exclusively in IDOexpressing cell lines suggests a possible broader role for this protein in cell cycle
checkpoint control, allowing for repair of DNA damage during G1 phase of the cell cycle
[276, 277]. I therefore decided to examine the role of IDO in DNA repair and and
sensitivity to drugs that induce DNA damage in cancer cells independent of the immune
system.
5.5

IDO Downregulation Decreases Intracellular NAD+

NAD+ is vital for PARP activity and DNA repair [215]. Since IDO is responsible for the
de novo synthesis of NAD+ from tryptophan, I examined whether anti-IDO shRNA could
decrease NAD+ levels in A549 clonal populations. After IFNγ stimulation, two
independently-derived A549 clones expressing anti-IDO shRNA had lower amounts of
NAD+ than two similarly-generated clones expressing scrambled control shRNA (Figure
4.19). These data indicate that shRNA-mediated suppression of IFNγ-induced IDO
decreases intracellular NAD+ levels and has the potential to modulate PARP function.
DNA damage-mediated PARP-1 activation can deplete the NAD+ pool in cells, which is
associated with inducing cellular apoptosis [278]. Therefore, IDO-mediated generation of
NAD+ might play a protective role in cancer cells during DNA damage inducing
treatments that normally result in hyperactivation of PARP and depletion of NAD+
sources in cells. This provides a rationale to examine the possible protective role of IDO
in response to genotoxic chemotherapy and radiation in cancer cells. In addition, NAD+
inhibitors are under consideration and evaluation for cancer treatment. In particular,
FK866, a pharmacological inhibitor of the NAD+ salvage pathway, is undergoing clinical
testing as a cancer therapy [279]. FK866 efficiently blocks NAD+ production in human
cancer cells [279]. However, a high concentration of NAD+ precursors (NAM and NA)
from the salvage pathway is able to reverse the inhibitory effect of FK866. IDO increases
de novo NAD+ production [220]. However, the possible inhibitory role of IDO on the
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efficiency of this drug has never been tested. Therefore, I examined the capacity of IDO
to decrease human tumour cell sensitivity to this candidate anticancer drug.
5.6

IDO in Tumour Cells Mediates Resistance to the NAD+ Inhibitor FK866
IDO inhibition decreased NAD+ levels in A549 cells by approximately 60%

(Figure 4.19), similar to the level to which FK866 inhibits NAD+ in other cell types [242].
IDO was therefore induced in A549 clonal populations before treatment with FK866.
IDO in A549 cells conferred resistance to FK866 (Figure 4.20). A549 clones express
anti-IDO shRNA, with the exception of clone 2-4 that expressed IDO at a slightly higher
level than the other anti-IDO shRNA-containing clones, retained sensitivity to FK866
(Figure 4.20). Higher IDO levels were also correlated with increased resistance to FK866
(Figure 4.20 C). This is a significant observation with respect to the capacity of FK866 to
block NAD+ in the presence of IDO because FK866 is a potent NAD+ inhibitor that
blocks NAD+ production through the salvage pathway [262].	
   However, IDO-mediated
NAD+ production from the de novo pathway can clearly undermine FK866 efficiency
(Figure 4.20). In addition, tumour-infiltrating cytotoxic T cells and NK cells are major
sources of IFNγ in the tumour microenvironment [280, 281]. As shown in Figure 4.20,
IFNγ-mediated increases in IDO induced resistance to FK866. Therefore, blocking IDO
in conjunction with FK866 treatment may have therapeutic value and further studies are
required.
5.7

IDO in Tumour Cells Mediates Resistance to Olaparib
IDO downregulation decreased NAD+ in A549 cells (Figure 4.19). Since NAD+ is

critical for PARP activity [214], I examined whether IDO could increase tumour cell
resistance to olaparib (a PARP inhibitor) and whether anti-IDO shRNA could reverse this
effect. Anti-IDO shRNA sensitized A549 and HeLa cells to olaparib (Figure 4.21-4.24
and Figure 4.26-4.27). Moreover, A549 and HeLa cells transfected with scrambled
shRNA had increased resistance to olaparib after IFNγ induction; the effectiveness of the
administered dose of the drug was reduced, while antisense-downregulation of IDO
during and after IFNγ induction resulted in sensitivity to olaparib equal to that of cells
untreated with IFNγ (Figure 4.25 and Figure 4.27). These findings show, for the first time,
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that IDO in tumour cells confers resistance to a PARP inhibitor, olaparib. Tumour cells
with BRCA mutations showed high sensitivity to olaparib monotherapy [207]. However,
secondary mutations that restored full-length BRCA2 protein in cancer patients conferred
resistance to olaparib [282]. These data identify a new resistance mechanism to olaparib
that is exerted by IDO and is independent of BRCA2 since A549 and HeLa cells have
intact BRCA2. Therefore combining IDO inhibition with PARP inhibitors could offer an
advantage over PARP inhibition monotherapy.
5.8

IDO Mediates Resistance to γ Radiation in Cancer Cells
Since PARP-mediated DNA repair is important in resistance to γ radiation [95], I

assessed whether IDO could increase A549 and HeLa cell resistance to γ radiation. A549
and HeLa clonal populations were equally sensitive to γ radiation prior to IDO induction
regardless of the presence of anti-IDO shRNA or scrambled shRNA (Figure 4.28-4.29
and Figure 4.32 and 4.33). However, IFNγ-induced IDO conferred resistance to γ
radiation in both A549 and HeLa cells. This effect was abolished by anti-IDO shRNA
(Figure 4.30 and Figure 4.34). Tumour cell resistance to γ radiation is generally attributed
to DNA repair mediated by PARP activity and BER [88-89]. These data show, for the
first time, that IDO plays a role in tumour cell resistance to γ radiation. This phenomenon
may be due to IDO-mediated increase in available NAD+ in cancer cells that supports the
capacity of PARP to mediate DNA repair. Furthermore, increased NAD+ has been
attributed to improved BER in cancer cells [283]. It can be speculated that the IDOmediated increase in NAD+ levels might increase the effectiveness of BER in cancer cells,
thereby increasing resistance towards radiation. Future studies are required to confirm or
modify this possibility. For example, examining the level of key BER proteins such as
XRCC1 after γ radiation of cancer cells in the presence or absence of IDO could provide
valuable information regarding the direct impact of IDO on BER-mediated resistance to γ
radiation.
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5.9

IDO in Human Tumour Cells Mediates Resistance to Combined γ Radiation
and PARP Inhibition
Inducing DNA damage and subsequently inhibiting DNA repair in cancer cells is an

attractive approach to maximize radiation-induced cell death in tumour cells [93]. I
therefore induced IDO in A549 and HeLa cells for 48 h and then treated them with γ
radiation to induce DNA damage, followed by culture in the presence of olaparib to
inhibit DNA repair for 72 h. A549 and HeLa cells harboring anti-IDO shRNA were
sensitized to combination therapy to a greater degree than cells harbouring scrambled
shRNA (Figure 4.35-4.36 and Figure 4.38-4.39). Clonal populations with scrambled
shRNA and capable of producing IDO showed increased resistance to combined radiation
and PARP inhibition (Figure 4.37 and Figure 4.40). In a combination treatment study, the
PARP inhibitor rucaparib significantly increased radiosensitivity and enhanced DNA
damage in BRCA-proficient prostate cancer cell lines [93]. The capacity of tumour cells
to develop resistance to combination therapy is not unexpected; these data identify IDO
as a possible underlying molecule for this phenomenon in combination treatment with γ
radiation and PARP inhibition.
5.10 The Effect of IDO Downregulation on Human Tumour Cell Sensitivity to
Cisplatin
Since IDO downregulation sensitized cancer cells to γ radiation, I determined
whether IDO knockdown sensitizes A549, HeLa and H441 cells to the DNA crosslinking agent cisplatin. IDO downregulation sensitized cancer cells to cisplatin (Figure
4.54-4.55, Figure 4.57-4.58 and Figure 4.60). Furthermore, IDO in cancer cells decreased
the effectiveness of the drug, and that increased effectiveness was reduced by anti-IDO
shRNA in both A549 and HeLa cells (Figure 4.56 and Figure 4.59). Blocking IDO
activity by the small molecule IDO inhibitor 1-MT has been previously attributed to
increased sensitivity of mouse breast cancer cells to cisplatin in the presence of an active
immune system [136]. This is in agreement with our results, but these data establish that
this effect can occur in the absence of any involvement of immune cells and, perhaps
more importantly, in human rather than rodent cancer cells.
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5.11 IDO in Human Tumour Cells Mediates Resistance to the Base Excision
Repair Inhibitor Methoxyamine
IDO induced resistance to olaparib (Figure 4.25 and Figure 4.27). In addition,
PARP is essential for the recruitment of the BER scaffold protein XRCC1 to the damaged
area of the DNA [199]. I therefore assessed whether IDO could induce resistance to the
BER inhibitor methoxyamine. Knocking down IDO sensitized A549 cells to
methoxyamine (Figure 4.41 and Figure 4.42). Moreover, IDO induced high levels of
resistance to methoxyamine in A549 cells and that resistance was abolished by anti-IDO
shRNA (Figure 4.43). Higher IDO levels were also positively correlated to
methoxyamine resistance in cancer cells (Figure 4.41 C). Several phase I clinical trials of
combined methoxyamine with chemotherapy drugs are currently underway [284]. One
clinical trial in particular has studied the combination effect of methoxyamine and the
TS-targeting drug pemetrexed in patients with advanced refractory cancers [284].
Therefore, IDO-mediated potent induction of resistance to methoxyamine could provide
critical information in designing pre-clinical and clinical studies in future.
5.12 IDO in Human Tumour Cells Mediates Resistance to the TS-targeting Drug
Pemetrexed
Since BER is reported to be involved in resistance to pemetrexed [179] and IDO
inhibited the effectiveness of the BER inhibitor methoxyamine (Figure 4.43), I decided to
assess whether IDO downregulation sensitized cancer cells to the TS-targeting drug
pemetrexed. Antisense knockdown of IDO sensitized A549 cells to pemetrexed (Figure
4.44 and Figure 4.45). In addition, IDO-mediated resistance to pemetrexed was decreased
by anti-IDO shRNA after IFNγ induction of IDO in A549 cells (Figure 4.46).
Pemetrexed inhibition of TS results in the misincorporation of uracil into DNA.
The BER enzyme uracil-DNA glycosylase (UNG) removes the misincorporated uracil
and, by mediating that process, confers resistance to pemetrexed (which exerts part of its
toxicity to tumour cells by uracil incorporation into DNA)[285]. All A549 clonal
populations were similarly sensitive to pemetrexed before IDO induction (Figure 4.44).
However, IDO induced resistance to pemetrexed (Figure 4.45). Therefore, further studies
241

are required to examine whether or not UNG function is affected by IDO. Examining
UNG kinetic and substrate binding assay [60] in the presence or absence of IDO can shed
light on the possible effect of IDO on UNG function.
5.13 IDO in Human Tumour Cells Mediates Resistance to Combined Treatment of
Pemetrexed and Methoxyamine
Pemetrexed-resistant sublines of H1299 adenocarcinoma cells have elevated levels
of UNG and combined treatment of these H1299 sublines with methoxyamine and
pemetrexed increased their sensitivity to pemetrexed [285]. However, despite their in
vivo IDO expression, many human cancer cell lines do not express IDO in vitro. I
therefore decided to test whether IDO in tumour cells can mediate resistance to combined
pemetrexed and methoxyamine treatment. IFNγ-induced IDO undermined the therapeutic
potential of the combined treatment of pemetrexed and methoxyamine (Figure 4.47 and
4.48). This effect was significantly reduced by anti-IDO shRNA in A549 cells (Figure
4.47 and 4.48). Moreover, IDO levels were positively correlated with resistance to
combined pemetrexed and methoxyamine treatment in A549 clonal cells (Figure 4.47,
Panel C). These results provide compelling evidence for a previously unidentified role for
IDO in induced resistance to a combination of the TS-targeting drug pemetrexed and a
BER inhibitor methoxyamine.
5.14 The Effect of IDO Human Tumour Cell Sensitivity to Other TS-targeting
Drugs (5FUdR and Gemcitabine)
Since IDO downregulation sensitized cancer cells to the TS-targeting drug
pemetrexed, I decided to examine whether IDO downregulation could sensitize A549
cells to other TS-targeting drugs, including 5FUdR and gemcitabine. IDO
downregulation did not sensitize cancer cells to 5FUdR, but did sensitize them to
gemcitabine (Figure 4.50-4.53). BER is considered to play a major role in resistance to
gemcitabine [286]. IDO may be involved in BER-mediated gemcitabine resistance in
these cells. Interestingly, BER has been invoked as a contributor to 5FUdR cytotoxicity
in cancer cells due to its participation in a futile repair cycle that potentiates 5FUdR
toxicity [287]. In futile repair, the DNA mismatch repair enzyme MutL removes some
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parts of the newly synthesized DNA strand. However, the removed part does not contain
the incorporated 5FUdR, FdUTP. Using the template strand that contains FdUTP for
resynthesizing DNA results in cycles of futile mismatches and eventually cell death [61].
IDO-mediated enhancement of BER could, potentially, increase the cytotoxicity of
5FUdR due to the enhancing effect of BER on futile repair. This hypothesis might
provide a rationale for the observed lack of sensitization to 5FUdR in A549 cells with
antisense-downregulated IDO, as observed in experiments reported in this thesis (Figure
4.50 and Figure 4.451). On the other hand, IDO downregulation sensitized tumour cells
to pemetrexed and gemcitabine (Figure 4.45 and 4.53). Pemetrexed and gemcitabine do
not exert their toxicity by inducing BER futile repair [288, 289], so the hypothesis
proposed above is consistent with the observation of sensitization to pemetrexed or
gemcitabine by IDO reduction, but not sensitization to 5FUdR. These results suggest that
combining IDO downregulation with chemotherapy agents does not universally sensitize
cells to all DNA-damaging agents, but instead requires sufficient understanding of the
mechanism of action of the chemotherapy drugs in question and the mechanism(s) by
which IDO mediates resistance.
5.15 Concurrent IDO and TS Downregulation Sensitized A549 Cells to Pemetrexed
More than Knocking Down Either Gene Alone
Knocking down TS can sensitize cancer cells to the TS-targeting drug 5FUdR
[266]. Antisense-mediated reduction in IDO also sensitized cancer cells to some TStargeting drugs, including pemetrexed (Figure 4.44 and Figure 4.45). To examine
whether combining IDO and TS downregulation sensitizes cancer cells to pemetrexed to
a greater degree than reduction of either target alone, A549 cells were transiently
transfected with TS siRNA, and then IDO was induced with IFNγ in all A549 clonal
populations before exposing them to pemetrexed. As shown in Figure 4.63 and Figure
4.64, simultaneous downregulation of IDO and TS increased the sensitivity of cancer
cells to pemetrexed to a greater degree than reduction of either target alone. TS siRNA
downregulation has been shown to sensitize A549 cells to pemetrexed [186]. I show here
that combining TS and IDO downregulation further sensitized A549 cells to this drug
(Figure 4.63 and Figure 4.64). The additive effect of TS and IDO downregulation in
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A549 cells sensitivity to pemetrexed might result from the effect of TS downregulation
on the available thymidylate to the cells [290] along with the IDO-mediated impact on
BER (Figure 4.41 and Figure 4.42). These observations could provide the basis for a
strategy to improve the effectiveness of the already-approved chemotherapeutic drug
pemetrexed.
5.16 Concurrent IDO and TS Downregulation Sensitizes A549 Cells to 5FUdR to a
Greater Degree than Reduction of Either Target Alone
Since IDO downregulation did not sensitize A549 cells to 5FUdR (Figure 4.50 and
Figure 4.51), I determined whether combined IDO and TS downregulation could
sensitize cancer cells to 5FUdR. As show in Figure 4.65 and Figure 4.66, concurrent IDO
and TS downregulation did, in fact, sensitize A549 cells to 5FUdR more effectively than
knockdown of IDO alone. This effect was less potent than observed with pemetrexed, but
provides evidence that combining IDO and TS downregulation has potential as a
therapeutic strategy to sensitize tumour cells to a range of TS-targeting drugs including
pemetrexed and 5FUdR.
5.17 Concurrent IDO and BRCA2 Downregulation did Not Sensitize A549 Cells to
5FUdR
To further examine whether concurrent IDO and TS downregulation have value in
sensitizing human tumour cells to the TS-targeting drug 5FUdR, I simultaneously
downregulated IDO and BRCA2 (a DNA repair molecule not involved in enzymatic
reactions mediated by TS), in A549 cells followed by treatment with 5FUdR. BRCA2
does not mediate BER [291], therefore, it is unlikely that, by targeting BRCA2 (which
involves other, non-BER DNA repair pathways), cancer cells would be sensitized to a
drug that requires BER for its toxicity. As shown in Figure 4.69, combining IDO and
BRCA2 downregulation did not sensitize cancer cells to 5FUdR. These data emphasize
the importance of simultaneous knockdown of IDO and a DNA repair molecule, to
sensitize cancer cells to a drug that requires that specific DNA repair molecule for
survival. In other words, reduction of IDO and BRCA2 does not appear to sensitize
cancer cells to a drug such as 5FUdR that targets TS.
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5.18 Concurrent IDO and BRCA2 Downregulation Sensitizes A549 Cells to the
PARP Inhibitor Olaparib More than Knockdown of Either Gene Alone
Cancer cells with BRCA2 mutations are sensitive to olaparib monotherapy, most
likely because of induced-synthetic lethality [207]. IDO could modulate PARP function
by providing more NAD+ (Figure 4.19). IDO downregulation also sensitized cancer cells
to olaparib (Figure 4.21 and Figure 4.26). I used BRCA2 siRNA to downregulate BRCA2
and transiently induce BRCAness in A549 cells to determine whether simultaneous
knockdown of IDO and BRCA2 would sensitize A549 cells to olaparib to a greater
degree than the knockdown of either gene alone. Combining IDO and BRCA2
downregulation increased cancer cell sensitivity to olaparib more than targeting either
gene product alone (Figure 4.67). These data support the hypothesis that sensitization of
tumour cells to PARP inhibitors by reduction of IDO does not eliminate the capacity for
reduction of other targets (including BRCA2) to contribute, in the context of IDO
reduction, to enhanced sensitization of cancer cells to those PARP inhibitors. IDO
reduction sensitizes tumour cells to PARP inhibitors independent of BRCA2 status
(BRCA2 mutant or wild type) (Figure 4.21-4.24 and Figure 4.26-4.27); this supports the
potential value of combining BRCA2 reduction with IDO reduction to sensitize human
tumours to PARP inhibition, at least in tumour cells with functional BRCA2. Phase III
trials of olaparib in ovarian cancer were terminated due to lack of increased overall
survival in spite of evidence of olaparib-induced increase in progression-free survival
[292]. These data support the concept of therapeutic targeting of IDO to decrease tumour
cell resistance to PARP-inhibiting drugs such as olaparib, whether they are BRCA2 intact
or deficient cells.
5.19 Concurrent IDO and BRCA2 Downregulation Sensitizes A549 Cells to
Cisplatin to Greater Degree than Knockdown of Either Target Alone
Cisplatin induces DSBs in DNA in cancer cells [186] and BRCA2 is critical for
repair of those breaks [186]. BRCA2 downregulation has been shown to sensitize cancer
cells to cisplatin [186]. IDO mediates resistance to cisplatin in A549, HeLa and H441
cells (Figure 4.56, 4.59 and Figure 4.60). I therefore determined whether simultaneous
downregulation of IDO and BRCA2 could increase cancer cell sensitivity to cisplatin
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more than targeting either gene product alone. As shown in Figure 4.68, simultaneous
knockdown of IDO and BRCA2 in A549 cells enhanced cisplatin toxicity in A549 cells
compared to knockdown of either IDO or BRCA2 alone. These data provide clear
evidence of the capacity of targeting IDO in conjunction with targeting other molecules
involved in DNA repair to sensitize cancer cells to chemotherapy drugs that induce DNA
damage and increase the requirement for, and dependence on, DNA repair on cancer cells.

5.20 A new function for IDO
Most human tumours express IDO [68] and IDO is linked to immune evasion,
immunosuppression, metastasis, and poor patient outcome [69,70]. Here we have
identified a previously unidentified role for IDO in human cancer that was independent of
direct involvement of immune cells. We showed that, in an in vitro model and in the
absence of immune cells, IDO increased intracellular NAD+ levels and decreased the
sensitivity of the tumour cells to the PARP inhibitor olaparib, a DNA cross-linking agent
cisplatin, a folate antimetabolite pemetrexed, a nucleoside analogue gemcitabine, a base
excision repair inhibitor methoxyamine, an NAD+ inhibitor FK866, and combined
treatments with olaparib and radiation, and methoxyamine and pemetrexed, in the
absence of immune cells.
Combining 1-MT to paclitaxel has been shown to increase the effectiveness of this
chemotherapy drug in the presence of an active immune system [76]. However, depletion
of CD4+ T cells completely abolished that synergistic effect [76]. In our model, however,
the lack of immune cells in the entire process verifies a tumour cell-autonomous effect
for IDO that is not dependent on the presence of immune cells. Chemotherapy drugs and
radiation that we used in this study actively induce DNA damage or block DNA repair in
cancer cells. We therefore identify, in this thesis, IDO involvement in DNA repair as a
major IDO function.
5.21 Limitations:
Our findings are somewhat limited due to the use of only an in vitro model. These
results therefore do not completely reflect what takes place in a tumour
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microenvironment in the body. However, they are valuable as proof-of-principle for a
new, and previously unidentified, function of IDO in cancer, independent of its
immunosuppressive activity. We have also focused mainly on tumour cell proliferation as
our final readout. Even though proliferation is of outmost importance in studying the
impact of an anti-cancer treatment it does not provide detailed insight of what takes place
as a consequence of treatment in cancer cells (for example, if reduced proliferation as a
consequence of treatment is only because of cell cycle arrest or increased apoptosis,
necrosis, or induced senescence in tumour cells). Reduced proliferation can also take
place as a result of a combination of the aforementioned events. Further studies are
therefore required to clarify the underlying mechanism of reduced proliferation in cancer
cells in the presence of chemotherapy and radiation when combined with IDO
downregulation in tumour cells. Finaly, we propose that IDO modulates DNA repair
mechanisms in cancer cells by increasing intracellular NAD+. We have used multiple
chemotherapy drugs with different mechanisms of action to induce DNA damage in
cancer cells and consequently activate DNA repair mechanisms in the presence or
absence of IDO. However, our findings are limited to indirect examination of DNA repair
mechanisms. A more direct approach of studying other enzymes involved in DNA repair
pathways (BER in IDO-downregulated or IDO-sufficient cells, for example) would have
significantly substantiated our findings at a molecular level. However, there are currently
limitations to such studies. For example, the only available kit to measure PARP activity
(HT universal colorimetric PARP assay kit, cat# 4677-096-k, Trevigen, Gaithersburg,
MD) requires lack of NAD+ in the cell lysate. Since IDO increases intracellular NAD+ the
experimental approach on which this kit depends would not be useful to our study. To
examine whether IDO increases the expression of DNA repair enzymes, we could
quantify them in cancer cells in the presence or absence of IDO to show a connection
between IDO and DNA repair. However, although this approach would assess the
capacity of IDO to modulate the amount of DNA repair enzyme, it would not assess the
effect of those amounts on DNA repair activity itself.
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6

Chapter 6

6.1

Significance
Data presented in this thesis provides evidence for the identification of a new and

previously undescribed function for IDO (i.e., independent of direct function of IDO in or
on immune cells). IDO mediates resistance to a number of chemotherapy agents and γ
radiation in human tumour cells. Conversely, knockdown of IDO increases the sensitivity
of the same cells to these agents. IDO is expressed by most human cancers and cells of
the tumour microenvironment, and its role in suppressing cytotoxic anti-tumour immune
activity is well-described. I identify IDO as a molecule involved not only in resistance to
immunotherapy (as reported before by others), but one that also plays a previously
unreported role in resistance to chemotherapy and radiation. The majority of literature
reports of in vivo IDO characteristics and function involve murine IDO in mouse tumours,
in the context of the immune system. In this thesis, human IDO in human tumour cells
was assessed. Furthermore, I looked at IDO effects in cancer cells in the absence of a
functional immune system. The observations made here provide clear evidence for the
benefit of targeting IDO. This not only avoids immunosuppression capable of hindering
endogenous immune recognition and destruction of tumour cells, but also sensitizes
tumour cells to conventional cancer therapies, including cytotoxic drugs and radiation in
a cancer cell-autonomous fashion and independent of immune function. In a preclinical
context, IDO in cancer cells can reduce the potential therapeutic effectiveness of
anticancer therapies applied singly and in combination, and antisense knockdown of IDO
abrogates that reduction in effectiveness – an observation revealing a previously
undescribed, cancer cell-autonomous value for therapeutic targeting of IDO. Finally,
TDO is overexpressed in brain tumours [293] and is involved in metabolizing tryptophan
similar to IDO. Brain tumours are among the most resistance cancers to chemotherapy
and radiation [293]. TDO downregulation in glioblastoma can therefore potentially
sensitize brain tumours to radiation and some chemotherapy drugs.
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6.2

Future Directions
It is valuable to reproduce these in vitro results in an in vivo model without the

immune system. Immunocompromised mice provide a useful tool for this purpose.
Searching the available patient databases to examine whether IDO levels were correlated
with clinical outcomes from radiation or chemotherapy agents that are tested in this study
would also be of great value. Testing the direct effect of IDO on enzymes involved in
BER such as DNA glycosylases could provide a clear evidence for IDO being directly
involved in an important DNA repair pathway. Adding conditioned media to IDOnegative cells and examining their drug sensitivity can shed light to the potential role of
kyneurenine metabolites on IDO-mediated drug resistance. To further examine the
underlying mechanism, we can add tryptophan or individual kynurenine metabolites to
cultured tumour cells and measure sensitivity to chemotherapy drugs and radiation to
provide a detailed insight of IDO’s role in drug sensitivity and drug resistance. Finally,
comparing the effectiveness of anti-IDO shRNA with conventional IDO inhibitors such
as 1-MT in sensitizing cancer cells to chemotherapy agents and radiation would be of
outmost importance.
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